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Summary
Mycobacterium tuberculosis, the aetiological agent of pulmonary tuberculosis (TB), is a 
re-emerging threat to global public health. TB continues to account for in excess of 2 
million deaths annually with mortality and morbidity set to rise over the next decade as 
a consequence of the global HIV/AIDS pandemic. Many of the problems associated 
with treating this ancient disease ar e related to the intrinsic drug resistance of the causal 
organism, a factor that is compounded by the relatively small number of effective 
chemotherapeutic agents available. The cuixent situation is frirther exacerbated by the 
emergence of multi-drug resistant strains ofM  tuberculosis (MDR-TB) in certain parts 
of south-east Asia and eastern Europe. The global spread of such strains, fuelled by the 
increased availability of air travel, represents a serious threat to even the rich, 
industrialised nations of the West since successful treatment of MDR-TB requires the 
use of expensive and highly toxic drugs.
These various factors underline the urgent need for new and effective TB drug 
treatments. The development of such agents will undoubtedly require a much-improved 
understanding of M. tuberculosis at the most basic biochemical and genetic levels. To 
this end the completion of the TB genome sequencing project in 1998 represents a 
major breakthrough. The genome provides not only a detailed blueprint of every 
potential drug target that might be used in treatment of the disease, but also eveiy 
conceivable drug resistance mechanism employed by the organism to evade our current 
treatments.
Active efflux is one of the key strategies used by microorganisms to avoid the 
deleterious effects of xenotoxic compounds, such transport processes being catalysed by 
an array of membrane-associated proteins. The ATP-binding cassette (ABC) 
transporters have been identified as one of the largest and most widely distributed 
families of such transmembrane transport systems. Virtually ubiquitous in nature, ABC 
transporters have been found in the genomes of every organism from the simplest 
archaea through to man. Whilst the vast majority of ABC transporters mediate standard 
cellular processes such as nutrient acquisition, a significant number have been shown to 
exhibit a broad substrate range and the capability to transport structurally diverse
molecules. It is the expression of these broad-substrate transporters that is most 
commonly linked with drug resistance phenotypes.
Little is currently known about the contribution of ABC transporter systems to the 
intrinsic drug resistance of M  tuberculosis. In fact, despite the presence of a large 
number of ABC transporters in the genome, very little is known about the biological 
role of any M. tuberculosis ABC transporter. Against this background it was the remit 
of this thesis to investigate the structure and function of just one such system. The M. 
tuberculosis drrABC operon was identified during the genome sequencing project as 
encoding a potential antibiotic resistance mechanism. The basis of this assumption was 
a significant level of sequence homology between the drr ABC genes and those 
encoding a known antibiotic efflux ABC transporter fiom the evolutionarily related 
organism Streptomyces peucetius. The overall experimental strategy adopted was to 
clone and over-express the three genes of the drrABC operon in a non-pathogenic 
heterologous host (E. coli). It was hoped that this approach might generate large enough 
quantities of the individual proteins to investigate not only the biological function of the 
DrrABC transporter but also the structure of isolated components.
Expression of the mycobacterial genes in E. coli proved to be a challenging undertaking, 
differences in the genetics of the host and donor organisms making co-expression of all 
three genes impossible. Expression of the individual proteins in isolation was somewhat 
more successful, with the ATP-binding sub-unit of the transporter, the DrrA protein, 
over-expressed and purified as a catalytically active fusion protein. The membrane- 
associated DrrB protein was successfully expressed in E. coli yet proved highly unstable 
and resistant to extraction from the membrane. The same problems applied to the 
second membrane-bound component of the transporter, DrrC. Issues of low expression 
and protein instability are not uncommon when working with membrane proteins and it 
appears that the M tuberculosis DrrB and C proteins are no different in this respect. The 
over-expression and purification of DrrA allowed a partial characterisation of the 
catalytic activity of the protein using traditional biochemical methods. As a cation- 
dependent ATPase DrrA was shown to exhibit biological activity broadly consistent 
with a role as the catalytic sub-unit of an ABC transporter. As such DrrA is only the 
second M. tuberculosis protein for which such activity has been demonstrated.
■ ■
The exact biological function of the DitABC transporter remains a matter of some 
doubt. Research by one group of scientists suggest that the transporter is indeed a 
functional antibiotic efflux mechanism, whilst another group argue that its primary role 
is the transmembrane transport of an important mycobacterial cell wall component.
Whilst these two roles are not mutually exclusive, they do suggest that DrrABC may yet 
prove to be an attractive target for drug intervention. Unambiguous demonstration of the 
roles of this transporter, and the many other M. tuberculosis transmembrane transport 
systems, will require a great deal of further research and the development of improved 
expression systems.
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Chanter 1 -  General Introduction -  Tuberculosis and the mycobacteria
1 . 1 .1 The global burden of tuberculosis
In April 1993 the World Health Organisation (WHO) declared tuberculosis (TB) to be a 
“global health emergency”. The basis for this unprecedented action was a world-wide 
resurgence m tuberculosis which, by 1998, was accounting for more than 2 million 
deaths annually (WHO Fact Sheet 104, 2002). Whilst the global H3V/AIDS pandemic is 
now believed to have overtaken TB as the leading cause of death due to an infectious 
disease, tuberculosis still kills more adults each year than diarrhoea, malaria and all of 
the tropical diseases combined. The vast majority of deaths due to TB still occur in the 
developing world (Raviglione et al, 1995). However, the period 1985 to 1992 also saw 
an increase in the number of new TB cases presented in the industrialised nations of the 
West. For example, cases in the USA alone rose by 20% during this period (with New 
York City at the centre of several serious outbreaks), reversing a general decline in new 
cases of TB that had been taking place since 1953 (Cantwell et al, 1994). A 
combination of factors, some of which are discussed later, are thought to be responsible 
for the observed global resurgence of TB. However, there is no doubt that the re- 
emergence of TB at the very heart of prosperous Western societies has prompted 
governments and scientists alike to once again focus significant efforts mto the control 
and treatment of this disease.
1.1 .2  Tuberculosis and the Mycobacteria
Famously described as “Captain of all the men of death” by evangelist Robert Bunyan, 
tuberculosis had been known as a deadly disease since antiquity. Despite this, it was not 
until 1882 that medical science was successfully able to identify and culture the 
etiological agent of the disease. This breakthrough came with the description of the 
''Tubercule bacillus ’ by Robert Koch, the man now widely regarded as the father of 
modern microbiology. We now know the organism as a member of the genus 
Mycobacterium, the vast majority of which are non-pathogenic, free-living, 
environmental saprophytes. Flowever, a number of species of mycobacteria have 
evolved as either obligate or opportunistic pathogens capable of causing disease in both 
humans and animals. In addition to Mycobacterium tuberculosis, the causal agent of 
human TB, a second major pathogen of the genus is Mycobacterium leprae, the 
organism responsible for human leprosy (Sasaki et ah, 2001). Whilst the mycobacteria
form a relatively small and distinct genus, they are most closely related, in evolutionary 
terms, to the genus Streptomyces. Streptomycetes are a group of spore-forming, 
filamentous bacteria, many of which produce a variety of biologically active secondary 
metabolites e.g. antibiotics (Baltz, R.H., 1998).
1.1. 3 The pathology of tuberculosis
Symptoms of ‘active’ TB include fits of coughing, sometimes bringing up blood, chest 
pain, exhaustion, fever, profuse sweating at night and weight loss (Tattevin et al, 1999). 
Left untreated the disease causes progressive destruction of the lung tissues and 
eventually death. The disease is transmitted when infected aerosols are expelled from 
the lungs of patients and are subsequently inhaled by those around them (Bermudez and 
Goodman, 1996). This mode of transmission means that the lungs are the most 
frequently affected organs, although infection can then spread to other areas of the body 
including the brain, blood and heart (von Reyn et al., 2001). These extra-pulmonary 
forms of TB are not widely regarded as infectious.
Whilst it is estimated that up to one third of the world’s population may be infected with 
Mycobacterium tuberculosis, only 10% of those infected ever develop the active disease 
(Sudre et ah, 1992). This is because the immune system of a healthy individual is 
usually able to combat the infection. It does so by isolating infected cells, most 
frequently lung alveolar macrophages, into thick walled, fibrous structures known as 
granulomas (Bermudez and Goodman, 1996). Once isolated in this fashion the bacteria 
are unable to spread to other areas of the lung, nor are they expelled as in the case of 
active TB (Saunders et a i, 1999). The bacteria are not necessarily destroyed within the 
granuloma, and appear to have evolved mechanisms for avoiding clearance by the 
immune system. A tliick, waxy cell wall and a number of scavengmg molecules may 
play a role in the ability of mycobacteria to survive in a dormant state whilst 
encapsulated in this hostile environment (Couture et a l, 1999). The exact mechanisms 
of host-pathogen interaction within the granuloma may one day represent a target for 
drug intervention and treatment of TB.
1.1. 4 Risk factors and the spread of TB
The WHO has identified a number of factors that have contributed to the global increase 
in new TB cases. Social factors such as homelessness, poverty, malnutrition, drug
addiction and incarceration all have long been recognised as risk factors in the 
development of TB. This may be because the immune system of these individuals is 
significantly weakened, compromising their ability to fight off initial infection, or 
facilitatmg the reactivation of a latent infection. Such social factors may also force 
many susceptible people to live together in large groups, thereby allowing rapid spread 
of infection via the aerosol route.
Severe immuno-compromisation due to HIY/AIDS is thought to be another of the major 
factors fuelling the global increase in deaths due to TB, particularly in sub-Saharan 
Africa and South East Asia where TB now accounts for 40% of AIDS related deaths 
(WHO fact sheet 104,2002). The two infections seem to have a deadly synergistic 
effect, with AIDS leaving sufferers both more susceptible to initial infection and less 
able to fight it. HIV co-infection may also allow reactivation of a dormant 
mycobacterial infection, increase the chances of the disease spreading to other areas of 
the body, and can leave patients open to opportunistic infection by other mycobacterial 
species not usually recognised as major human pathogens (Zurawski et a l, 1997), A 31 
month study amongst intravenous drug users in New York City has suggested that the 
likelihood of developing active TB increases from a 10% lifetime chance in immuno­
competent patients, to a 7-10% yearly chance in HIV/TB infected patients (Selwyn et 
aL, 1989). These figures now make HIV infection the number one risk factor in the 
development of active TB disease.
The increasing availability of air travel and large volumes of displaced peoples, such as 
refugees, have facilitated the spread of TB across national borders and throughout the 
world. These cases represent a significant reservoir of infection as they move from one 
part of the world to another. In the industrialised nations, where TB is relatively rare, a 
large proportion of TB cases are amongst foreign-born nationals. The WHO cites this as 
another reason why the affluent nations of the West cannot afford to ignore the growing 
burden of tuberculosis (WHO Fact Sheet 104,2002).
1.1. 5 Clinical diagnosis of M  tuberculosis infection
The identification of patients infected with M  tuberculosis, whether they exhibit active 
disease or not, is of vital importance in controlling the spread of TB on both local and 
global scales. The Tuberculin Skin Tests (TST), and variants the Mantoux and Heaf
tests, are the most commonly used tools for screening large populations for potential 
exposure to M  tuberculosis. These tests rely upon a hypersensitivity reaction to an 
intradermal injection o f a protein mixture derived from autoclaved cultures o f M  
tuberculosis. The extent o f an individual’s immune reaction to the injected protein is 
measured 48-72 hours after the injection. If a patient has latent M tuberculosis 
infection, there will be an extensive reaction due to the presence o f antibodies in the 
patient’s blood. A significant limitation o f hypersensitivity testing o f this type is that 
false results, both positive and negative, are quite common. False positives may occur as 
a result o f the cross-reactivity o f antibodies that have been produced as a result o f  
exposure to non-pathogenic, environmental mycobacteria. False negative results, a 
particularly dangerous form o f failure, can occur in elderly people, HIV infected 
patients or very young children. This is because these groups o f people display a 
generally weakened immune response. The TST may also fail in patients who have 
become infected with M  tuberculosis less than 10 weeks before testing. This is because 
the bacteria grow slowly within the body and it can take 8-10 weeks for the bacterial 
load to reach a threshold level capable o f eliciting an immune response (Farr, B.M., 
2001). Regardless o f the result o f  a TST, those patients exhibiting the symptoms o f  
active pulmonary TB should be given a chest X-ray. Usually, when a person has TB 
disease in the lungs, the chest X-ray will appear abnormal. It may show infiltrates 
(collections o f fluid and cells in the tissues o f the lung) or cavities (hollow spaces within 
the lung that may contain bacilli). It is important to note that an X-ray is not a definitive 
tool for diagnosis since other diseases can give rise to abnormalities, nor will an X-ray 
detect the early stages o f M. tuberculosis infection. Another problem is that X-ray 
facilities are by no means widespread in certain areas o f the developing world where TB 
is now endemic.
Figure 1.1 -  Lung damage caused bv TB infection
Large granuloma
Cavitation
The ‘gold standard’ for clinical diagnosis o f M  tuberculosis infection is a complete 
bacteriological examination. This entails collection o f a clinical specimen (e.g. lung 
sputum for suspected pulmonary TB), staining and microscopic examination o f the 
specimen, and culture o f the infective organism. A useful diagnostic feature o f the 
mycobacteria is that they are acid fast to particular stains, i.e. remain strongly stained 
even after a smear slide is washed in acid. The detection o f many acid fast bacilli in a 
sputum smear means that the patient is highly likely to be contagious since it is these 
bacilli that may be aerosolised during fits o f coughing. A variety o f mycobacterial 
species are acid fast, and thus the test is not necessarily a direct indication o f M  
tuberculosis infection. However, since the results o f a smear test are available to the 
clinician within a day, this test may allow potentially infectious patients to be isolated 
before they can pass the infection on to others. The final and definitive step o f diagnosis 
is the culture o f organisms from the clinical specimen under conditions specific for the 
growth o f M. tuberculosis. Because o f the slow growth o f the organism a definite result 
may take 4-6 weeks to obtain, a period in which the affected individual should ideally 
be isolated in order that they do not infect anybody else. In certain instances drug 
susceptibility testing may also be necessary in order to identify a drug regime that will 
be effective in clearing the infection. Such investigations are performed by growing 
clinical isolates on solid media in the presence and absence o f antibiotics and can take 
an additional 3 to 6 weeks to complete.
Figure 1.2 -  Lung sputum smear showing acid fast bacilli
M  tuberculosis
cells
The slow growth of M tuberculosis and the absence of reliable, specific 
imiranimodiagnostic tests represent major problems in the diagnosis of pulmonary TB. 
The same problem also contributes to the high rates of morbidity and mortality 
associated with dissemhiated and meningeal TB, where rapid diagnosis and treatment 
are key factors in tlie prognosis of the patient. As a result of these problems, researchers 
are developing novel molecular assays for identifying and typing mycobacterial 
infections. It is hoped that these techniques, some of which are discussed below, will 
allow diagnosis to become far more rapid and specific.
1.1. 6 Molecular diagnostics
The increased risk of TB infection in the developed world, and the concomitant increase 
in funding that basic research has received, has lead to some improved methods for the 
early detection and diagnosis of the disease. The advent of PCR in 1987 offered a 
potential means for the rapid amplification of specific nucleic acid sequences from 
clinical samples. Soon applied to TB, genomic techniques of this kind ultimately aim to 
identify and amplify species-specific sequences that are not present in other closely 
related bacteria. The first sequence successfully employed was that encoding the 65 kDa 
heat-shock protein (Hance et ah, 1989). Subsequently a variety of amplification targets 
have been described, including mycobacterial antigens, repetitive sequences and 
ribosomal RNA genes (Woods, G.L., 1999). One of the most common targets is a 
mobile genetic element unique to 5 species of mycobacteria that constitute the so-called 
M tuberculosis complex. Insertion sequence 6110 has the major benefit of being present 
in multiple copies in the genome of these organisms. \S6110 has also proven to be 
useful in strain typing, with the number of repeats and restriction fragment length 
polymorphisms associated with the sequence indicative of individual strains. The US 
FDA currently approves three nucleic acid amplification tests for the identification of 
M tuberculosis in clinical samples. These tests have been found to be more sensitive 
than staining and microscopy techniques, yet tend to perform worse than the gold 
standard culture procedme (Bonington et al., 1998; Brown et aL, 1999; Scarparo et al., 
2000). Whilst problems exist with the use of these systems in poorer countries, in an 
industrialised setting they offer the major advantage that the results are usually available 
within 24 hours and can detect the presence of mycobacteria in smear negative samples.
Progi'ess has also been made in respect of culture techniques for the slow growing 
mycobacteria. A radiometric system based upon the release of from labelled 
liquid growth media by the action of mycobacterial metabolism was one of the first 
systems to be licensed. More recently systems based upon oxygen consumption and 
redox indicators have been employed to detect the growth of mycobacteria in liquid 
culture. These latter methods enjoy the same advantages as the radiometric system 
without the need for the use of radiochemicals (Heifets et al., 2000, Liu et al., 1999). 
Such systems, combined with nucleic acid amplification tests, now allow the detection 
of M. tuberculosis in 12-20 days, comparing favourably with conventional culture and 
identification teclmiques which may take up to 6  weeks (Katila et a l, 2000). Liquid 
culture systems are also now being used for drug susceptibility profiling, replacing the 
traditional solid media technique (Rusch-Gerdes et al., 1999).
Basic research has also spawned a genuinely novel system, currently under evaluation, 
for the monitoring of mycobacterial growth and dmg susceptibility profiling. 
Engineered mycobacteriophages producing fire-fly luciferase are used to infect early 
stage liquid cultures growing in the presence and absence of antibiotics. Viable bacilli 
proliferate and produce light when luciferin is added to the culture media. The amount 
of light produced by each culture is measured and provides an accurate guide to the 
number of viable bacilli present. Susceptible cultures can exhibit as much as a 90% 
decrease in the light signal produced (Riska et al, 1999),
As with all novel teclmologies, continual evaluation and innovation will be required if 
molecular diagnostics are ever to find widespread use. This is particularly relevant with 
regard to TB diagnosis since the bulk of the global TB burden is located in third world 
or developing countries where facilities, teclmical expertise and financial resources are 
limited.
1 . 1 . 7  Aiitimycobacterial chemotherapy
Less than 60 years ago there were no effective aiitimycobacterial drugs. However, the 
beginning of the antibiotic era was a time of great optimism since it heralded the 
introduction of the first effective treatments for TB. Streptomycin, discovered in 1944 
by Selman Waksman, was initially found to be a highly successful treatment for those 
suffering from tuberculosis. Unfortunately, it soon became apparent that treating the
disease with this drug alone was insufficient. It was found that complete elimination of 
the bacillus was extremely difficult, requiring both high doses and long periods of 
treatment. This in turn lead to problems of streptomycin toxicity, and unpleasant side 
effects such as hearing loss. In addition it was found that resistant strains of the 
bacterium would develop rapidly, being present in approximately 80% of patients after 
just 3 months of treatment with streptomycin. The problem of streptomycin resistance 
was eventually overcome during the 1950’s. It was noted that treatment of patients with 
p-aminosalycilic acid (PAS), a derivative of asprin, as well as streptomycin, was highly 
effective in suppressing the emergence of streptomycin resistant bacteria. This 
discovery was a key factor in establishing ‘multidrug’ or ‘combination’ therapy as the 
most effective means of treating tuberculosis.
The next breakthrough in TB chemotherapy came in 1952 with the introduction of the 
syntlietic drug Isoniazid. This drug, now known to be a highly effective inhibitor of 
mycobacterial cell wall synthesis, is still the most commonly prescribed 
antimycobacterial agent. In fact, isoniazid forms the cornerstone of most modern 
multidrug treatment regimens used to treat tuberculosis and is still the most effective 
drug for targeting actively dividing bacilli. At this point in time it was discovered that a 
regimen of all tliree drugs, isoniazid, streptomycin and PAS, could be used to 
successfully treat pulmonary tuberculosis in just 18 months, without the emergence of 
resistant bacteria.
Rifampicin, a bacterial RNA polymerase inhibitor, was the next drug to be pressed into 
service against tuberculosis infection. Rifampicin had the major advantage of being 
active against dormant M  tuberculosis as well as actively dividing ceils. It is the 
incomplete elimination of ‘persisting’ bacilli of this type that is most conmionly 
responsible for patient relapses after the completion of a therapeutic course. A highly 
lipophilic molecule, rifampicin is able to cross the tliick cell wall of M tuberculosis to 
its site of action in the cytosol. Despite this, certain species of non-tuberculous 
mycobacteria are intrinsically resistant to rifampicin. Tills feature is often attributed to 
species-specific differences in cell wall structure and means that rifampicin and its 
derivatives are not suitable for the treatment of all mycobacterial infections. As with 
most antimycobacterial drugs, resistance arises rapidly if rifampicin is used alone, but.
introduced as part of a multidrug therapy regime allows the period of treatment to be 
shortened from 18 months to just 9.
From the 1960’s onwards, a number of other drugs were tested against TB infection and 
were found to have some efficacy. For example, pyrazinamide, like rifampicin, was 
found to be active against dormant bacilli and those present inside macrophages. The 
inclusion of pyrazinamide in the initial treatment regimen for pulmonary tuberculosis 
has further shortened the treatment cycle to 6  months. Ethambutol, like isoniazid, is an 
inhibitor of cell wall biosynthesis but is less effective at actually killing the bacterium. It 
is however useful for suppressing the emergence of resistance. Other drugs such as , ;etliionamide and cycloserine have both poor bactericidal properties and troublesome 
side effects but are useful back-up treatments in cases where resistance to the front-line 
agents is a problem.
Cure rates of up to 95% can now be acliieved through the use of the five front line anti- 
tubercular drugs, but only when they form part of a well-defined and organised 
treatment strategy. Failure to complete the entire course of chemotherapy can lead to 
patient relapses and the emergence of resistance. To help prevent this from happening, 
the WHO now recommend Directly Observed Therapy (DOT) where patients are 
administered the drug combinations in the presence of a health practitioner.
Implemented throughout the world, DOT is now producing much improved results in 
the treatment of pulmonary tuberculosis, even in the poorest countries. DOT ensures 
that a far higher proportion of people complete the treatment schedule, and are thus 
cured of M. tuberculosis infection, thereby preventing the spread of the disease (WHO 
report on Global Tuberculosis Control, 2000). Table 1.3 and figure 1.4 show the front­
line and secondary drugs used in modern TB treatment regimens and how they are used 
in a typical 6  month DOT setting.
Table 1.3 — Drugs used in the treatment of tuberculosis
Front-Line Drugs Secondary Drugs
Essential Supplemental Modem Era Older
Isoniazid
Rifampicin
Pyrazinamide
Streptomycin
Ethambutol
Ouinolones
Ofloxacin
Sparfloxacin
Ciprofloxacin
Macrolide
Clarithromycin
PAS
Ethionamide
Cycloserine
Capreomycin
Kanamycin
Thiocetazone
Figure 1.4 -  A typical DOT drug regimen for the treatment o f tuberculosis
Isoniazid 
Rifampicin 
Pyrazinamide
+
Ethambutol or 
Streptomycin 
until drug 
susceptibility 
profile is 
complete
Time (Months)
Rifampicin and 
Isoniazid
1.1.8 Drug resistance and MDR-TB
Since the beginning o f the widespread use o f antibiotics in the 1940’s the development 
o f resistance amongst pathogenic organisms has been a significant problem in the 
effective treatment o f clinical disease. As our arsenal o f chemotheraputics has grown to 
include novel and semi-synthetic compounds, as well as naturally produced antibiotics, 
resistant organisms have emerged at every stage. In fact, the massive increase in the use 
o f antibiotics over the last 60 years has almost certainly hastened the emergence o f
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resistance by placing susceptible organisms under increased evolutionary pressure. As 
molecular biology, biochemistry and genomics have provided insights into the 
mechanisms of antibiotic action, so they have also led to an increased understanding of 
how organisms evade antibiotic clearance.
The treatment of tuberculosis has not escaped the problems of drug resistance, a 
situation exacerbated by the relatively small number of effective agents. The use of 
combination therapy has however proven to be highly effective when adhered to 
correctly. Significant problems do however arise when treatment regimens break down. 
With the observed global increase in new TB cases, there is a major risk that the number 
of drug resistant cases may also be increasing. The widespread emergence of Multiple 
Drug Resistant TB (MDR-TB) is a real and serious threat. Minimally defined as 
resistance to botli isoniazid and rifampicin, the two most effective drugs against TB 
infection, new cases of MDR-TB are currently relatively small in number compared 
with overall TB infection rates. In the year 2000 an estimated 273,000 cases of MDR- 
TB were identified out of a total of 8.7 million new cases, just 3.2% (Dye et al., 2002). 
The global distribution of MDR-TB cases is also currently rather restricted, with the 
highest incidences in parts of China and Eastern Europe. Any serious spread of the 
disease is however potentially disastrous. This is because the treatment of MDR-TB is 
very difficult and expensive and utilises drugs which are poorly tolerated. The cost of 
treating a single case of MDR-TB in the USA will normally run to tens of thousands of 
dollars. Additionally, running at just 60-70%, cure rates for MDR-TB are significantly 
lower then those observed for the fully sensitive disease.
In order to prevent the possible spread of MDR-TB, research is being conducted in 
order to furtlier our understanding of the rmderlying mechanisms of mycobacterial drug 
resistance. These efforts will hopefully yield new and effective drugs that circumvent 
the problems of resistance. Molecular biology and biochemistry have identified 4 basic 
mechanisms that contribute to drug resistance across all classes of pathogen (see table 
1.5).
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Table 1.5 -  Mechanisms of drug resistance
(I) Enzymatic destruction or inactivation of the drug molecule
(II) Mutational alteration of the molecular target of the particular drug
(III) Decreased permeability of the cell towards drug molecules
(IV) Active efflux of drugs reducing cellular concentrations to sub-cytotoxic levels
All of these mechanisms have been shown to operate in mycobacteria and contribute, to 
a greater or lesser extent, to tire liigh levels of drug resistance exhibited by M 
tuberculosis. Of the above mechanisms mutational changes in diug targets are the most 
clinically significant. The aminoglycoside class of antibiotics, of which streptomycin is 
a member, operate by binding to the 30s ribosomal subunit and interfering with the 
transition between the initiation and elongation phases of protein synthesis. M 
tuberculosis possesses only a single copy of the 16s rRNA gene and a number of 
mutations in this gene seem to prevent streptomycin fi’om binding to the ribosome and 
exerting its action. Additionally, mutations in the ribosomal S12 protein have a similar 
effect and give rise to streptomycin resistance also (Finken et ah, 1993). Interestingly, a 
class of aminoglycoside detoxifying enzmes called N-acetyltransferases have been 
identified in the genomes of a number of mycobacterial species, including M 
tuberculosis. As yet there is no direct evidence supporting a role for these enzymes in 
clinical drug resistance, and it seems likely that they perform some other physiological 
function (Ainsa et ah, 1997).
Target site mutation is also the major mechanism by which M  tuberculosis is able to 
escape the effects of the front-line agents rifampicin and isoniazid. Rifampicin is an 
inhibitor of bacterial RNA polymerase, a complex multi-subunit enzyme that mediates 
DNA transcription. Mutations in the rpoB gene that encodes the p-subunit of this 
enzyme are responsible for most rifampicin resistance phenotypes observed for M. 
tuberculosis. Most of the relevant mutations in fact occur in a very small locus of just 
27 codons near the centre of the rpoB gene, and consist primarily of point mutations 
(Cole, S.T., 1994). In contrast, a great deal of literature regarding the exact mode of 
action of isoniazid has been accumulated without ever providing a complete, definitive 
explanation for its anti-tubercular activity. It is known with some certainty that isoniazid 
is a potent Miibitor of cell wall biosynthesis and that it inhibits one or more stages in
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fatty-acid metabolism. Fatty-acid compounds are a known to be a vital component of 
the unique and highly complex M. tuberculosis cell wall structure (see next section). It 
is also known that isoniazid, in its administered form, is a pro-drug. i.e. it is converted 
into its active inliibitory form in vivo by the action of a bacterial enzyme. One proposed 
model of isoniazid action has the drug converted to its active form tlii’ough the action of 
the catalase-peroxidase enzyme encoded by the katG gene, whereupon it binds to and 
inhibits the hiliA protein, an enoyl-ACP reductase (Mdluli et al., 1998). This model is 
supported by the fact that mutations in both the structural gene inhA and the activator 
katG have been correlated with isoniazid resistance (Rouse et al., 1995). The 
importance of the mycobacterial cell wall is further underlined by the fact that another 
of the front-line anti-tubercular agents, ethambutol, is also a cell wall synthesis 
inliibitor. Ethambutol targets the production of the arabinogalactan component of the 
cell wall by inhibiting the activity of arabinosyl transferase enzymes (Telenti et at,, 
1997). The product of the emh'B gene is the most likely target of the drug in M. 
tuberculosis with over 60% of resistant organisms having a mutation in the codon for 
Mets06 (Sreevatsan et a l, 1997). The fact that 40% of ethambutol resistant mutants 
have no mutation in the emh'B gene raises the possibility that ethambutol, like isoniazid, 
acts at multiple points in the biosynthetic pathway.
All of the above examples of clinically relevant resistance mechanisms are dependent 
upon target site mutations. Despite this, it is almost certain that multiple mechanisms 
contribute to M. tuberculosis drug resistance. For example, the unique structure of the 
lipid-rich cell wall represents a major permeability barrier to hydrophilic dmg 
molecules, a feature which is discussed in the next section. Active efflux of drugs is 
another mechanism commonly employed by pathogenic organisms to avoid cytotoxic 
effects. Whilst active efflux has yet to be demonstrated to be a clinically relevant 
resistance mechanism in M. tuberculosis, the sequencing of the genome has shown that 
a number of potential drug pumps are encoded. The various types of active efflux 
pumps are discussed in greater detail in chapter 1 .2 , and it is the aim of this thesis to 
investigate the role of one such potential pump, the putative ABC transporter encoded 
by the M  tuberculosis r/rrABC genes.
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1.1. 9 The mycobacterial cell wall
The mycobacteria fall into the class of Gram-positive prokaryotes, i.e. the cytoplasmic 
membrane of the cell is surrounded by a thick cell wall that lends the cell its shape and 
rigidity. However, significant differences exist between the mycobacterial cell wall and 
those of other Gram-positive organisms, such as the nocardia and corynebacteria, to 
which the mycobacteria are evolutionarily related. The differences are in fact so great 
that the classic Gram stain, used to differentiate between Gram-positive and Gram- 
negative organisms, works poorly on mycobacterial cells. The mycobacterial cell wall is 
the most complex of all organisms and is a structure essentially unique in nature. Its 
major distinguishing feature is the unusually high lipid content. Lipids may account for 
as much as 60% of the cell wall weight and include a number of molecules unique to the 
mycobacteria. The acid-fastness of mycobacterial cells, that is theh resistance to 
destaining by weak organic acids, is another feature attributable to the unusual 
properties of the cell wall and is the basis of the Ziehl-Neelsen stain used to diagnose 
mycobacterial infection in lung sputum samples.
Significant amounts of research have been conducted into the physical structure and 
biochemical components of the cell wall. Much of this interest is stimulated by the fact 
the cell wall appears to play a large part in host-pathogen interactions and has a possible 
role in pathogenicity. The currently accepted model was first proposed by Minmkin in 
1982 and later modified by McNeil and Brennan (Minnikin, 1982; McNeil and Brennan, 
1991), This model, illustrated in figure 1.6 , has the cell wall scaffold composed of three 
covalently linked structures; peptidoglycans, arabinogalactans and mycolic acids. In 
addition to these components are the liporabinomannans and the mycosides. The 
mycosides are a heterogeneous group of species-specific, surface exposed, lipid- 
containing molecules. Being the outermost layer of the mycobacterial cell wall they ai e 
believed to have a biological role analogous to the O-antigens of Gram-negative enteric 
bacteria such as E. colt i.e. account for such properties as agglutination serotype and 
colony morphology. It should be noted that the mycosides are not covalently attatched 
to the underlying scaffold structure, and for this reason they may sometimes be temied 
'extractable lipids’. The various components of the cell wall are now considered in 
isolation and with reference to figure 1 .6 ,
14
Figure 1.6 -  Schematic representation o f the mycobacterial cell wall
— Mycosides
Mycolic 
~  Acids
Arabinogalactan
_  Peptidoglycan
LipoarabinomannanCell Membrane
Peptidoglycan
The peptidoglycan layer o f the cell wall is perhaps the simplest o f the various 
components and is the only part o f the cell wall to bear any significant similarity to the 
cell wall o f other Gram-positive organisms. It is the innermost component o f the wall, 
i.e. lies closest to the cytoplasmic membrane o f  the cell. Biochemically, the 
peptidoglycan consists o f long chains o f  polysaccharide, cross-linked at various points 
by tetra-peptide chains. The overall effect is to create a mesh-work or lattice around the 
cell membrane that is responsible for cell morphology and rigidity. The polysaccharide 
chains consist o f alternating residues o f  N-acetyl glucosamine and N-glycolyl muramic 
acid. This is very similar to the arrangement found in the peptidogylcan o f other genera 
except for the incorporation o f N-glycolyl muranic acid rather than the more common 
N-acetyl derivative.
Arabinogalactan
The arabinogalactan layer is the second innermost component o f the cell wall and is 
linked to the underlying peptidoglycan by phosphodiester bridges. Arabinogalactan
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constitutes the major polysacehaiide component of the cell wall, but its structure is 
unusual in that it seems to lack repeating units (as is the case for the peptidoglycan).
The structure is branched at many points, with the galactan portion of the molecule 
lying parallel to the underlymg peptidoglycan, and the arabinan portion projecting 
perpendicularly from the branch points. The arabinose subunits branching from the 
galactan are arranged into groups of six and are frirther modified by the addition of 
mycolic acids to their reducing termini. The anti-tubercular ethambutol is believed to 
inliibit the arabinosyl transferase enzyme(s) that construct the hexa-arabinose units. The 
arabinogalactan portion of the cell wall essentially forms a ‘bridge’ between the 
peptidoglycan below and the major lipid component of the cell wall, the mycolic acids.
The Mycolic acids
The mycolic acids are a complex group of long-chain, branched fatty-acids. They are 
the largest (by weight) component of the mycobacterial cell wall, and can contain as 
many as 60-90 carbon units in M. tuberculosis. Mycolic acid synthesis has been shown 
to be the biochemieal target of the anti-tubercular drug isoniazid (Mdluli et a l, 1998). 
The mycolic acids are attatched in groups of 4 to the reducing termini of hexa-arabinose 
imits that form part of the underlying arabinogalactan layer. Only about two-thirds of 
these arabinose termini are modified by mycolation. The generalised structiue of 
mycolic acids is illustrated below in figure 1.7. The two branches of the mycolic acid 
molecule are usually uneven in length with one arm containing significantly more 
hydrocarbon units than the other. In addition, the longer (or meromycolate) branch may 
contain functional group modifications such as oxygen containing groups, cyclopropane 
groups or unsaturated bonds. The mycolic acids are proposed to lie perpendicular to the 
cell membrane, and despite their modifications possess a low degree of unsaturation. 
Modifications occur at only two points in the meromycolate arm with the shorter arm 
always fully saturated. This allows the mycolic acids to pack tightly, forming a 
significant barrier to the passage of hydrophilic molecules, including drugs.
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Figure 1.7-mvcolic acid
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Unlike the mycolic acids and the arabinogalactan, the liporabinomannans of the 
mycobacterial cell wall are not covalently linked with tlie basal peptidogycan layer. 
Rather, these very long, branched sugar molecules are anchored directly in the cell 
membrane by attachment to phosphatidyl-inositol phospholipids. Two sub-classes of 
LAM’s are known to exist, those that tenninate in arabinose residues, and those 
terminating with mannose. This distinction is relevant because AraLAM, but not 
ManLAM, is able to induce cytokine production by macrophage cells. In fact, LAM is 
one of the immunodominant antigens of M  tuberculosis and its structure may be an 
important modulator of host-pathogen interactions and virulence (Roach et ah, 1993). 
LAM’s are believed to stretch all the way across the cell wall from the cell membrane to 
tlie outermost regions, hr so doing, the LAM is believed to be an important ‘anchor’ 
molecule that helps to bind together components of the cell wall, such as the mycosides, 
that are not covalently linked with the underlying structures.
The Mycosides
Amongst the molecules exposed on the outer surface of the mycobacterial cell wall are a 
group of complex lipids collectively termed mycosides. These molecules can be sub­
divided into two major classes, the peptidoglycolipids, and the phenolic glycolipids. The 
peptidoglycolipids are built up from amino acids, sugars and lipid moieties, whilst the 
phenolic glycolipids are lipid esters of the diol molecules phthiocerol or 
phenolphthiocerol lacking any further amino acid modifications. The lipid moiety of 
these molecules consists of lipids known as the mycoserosic acids. These are long chain 
multiple methyl-branched fatty acids synthesised by a single multifunctional enzyme 
encoded by the mas gene (Rainwater and Kolattukudy, 1985). The phenolic glycolipids
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Ill addition to the major structural components of the mycobacterial cell wall given 
above, significant quantities of other molecules have been identified. These are known 
to include triacyl-glycerols, acetylated trehalose molecules and sulpholipids. The exact 
roles of the many components of the cell wall are yet to be fully elucidated and much is 
still to be understood about how the various components contribute to physiological 
properties of the cell such as virulence and colony morphology. Moreover, researchers 
are still trying to isolate the various genes and biochemical pathways that are used in 
construction of the cell wall. The genome sequences of the various mycobacterial 
species completed so far will be of vital importance in future efforts to understand the 
uniquely complex nature of the cell wall structure. The above description of the 
mycobacterial cell wall is by no means exhaustive, and many excellent reviews on the 
subject have been written (e.g. see Liu et al. and Baulard et al. in Mycobacteria -  
Molecular Biology and Virulence, Eds. Ratledge and Dale, Blackwell, 2000).
are of particular interest currently since they have been identified as cell wall 
components in only eight mycobacterial species, seven of which are strict or 
opportunistic pathogens and include M  tuberculosis (Azad et uA, 1997). Furthermore, it
has been shown that mutations in the genes encoding the biosynthesis or transport of 
phenolic glycolipids result in attenuated virulence of M  tuberculosis in a mouse model 
(Cox et ah, 1999; Camacho et ah, 1999). Certain experimental data also suggest that 
phenolic glycolipids may interact with the host immune system and cause activation of 
human neutrophils. Once again, it appears that the lipid components of the 
mycobacterial cell wall are key determinants of virulence, and that successful disruption 
of cell wall biosynthesis may be an ideal target for new antitubercular agents.
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Chapter 1 -  General introduction -  The ATP-binding cassette transporters 
1. 2.1 Introduction to membrane transport
The cytoplasmic membrane forms a relatively impermeable barrier between a cell and 
its siirromidmg enviromnent. The ability to selectively transport solutes across this 
barrier is a fundamental requirement of all cells in order to perform such basic 
functions as the acquisition of nutrients and the export of metabolic wastes. These 
transport processes are universally mediated by an array of integral membrane 
proteins collectively known as membrane transport proteins. Membrane transport 
proteins are currently the focus of intense research interest because a significant 
number have been implicated as mediators of drug and multidrug resistance in 
clinically important microbial pathogens.
We now know that membrane transport is dominated by two large protein 
“superfamilies”, each one transporting solutes from one side of a membrane to the 
other by a fundamentally different mechanism. The first group to consider are known 
as primary active transporters, membrane transport systems that use a direct source of 
energy such as ATP hydrolysis or photon absorption to drive substrate translocation 
(Saier, 2000). Amongst the primaiy active transporters by far the largest sub-type are 
those energised by ATP hydrolysis. These transporters all shaie a common structural 
motif, the so-called ATP-Binding Cassette, a feature that has led this entire class of 
transporter to become known as the ABC transporter superfamily (Higgins, 1992). 
Members of this family have been identified in archaea, eukaryota and prokaryota 
alike, their universal distribution hinting at the essential role of these transporters in 
all forms of life. Indeed, ABC transporters are now known to contribute to such 
diverse phenomena as microbial antibiotic resistance (van Veen and Konings, 1998) 
and human inherited genetic disease (Riordan et ah, 1989). Structural and functional 
aspects of the ABC transporter superfamily, particularly their role as mediators of 
microbial drug resistance, are discussed in far greater detail in subsequent sections of 
this thesis.
The second major grouping of transmembrane transport proteins is known as the 
Major Facilitator Superfamily (MFS). These transporters operate by a variety of 
mechanisms including substrate uniport, substrate/cation symport and substrate/cation
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antiport (Pao et al., 1998). MFS transporters have been identified that catalyse both 
uptake and efflux reactions, the vast majority of which involve the transport of small 
molecules such as sugars, amino acids, drugs and metabolic intermediates. Whilst 
ABC transporters are known to be capable of transporting a similar range of small 
molecules, they are also known to catalyse the transport of much larger 
macromolecules such as protein toxins (Koronakis and Hughes, 1993). Another major 
difference between the ABC transporters and the MFS concerns the structure and 
genetic organisation of the systems. All MFS transporters are encoded by a single 
gene producing a polypeptide chain of approximately 400 amino acids. The chain is 
believed to traverse the cytoplasmic membrane multiple times (either 1 2  or 14) with 
the membrane-spanning regions adopting an a-helical conformation (Huang ei aL, 
2003). This is in stark contrast to the ABC transporters which are frequently encoded 
by multiple genes, the complete transporters often being the product of multiple, 
discrete protein subunits (see subsequent sections).
The MFS is now known to constitute at least 29 distinct sub-families of transporters, 
each family specific for a particular substrate or range of closely related substrates 
(Saier et aL, 1999). Two particular sub-families of MFS transporter are particularly 
relevant in the context of this work, these proteins all being involved in the active 
efflux of drugs via a drug/proton antiport mechanism. The two families differ in their 
transmembrane topology, one family constituting transporters which have 1 2  
membrane-spanning helices, the other, smaller family including those transporters 
with 14 membrane-spanning regions. Well characterised members of each family 
include the TetA(B) tetiacycline transporter of E. coli (12-helix), and the 14-helix 
TetA(K) tetracycline transporter of Staphylococcus aureus (see Borges-Walmsley et 
al, 2003)
Whilst the ABC transporters and MFS account for more than 50% of all known active 
efflux systems, they are by no means the only membrane transport proteins that 
contribute to the damaging phenomenon of antimicrobial drug resistance. Of the 
approximately 250 identified families of membrane transport proteins at least tliree 
further families appear to play a significant role in the extrusion of toxic compounds 
from the cytoplasm. These families include the Small Multidrug Resistance (SMR) 
family, the Resistance-Nodulation-Division (RND) family and the newly
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characterised Multidrug And Toxic compound Extrusion family (MATE transporters).
The SMR and RND transporters seem to operate by a drug/proton antiport mechanism 
similar to that exhibited by MFS drug efflux systems (Borges-Walmsley et aL, 2003).
However, the less well characterised MATE transporters, exemplified by the NorM 
multidrug transporter of Vibrio parahaemolyticus, function as drug/Na^ antiporters 
(Monta et aL, 2000).
It is well beyond the scope of this introduction to embark upon a detailed analysis of 
the structural and functional aspects of all the different groups of transporters 
involved in antimicrobial drug resistance, excellent reviews of these matters being 
available elsewhere in the literature (for example see Borges-Walmsley et aL, 2003;
McKeegan et aL, 2003). However, it is worth noting that significant advances in the 
field of membrane protein structural biology are beginning to shed light on the
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mechanisms by which certain drug efflux systems may operate. Foremost among 
these advances is the publication of the 3D crystal structure of the E. coli AcrB RND- 
family multidrug efflux pump (Murakami et aL, 2002). This structure not only 
provides researchers with their first glimpse of the detailed structure of a multidrug A:efflux pump, but also suggests a mechanism by which a single transporter may be Q
able to recognise and extrude multiple, structurally unrelated compounds. The first 
MFS 3D crystal structures have also recently been published, those of the glycerol-3- 
phosphate and lactose import transporters of E. coli (Fluang et aL, 2003; Abramson et 
aL, 2003) Whist neither of these transporters is involved m antimicrobial resistance, 
both structures confirm the a-helical nature of the membrane-spanning regions and 
also suggest possible transport mechanisms.
Much remains to be learned regarding the structure and mechanism of the many 
different transport systems involved in antimicrobial resistance, and many teclmical 
challenges remain to be resolved. The following sections will go on to describe in 
detail our current knowledge of the ABC transporter superfamily and the role that 
these systems play in drag resistance phenomena.
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1. 2. 2 Identification of the ABC transporter superfamily
The identification of the first ABC transporters can be traced back to the 
investigations of Leon Heppel and co-workers into the nature of nutrient uptake in 
Escherichia coli. They noted that osmotically shocked cells exhibited dramatically 
reduced transport rates for certain amino acids, whereas the import of others was 
largely unaffected by this treatment. Subsequent studies revealed that the shock- 
sensitive systems were inactivated due to the loss of periplasmic substrate binding 
proteins (SBP’s) that perform a vital role in the function of these multi-component 
transporters (Heppel, 1969). The shock-insensitive systems on the other hand 
appeared to function independently of SBP’s, their activity being maintained in cell 
free systems such as isolated cytoplasmic membrane vesicles. This led to the idea that 
two distinct classes of transporter were operating in E. coli.
Further evidence for the existence of two distinct types of transporter was gathered 
when the mechanisms of energy coupling in the two groups of transporters were 
investigated (Berger, 1973; Berger and Heppel, 1974). The activity of the shock- 
insensitive transporters was found to be severely inhibited by chemical uncouplers of 
oxidative phosphorylation, whilst the SBP-dependent transporters were able to 
function in the presence of these agents provided that adequate supplies of glycolytic 
substrates were supplied. Together these data suggested to Heppel and others that the 
two groups of transporters operated by fundamentally different principles. The SBP- 
dependent systems required phosphate bond energy in order to drive the transport 
process, whilst the shock-insensitive systems were reliant on the presence of an 
“energised membrane state” which we now know to be the transmembrane ion 
gradients generated via oxidative phosphorylation.
1982 saw a major advance in the study of ATP driven membrane transport when the 
first complete nucleotide sequence of the genes encoding a SBP-dependent transporter 
was deteimined (Higgins et al,, 1982). Once again the breaktlrrough was made in 
studies of amino acid transport in a model prokaryote, in this case the histidine 
transporter of Salmonella typhimurium. The multi-component nature of the SBP- 
dependent transporters was confiimed by the presence of four structural genes 
encoded in a contiguous operon. The first gene in the operon had previously been 
shown to encode the periplasmic SBP, HisJ, whilst the remaining three structural
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genes encoding the HisQ, M and P proteins were thought to form a complex present 
in the cytoplasmic membrane via which the substrate might be translocated. However, 
the sequences of the genes and their presumed protein products did not suggest any 
mechanism by which the transport process might be coupled to ATP hydrolysis.
Another SBP-dependent transport system under investigation at this time was the 
maltose permease of E. coli. This transporter was known to comprise of a minimum 
of five proteins encoded in two clustered but divergently transcribed opérons 
(Raibaud, 1979; Silhavy, 1979). Biochemical data suggested that the E. coli maltose 
transport complex and the histidine transporter of S. typhimurium shared certain 
stractural commonalties. Firstly there was the presence of a high affinity SBP 
encoded by the malE gene. The products of two further genes in this operon, malE 
and malG, were located to the cytoplasmic membrane along with the product of the 
malK gene present in the second operon (Bavoil et aL, 1980). The first suggestion that 
the histidine and maltose transport systems were related at a genetic level came with 
the sequencing of the E. coli malK gene (Gilson et aL, 1982a). The malK. gene 
product was shown to share extensive homology with the HisP protein of S. 
typhimurium by alignment of their respective amino acid sequences. This process 
demonstrated that 32% of the residues occupying equivalent positions in the two 
proteins were identical, whilst an additional 35% represented conservative 
substitutions of similar amino acids (Gilson et aL, 1982b). Interestingly, neither MalK 
nor HisP exhibited a strongly hydrophobic character typical of integral membrane 
proteins, raising the prospect that they were peripherally associated with the transport 
complex. These observations of sequence homology led to the formation of a number 
of key hypotheses regarding the SBP-dependent transporters of prokaryotes. Firstly 
the data suggested that transporters of structurally diverse solutes may have evolved 
from a commoh evolutionary ancestor, and secondly that HisP and MalK might 
perform a conserved function in the two transporters, possibly coupling transport to 
ATP hydrolysis.
In 1985 a third protein sharing significant sequence homology to the HisP and MalK 
proteins was identified. The product of the oppD gene of S. typhimurium was known 
to form one component of the S. typhimurium oligopeptide permease. Once again this 
transporter was encoded by multiple genes and dependent upon a periplasmic SBP.
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Close inspection of the sequences of the three proteins revealed two regions that were 
particularly well conserved. These sequences, now known as the “Walker A” and 
“Walker B” motifs, had previously been identified in a range of non-transport related 
ATP-binding proteins and were believed to contribute to an adenine nucleotide 
binding fold (Walker et aL, 1982). The identification of a consensus nucleotide 
binding motif on these three proteins, each involved in the transport of a different 
substrate, provided strong evidence that ATP was indeed the energy source driving 
the transport process (Higgins et aL, 1985). With all of this indirect evidence in place, 
it was not long before it was unambiguously demonstrated that HisP and MalK were 
capable of binding nucleotide analogues (Hobson et aL, 1984; Higgins et aL, 1985), 
and that ATP hydrolysis occurred during the transport cycle (Bishop et aL, 1989).
As more and more gene sequences were completed, it became apparent that the ATP- 
binding components of the bacterial SBP-dependent transporters were just pait of a 
much larger family of proteins, all of which shared extensive amino acid homology 
along their entire length (Higgins et aL, 1986). Not all of these homologous proteins 
were involved in transmembrane transport. For example, the UvrA protein of E. coli, 
known to be involved in DNA repair, showed a similar level of homology to HisP as 
HisP had shown to MalK (Doolittle et aL, 1986). Despite their various different 
physiological flinctions, all of these proteins were thought to bind and/or hydrolyse 
ATP, and in doing so were providing a means of energy coupling to diverse cellular 
requirements. The ubiquitous nature of these ATPases was further underlined when 
the first eukaryotic homologue was identified, the mammalian multidrug resistance 
protein, P-glycoprotein (Gerlach et aL, 1986).
The term ABC {ATP-Binding Cassette) transporter was first used in 1990 in 
recognition of the similar structure adopted by the ATP-binding domains of the 
transport related proteins (Hyde et aL, 1990). Almost tliirty years on from their 
identification in model prokaryotes, members of the ABC transporter superfamily ai e 
continually being discovered in archea, prokaryotes and eukaryotes alike. It is now 
clear that these proteins catalyse both export and import of solutes across cellular 
membranes of all kinds, and that their substrate specificity can vary from a single ion 
or small molecule to a broad range of large, structurally unrelated, hydrophobic 
molecules. Whilst much attention is currently being paid to those ABC transporters
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implicated in human disease, studies in model bacteria continue to feature heavily in 
the literature. It is of note that the first complete atomic resolution structures of ABC 
transporter core domains have all been from prokaryotic systems, tlie first of them 
being the HisP ATP-binding protein of S. typhimurium (Hung et aL, 1998).
1. 2. 3 Universal distribution of the ABC transporters
Teclmical advances over the last decade in the fields of DNA sequencing and 
bioinformatics have resulted in an extraordinary increase in the rate at which gene 
sequences have been deposited in public databases. The complete sequencing of entire 
bacterial genomes is becoming almost “routine”, with numbers of completed 
sequences growing monthly. Whilst this avalanche of raw data has presented certain 
challenges in terms of data storage, searching and retrieval, it has also spawned the 
new discipline of comparative genomics. Researchers hope that by comparing the 
genomes of two or more different organisms they will be able to extract important 
evolutionary and functional relationships between similar genes. Differences between 
genomes are likely to prove just as instructive, revealing sequences that are important 
in conferring such features as pathogenicity, host range or drug resistance.
The availability of complete genomes from all kingdoms of life has revealed the true 
extent of the ABC transporter superfamily, and the relative contribution that it makes 
to membrane transport as a whole. The ability to identify genes as components of 
ABC transport systems is made relatively simple by the highly conserved nature of 
the ATP-binding cassette (see next section). However, prediction of the physiological 
role of any given transporter is hampered by the lack of sequence conservation 
amongst the membrane-associated components of the transporter complex. The rate at 
which new transporters are being identified tlirough bioinformatic methods is far 
outstripping the ability of researchers to verify computer-generated predictions of 
function by experimental means. Furthermore, in a large number of cases, functional 
assignment is impossible since no experimeiltally verified substrate or physiological 
role has been defined for a particular group of transporters. Nonetheless, a number of 
comparative genomics projects have sought to classify the ABC transporters into 
various families as well as identifying homologous systems across species (Tomii and 
Kaneshia, 1998).
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The complete genome of Escherichia coli K~12 (Blattner, 1997) revealed that genes 
encoding membrane transport systems accounted for almost 1 0 % of the genes present. 
Analysis of the various types of transport systems present indicated that a full 4.9% of 
the genome encoded components of ABC transporters. As such, the ABC transporters 
were found to constitute the largest paralagous family of proteins present in the E. coli 
genome (Linton and Higgins, 1998). Whilst this figure undoubtedly establishes the 
importance of ABC transporters in E, coli, what about other microorganisms? An 
analysis of eighteen complete prokaryotic genomes revealed that whilst the ABC 
transporters were indeed the most numerous of the transport systems as a whole, both 
the total number of transporters in an organism and the relative proportion of 
secondary and primaiy transporters exhibited large variations (Paulsen et a l, 2000). 
For example. Mycoplasma genitalium was found to encode just twenty membrane 
transport systems in total, whilst E. coli and Bacillus subtilis encoded 304 and 265 
respectively. This large variation is not merely a function of genome size since E. coli 
and B. subtilis also exhibited the highest numbers of transport systems per megabase 
of genomic DNA. Paulsen has suggested that the increased transport capabilities of E. 
coli and B. subtilis may allow these organisms to adapt readily to changes in their 
external environment. The ability of these heterotrophs to make full use of all 
available nutrients might contribute to the rapid growth of these organisms in complex 
media. In this respect these commonly studied “model” organisms may not 
necessarily be representative of all prokaryotes.
Paulsen also noted that the relative proportions of ABC transporters and MFS 
transporters within an organism vary in relation to the organisms primary means of 
energy generation. Strict aerobes such as Mycobacterium tuberculosis generate ATP 
via an electron transport chain and subsequent oxidative phosphorylation. This form 
of metabolism generates a strong transmembrane proton gradient that can be used to 
drive secondary transporters directly. Conversely, those organisms with a strictly 
fermentative metabolism (e.g. Mycoplasma genitalium and Treponema pallidum) 
generate ATP via substrate level phosphorylation only. In the absence of strong ion 
gradients these organisms are far more reliant on ATP driven ABC transporters. Thus, 
the nmnber of ABC transporters maintained in the genomes of different organisms is 
likely to vary considerably, variations being a reflection of an organism’s mode of 
metabolism and the ecological niche that it occupies.
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The same bioinformatic methods that are used to identify members of the ABC 
transporter superfamily can also be used to examine the evolutionaiy relationships 
between transporters from different organisms. Such phylogenetic analysis can be 
used to subdivide the large number of transporters into groups based on featuies such 
as sequence similarity and substrate specificity. By comparing the sequences of ATP- 
binding components of ABC transporters from many different species, both 
prokaryotes and eukaryotes, a nmnber of general features have emerged (Saurin et ah, 
1999; Dassa and Bouige, 2001). Firstly, the transporters divide into two broad groups 
based upon their general function i.e. import vs. export (see figure on the next page). 
The family of importers is dominated by prokaiyotic SBP-dependent systems 
exemplified by the E. coli maltose importer. The absence of such nutrient uptake 
systems from eukaryotic genomes probably accounts for the far larger numbers of 
ABC transporters identified in prokaryotes (e.g. 67 in E. coli vs. 29 in S. cerevisiae). 
On the other hand, the export related ABC transporters, have been found in all 
genomes so far analysed. The high level of sequence conservation amongst ABC 
modules involved in both import and export suggests that these proteins are under 
significant evolutionary pressure. The clustering together of homologous systems 
fr om archea, eubacteria and eukaryotes would suggest that these proteins are 
evolutionarily ancient and that the functional division of the ABC transporters into 
importers and exporters took place before the tliree kingdoms of life diverged. The 
only other possible hypothesis consistent with these observations is massive 
horizontal gene transfer between organisms. The fact that ATP-binding proteins 
associated with transport of similar substrates cluster together in these phylogenetic 
analyses is a good indication that sequence similarity is of predictive value in 
assigning function to newly identified ABC transporters. This assertion is 
strengthened when it is considered that, despite a much reduced level of sequence 
homology, a similar clustering of related proteins is observed when the hydrophobic 
components of ABC transporters are considered in isolation (Saurin and Dassa, 1994). 
Saurin has proposed that the many different specificities and architectures of ABC 
transporters have arisen through multiple gene duplication and fusion events.
Phylogenetic analysis reveals that the importers and exporters can each be subdivided 
many times over into groups of closely related transporters sharmg similar function.
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Phylogenetic analysis o f ABC transporter ATP-binding domains
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The phylogenetic tree shown above is taken from Saurin et aL, 1999. The tree clearly 
shows early segregation o f ATP-binding domains into two large families, those 
associated with an export function (blue background), and those associated with an 
import function (pink background). Each large family is then further sub-divided to 
give a total o f 34 distinct ATP-binding domain families, each one associated with the 
transport o f a particular substrate or range o f substrates. A third class o f ATP-binding 
domain is shown in the tree (green background). These proteins are associated with 
non-transport cellular processes such as DNA repair and regulation o f gene 
expression.
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The next section will go on to describe just a few of these groups in order to illustrate 
the many roles of the ABC transporters.
1. 2. 4 Physiological roles of the ABC transporters
The enormous extent of the ABC transporter superfamily precludes an extensive 
discussion of all of the various roles of these transporters. However table 1.8, giving 
just a few examples of well characterised ABC transporters, illustrates the huge 
substrate diversity observed amongst members of this superfamily. Substrates include 
ions, amino acids, oligopeptides, proteins, mono- and disaccharides, lipids, vitamins, 
steroids, pigments and complex carbohydrates. Most of the transporters listed ai*e 
specific for a single substrate or a range of closely related compounds. However a few 
ABC transporters, particularly those mediating export reactions, will transport a 
variety of structurally umelated molecules e.g. mammalian P-glycoprotein or the 
LmrA transporter of Lactococcus lactis. It is btoad-specificity transporters of this kind 
that are most frequently associated with multidrug resistance phenotypes in 
microorganisms and mamihalian cancer cells (see below). Not only do the various 
transport substrates possess markedly different physico-chemical properties, but they 
are also very different in size. Understanding how tire ABC transporters recognise and 
transport such a widely differing array of molecules is one of the key challenges 
facing researchers in this area.
In accordance with their wide range of substrates, the ABC transporters contribute to 
a number of physidlogical processes within a cell. A few of these processes are 
described below using examples taken from table 1.8.
Nutrient untake
The eubacterial and ai cheal SBP-dependent ABC transporters can be thought of as 
low capacity, high affinity transporters that perform a vital scavenging rôle Ibf 
organisms growing and competing in a changing environment (Higgins, 1992). Under 
conditions where nutrients are scarce the potential growth advantage conferred by 
such systems may be significant. For example the energetic cost of de novo histidine 
synthesis is 41 ATP equivalents, whereas the requirements of ABC transporters are 
generally believed to be 1 -2 ATP molecules consumed per transport cycle (Ames, 
1986). The high affinity of the SBP-dependent importers also makes them ideal for
29
VI M 00 CO ^ON o\I—I r—I OO ^ ON
ON
11
Çj Q'Kj -Ki%) %) QCA CA -küA  Ü  %
■gg ' i g |
a  a  S
%
a
II
S
m
O nON
^ 3 :OO ON On r-H
O n
"S  Og I i^  PS ty NI Ph hJ
r s  r-H t n
^  S  8^'—' M ,—I
"S
% % %)
l i î
&O n
NOONO n
S ' ^ON lO
2  ^  ■g
^ T—H "*..<1. \ / <a
' q  --v»'-Ui Q
T:"a  ^III§  .2  Q
1
mON ^  ON r~ r - 4 On ^ On
'S ’q
2P ^
l î
ON
I
1 111f f t■I111i
'M 'â il 'â i
- 9P
o  " a  G  ^^
V u  u î i
I
i )
. 2  3
eut+-4
üI
a
dJ QJ Œ) O O O
%  %  %  
S s 'SV-< Ui Vh 00 00 00IIIi i i
s Ii l
^  Î3i li l
II
§1S %
B" Oo
1 3 I  2  Iîilîi D 23 1 1 1s g 11 1 1
c/>'U ço'G o>cd %
I
I
I"O
L )
' It1
I 11 î
1 t t 1 1 1k3tôCri fij tq fii
(cl:gÇ) % g8  R
1:4 bq %) hq a:) 0 :;
I
8
CO
ailV)
v.q ktq cô
S?i l i
bq Oj fi;
IIî
l î l i ïM i l l i l l I N IP h-4 Ph P-ia R f 6
30
the uptake of essential ions or co-factors that may be veiy scarce in the external 
environment. Examples of such dedicated transporters include the molybdenum 
(ModBC) and vitamin B12 (BtuCD) importers ofE. coli (see table 1.8 for references). 
The large numbers of SBP-dependent systems identified in bacterial genomes account 
for a significant proportion of all known ABC transporters.
Protein export
A number of proteins perform their biological fiinctions extraceliularly. The majority 
of these secreted proteins are synthesized with a cleavable N-terminal leader peptide 
which directs their export via the Sec pathway (Mori, 2001). However, some proteins 
lack the characteristic signal peptide and are thought to be transported via a non- 
classical pathway involving ABC tiansporters. Proteins exported in this Sec- 
independent manner are often associated with ‘secondary’ functions such as 
virulence. The best characterised of these is the haemolysin export ABC transporter of 
E. coli, HlyB (Holland et al, 1990). The hly operon encodes a number of other 
proteins required for production and activation of the toxin, as well as an additional 
protein facilitating passage of the toxin molecule, HlyA, across the periplasmic space. 
Such accessory proteins are commonly required in Gram-negative organisms since the 
transport substrate has to be exported across both membranes that form the cell 
envelope of these bacteria. A phylogenetically related system is utilised by the 
phytopathogen Erwinia chrysanthemi to secrete several extracellular metalloproteases 
involved in the virulence of this organism. It is believed that the secretion signal for 
both HlyA and the E. chrysanthemi proteases lies in a structural motif at the C-termini 
of these proteins (Koronakis et aL, 1989; Binet et aL, 1997).
Export of structural and cell surface components
Both Gram-positive and negative eubacteria produce extracellular structures that they 
present to the external enviromnent. Some of these components ar e khd\\n to be of 
importance in bacterial pathogenicity and interaction with hosts e.g. cells of the 
mammalian immune system. The Gram-positive bacteria possess a thick 
peptidoglycan cell wall interwoven with teichoic acids, whereas the Gram-negative 
bacteria have a much thinner cell wall surrounded by a second membrane, the outer 
leaflet of which consists of lipopolysaccharides (EPS). Additionally, some species of 
bacteria secrete an extracellular' matrix, or capsule, primarily composed of
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carbohydrates. Many of the molecules that make up these extracellular structures are 
synthesised in the cytoplasm and then transported across the plasma membrane by 
dedicated ABC transporters. E, coli is known to produce a nmnber of antigenically 
distinct polysaccharide capsule types, one of which, the K5 serotype, has been well 
characterised. Rigg and co-workers were able to identify as many as twelve genes in 
three closely located opérons that are responsible for biosynthesis and export of the 
capsular carbohydrate. One of the opérons, consisting of the kpsM. and kpsT genes, 
encodes an ABC transporter mediating export of the newly synthesised molecule from 
the cytoplasm. Iimnunolocalisation experiments suggested that the biosynthetic 
proteins and the ABC transporter formed a large macromolecular complex on the 
inner surface of the cytoplasmic membrane (Rigg et ah, 1998). This system is anotlier 
example of genes encoding a biosynthetic function being closely linked to those for 
export of the end product, similar to the E. coli hly operon. Export ABC transporters 
have also been characterised for Lipid A, a major component of Gram-negative LPS, 
and teichoic acids of the Gram-positive cell wall (table 1.8, MsbA and TagGH).
Cellular signalling and differentiation
The Gram-positive organism Bacillus subtilis is one of a number of bacterial species 
that produce hardy spores as a stress response to harsh environmental conditions.
Such a response requires an array of systems that are constantly able to monitor the 
presence of nutrients and the changing state of the external environment. B. subtilis 
encodes an ABC transporter, YbdAB, that is believed to be responsive to external 
conditions and plays a role in the initiation of sporulation. Whilst the exact nature of 
the substrate is unclear, YbdA and B mutations result in decreased spore formation 
and down regulation of a number of genes important in sporulation. These data 
suggest that YbdAB may be a component of, or interact with, cellular signalling 
pathways (Isezaki et ah, 2001).
Members of the genus Rhizobium are nitrogen fixing symbiotic bacteria which form 
nodules on the roots of leguminous plants. The formation of nodules requires 
intercellular signalling between the bacteria and their host. In the case of the rhizobia 
this signalling is mediated by modified sugars (lipo-chitooligosaccharides) known as 
Nod factors. Secretion of these signalling molecules from the cell requires the action 
of an ABC transporter encoded by the nodU genes (Spaink et aL, 1995). Similar to the
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capsular polysaccharide exporter of E. coli, KpsMT, the nodU genes are closely 
linked in the genome to those required for Nod factor synthesis and modification. 
Phylogenetic analysis suggests that these two systems are closely related, possibly a 
reflection of their similar substrate specificities (Reizer et ah, 1992).
Self protection in antibiotic producing organisms
Bacteria of the family Actinomycetales produce a large number of bioactive 
secondary metabolites, many of which are medically useful antibiotics. In many 
instances circumventing the toxicity of these compounds to the organism producing 
them is achieved by the active transport of the antibiotic substance out of the cell. 
ABC transporters are frequently employed as a means of extruding these metabolites, 
maintaining their concentrations at a level below which they become autotoxic 
(Mendez and Salas, 2001). DNA sequencing of antibiotic production loci frequently 
identifies the presence of an ABC transporter associated with the biosynthetic genes, 
many of which have yet to be biochemically characterised. One of the better 
characterised systems is the DrrAB transporter of Streptomyces peucetius. This 
organism produces the anthracycline antibiotics doxorubicin and daunorubicin, both 
of which are used in the treatment of human cancers. The DrrAB pump has been 
experimentally confirmed as a resistance determinant by expressing the genes in a 
heterologous host normally sensitive to the action of these compounds (Kaur, 1997).
Multidrug resistance
The phenomenon of multidrug resistance (MDR) is commonly defined as the ability 
of a cell to withstand doses of more than one drug that are normally lethal to non- 
resistant cells (Brennan, 2001). MDR is of significant clinical importance as a cause 
of chemotheraputic failure in the treatment of bacterial infection and cancer. Research 
into the molecular determinants of MDR in mammalian cells frequently pointed to the 
activity of a 170 kDa plasma membrane protein, known as P-glycoprotein (Pgp), the 
expression of which was found to be amplified in multidrug resistant cell lines 
(Riordan et ah, 1985). When the gene for Pgp (MDRl) was cloned it was found to 
bear significant homology to bacterial transport genes that we now know encode 
members of the ABC transporter superfamily (Gerlach et ah, 1986). Since its 
discovery Pgp has been the focus of extensive research. Whilst most ABC 
transporters are relatively specific, Pgp has been shown to pump an array of diverse
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molecules including anthracyline antibiotics, vinca alkaloids and paclixatel, all of 
which are used in the treatment of cancer (Dean, 2001). Interestingly, Pgp has been 
shown to pump drugs directly from the iimer leaflet of the plasma membrane, rather 
than from the cytoplasm suggesting that this transporter may interact with its 
substrates on the basis of their hydrophobicity (Shapiro and Ling, 1997), Normally 
expressed in the liver and at the blood-brain barrier, a full characterisation of the 
natural substrates of the MDRl gene product has yet to be completed. However, we 
now know that MDRl is just one of a multigene family in humans, several of which 
are involved in the cellular transport of hydrophobic compounds such as 
phospholipids (MDR3) and bile salts (van Helvoort et al., 1996; Borst et al,, 2000). It 
has been suggested that the ability of this family to confer multidrug resistance upon 
cells may be a result of cross-specificity towards many different hydrophobic 
molecules.
MDR phenotypes are not limited to human cancer cells. Analogous systems operate in 
lower eukaryotes and prokaiyotes. The best characterised of the prokaryotic ABC 
transporters conferring multidrug resistance is the LmrA pump of Lactococcus lactis. 
Identified by van Veen in 1996, LmrA shows remarkable conservation of both 
sequence and function with mammalian Pgp (van Veen et aL, 1996). Similar to Pgp, 
LmrA is known to extrade multiple, structuially unrelated, hydrophobic drugs directly 
from the cytoplasmic membrane and has proven to be of great use as a bacterial 
model of Pgp function (van Veen and Konings, 1997). Homologues of LmrA have 
been identified in a number of pathogenic and non-pathogenic bacteria raising the 
prospect that broad-substrate multidrug resistance determinants may be widely 
distributed amongst prokaryotes (van Veen and Konings, 1998). This fact has 
significant implications for the future effectiveness of antibiotic treatment of human 
infections.
Yeasts have frequently been used as model organisms in the study of eukaryotic 
cellular processes. The phenomenon ofpleiotropic drug resistance (PDR) in yeast is 
essentially analogous to mammalian MDR. PDR is dependent upon a complex 
network of interacting proteins and genes which combine to control the expression of 
a variety of ABC transporters. At the heart of this network are the S. cerevisiae PdrSp 
and Snq2p ABC transporters, homologues of Pgp, which have been shown to confer
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resistance to literally hundreds of diverse drugs including the important azole class of 
antifungals. Importantly, homologues of Pdr5p have been identified in opportunistic 
pathogenic yeasts such as Candida albicans. Cryptococcus neoformans and 
Aspergillus nidulans. As such, these pumps have the potential to give rise to clinical 
drug resistance (Bauer et ah, 1999). Additionally, work in our laboratory has recently 
identified two ABC transporters from the thermally dimorphic fungal pathogen 
Paracoccidioides brasiliensis. Expression of the genes encoding these transporters is 
upregulated in response to exposuie to azole antifungals, strongly suggesting a 
potential function as drug resistance determinants (Gray et a l, 2003).
Intracellular transport
A number of eukaryotic ABC transporters are associated with intracellular 
membranes. This is perhaps unsurprising given the proposed evolution of modern-day 
organelles from putative endosymbiotic bacteria. The first mitochondrial ABC 
transporter to be identified was the Atm Ip transporter of S', cerevisiae. This protein is 
believed to function as mitochondrial exporter, probably transporting chelated Fe/S 
clusters synthesised in the mitochondrial matrix and subsequently utilised by cytosolic 
enzymes (Till and Kispal, 2001). A human homologue of Atm Ip, ABC7, has been 
linked with inherited X-linked sideroblastic anemia, a disease characterised by the 
abnormal accumulation of iron within mitochondria (Allikmets et ah, 1999). Thus, 
ABC transporters appear to play an important role in iron homeostasis in both yeast 
and humans.
Mutations in one of thiee peroxysomal ABC transporter genes gives rise to the 
disease X-linked adrenoleukodystrophy. This is a neurodegenerative disorder 
characterised by defective oxidation of very long-chain fatty acids, a process that is 
initiated in the peroxysome. This suggests that the ALDP ABC transporter may play a 
role in transporting fatty acids into the peroxysome (Liu et ah, 1999). Interestingly the 
ATP-binding domains of the ALDP transporter are exposed to the cytosol rather than 
the interior of the peroxysome. This finding suggests that transport into the 
peroxysome is functionally equivalent to an export reaction taking place at the cell 
surface (Contreras et ah, 1996). The best characterised of the human intracellular 
ABC transporters is the transporter associated with antigen processing (TAP). This 
ER-resident protein is responsible for transporting viral or bacterial peptides fi-om the
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cytosol into the lumen of the ER where they are complexed with MHC class I 
molecules. The antigen-MHC complex is then trafficked from the ER to the cell 
surface where the foreign antigen is presented to the cellular immune system (Lankat- 
Buttgereit and Tampe, 2001).
CFTR - An unusual transporter
In addition to TAP and Pgp another human ABC transporter has become the focus of 
significant research attention, the Cystic fibrosis transmembrane conductance 
regulator (CFTR). Mutations in this gene are a major cause of the most common 
inherited disease amongst Caucasians, cystic fibrosis (CF). Cloning of the CF gene 
showed it to be a member of the ABC transporter family, and yet a significant body of 
evidence had built up suggesting that CF was caused by a defect in epithelial cell 
chloride ion regulation (Riordan et aL, 1989). We now know that CFTR is an unusual 
member of the ABC transporter superfamily in that it operates as an ATP-regulated 
channel, rather than a transporter per se. The passage of chloride ion across the apical 
membrane of epithelial cells via CFTR is not dependent upon stoichiometric ATP 
hydrolysis. However, the open/closed state of the channel is thought to be influenced 
by ATP binding as well as the action of intracellular kinases and phosphatases that 
interact with the CFTR protein (Gadsby and Nairn, 1999). It remains to be seen 
whether other ‘apparent’ ABC transporters are in fact nucleotide gated ion-channels.
1. 2. 5 Structural organisation of the ABC transporters
After thirty years of research we now understand the ABC transporter complex to be 
highly modular in nature, with the generally accepted model consisting of four “core” 
domains (Higgins et aL, 1992). Firstly, two hydrophobic domains span the membrane 
multiple times and contribute to a transmembrane pathway via which solutes are 
transported fi'om one side of the membrane to the other. These integral membrane 
components of the complex are thought to possess one or more substrate binding sites 
which affect the specificity of the transporter. The transmembrane topology of these 
domains gives rise to their description as ‘membrane-spanning domains’ or MSD’s. 
The remaining components of the complex are two relatively hydrophilic domains 
that bind and hydrolyse ATP, providing energy for the transport process. These two 
‘nucleotide-binding domains’, or NBD’s, are closely apposed to the MSD’s at the 
cytoplasmic face of the membrane barrier. The NBD’s contain the highly conserved
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ATP-binding cassette that lends its name to this class of transporter. This minimal 
model of the ABC transporter complex is illustrated in figure 1.9. No ABC 
transporters have yet been identified that are able to function without this minimal 
complement of four domains.
Figure 1.9 -  The four core domains of an ABC transporter
MSD1 MSD2
Membrane bilayer
The arrangement illustrated in figure 1.9 indicates the situation most commonly 
encountered in prokaryotic systems, each of the four domains being encoded 
separately and the overall complex formed by four distinct polypeptide chains. 
However, in many cases, particularly in eukaryotic systems, two or more of the 
domains may be fused together and encoded by a single gene. This situation is 
exemplified by the mammalian MDRl gene, the product of which, P-glycoprotein, is 
a single multidomain polypeptide. Another common arrangement of domains, once 
again prominent in eukaryotic systems, is the so-called half-transporter. In these 
cases a single gene encodes a two-domain protein in which one MSD is fused to a 
single NBD. In fact, examples of virtually all conceivable arrangements of MSD and 
NBD have been identified amongst members of the ABC transporter superfamily, a 
few examples of which are illustrated in figure 1.10.
Genetic loci encoding ABC transporters may initially seem to contain fewer genes 
than necessary to account for all four core domains of the functional transport 
complex. For example, the core of the well-characterised S. typhimurium histidine 
importer is encoded by just 3 genes, a NBD encoded by hisV, and two MSD’s 
encoded by hisQ and hisM. In such cases experimental evidence suggests that one of
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the domains, in this case the NBD, operates as a homodimer, thereby generating the 
complete four domain structure (Kerppola et aL, 1991). A similar situation exists 
regarding the maltose transporter of E. coli where only one NBD gene is present in 
the mal operon (Kennedy and Traxler, 1999). It should be noted that whilst both the 
histidine and maltose transporters are SBP-dependent systems, the SBP itself is 
reversibly associated with transport complex and does not constitute one of the four 
core domains. Hal ft transporters, such as the LmrA multidrug transporter of L  lactis, 
only possess two of the four domains required for a functional transport complex. 
Consequently, these proteins must dimerise in order to complete the structure of the 
transporter. Such systems may be homodimeric, as in the case of LmrA, or even 
heterodimeric through combination with another half-transporter encoded elsewhere 
in the genome e.g. the Tapl/Tap2 transporter (van Veen et aL, 2000; Antoniou et aL, 
2002).
Figure 1.10- Molecular architectures of the ABC transporters
B
D E .
Shaded rectangles 
represent MSD’s
Un-shaded ovals 
represent NBD’s
A = HisQMP] All modules encoded individually
B = RbsAC Fused NBD’s
C = P-glycoprotein All 4 domains fused, single polypeptide
D = HylB Homodimeric half-transporter
E = CFTR 4 fused domains plus regulatory domain
F = FhuBC Fused MSD’s
After its initial proposal, and in the absence of high resolution structural data, various 
biochemical and genetic means were used to test and refine the four domain
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hypothesis. For example, the use of computer algorithms to predict the topology of 
MSB’s, backed-up by experimental teclmiques such as epitope mapping, suggested 
that each MSB contributes six membrane-spanning regions to the translocation 
pathway, a total of twelve forming the overall complex (Pearce et aL, 1992;
Gentschev and Goebel, 1992). By analogy with the archetypal membrane protein 
bacteriorhodopsin, the membrane-spanning segments were predicted to be a-helical in 
nature. The basic 4 domain model has also come to be known as the ‘two-times-six’ 
model.
Unsurprisingly amongst such a large class of proteins, a number of ABC transporters 
exhibit deviations horn the four domain, two-times-six model. For example, the malF 
encoded MSB of the E. coli maltose importer seems to possess eight membrane- 
spanning segments. However, deletion of two of the a-helices at the N-terminal of 
this protein can be achieved without affecting maltose accumulation. It has been 
suggested that these additional helices may form a separate domain, not directly 
involved in transport, perhaps facilitating membrane insertion, packaging of the 
helices or correct orientation of the protein within the membrane (Froshauer et aL, 
1988). CFTR, the mammalian chloride channel, possesses an additional fifth domain 
present between the first NBB and second MSB of tliis multidomain protein (figure 
1.10). Reversible phosphorylation of this so-called ‘R-domain’ is thought to play an 
important role in regulating the function of the channel (Gadsby and Nairn, 1999). In 
fact, an entire sub-family of human ABC transporters, the MRP (multidrug resistance 
protein) family, possess an additional N-tenninal membrane-bound domain known as 
TMBO. Bakos and colleagues were able to demonstrate that TMBO contains as many 
as four or five transmembrane a-helices that do not directly participate in substrate 
transport (Bakos et aL, 1998). The presence of additional domains, even relatively 
large ones such as TMBO, do not seem to affect the core function of ABC 
transporters. These domains have probably evolved much later in evolutionaiy time, 
performing some specific role related to individual transporters.
As the various structural and functional models of ABC transporters were tested, a 
great deal of biochemical and genetic data were accumulated in order to understand 
how the various domains of the transporter contribute to its function. Site-directed
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mutagenesis and deletion experiments were particularly important in defining regions 
and sub-domains of the transporter involved in key processes such as ATP binding, 
substrate binding and protein-protein interactions. The following sections will go on 
to describe what is known about the individual components of the transporter 
complex, and how recently available structural data have shed light on how the 
various components interact to transport such a diverse array of molecules.
1.2.6  Conserved Sequences within the NBD
The central role of the NBD within the ABC transporter complex is to bind and 
hydrolyse ATP, thereby providing the energy required for the transport of solutes 
against potentially large concentration gradients. Wlien two ABC transporters are 
compared, the NBD’s are invariably the most highly conserved modules. Levels of 
identity ranging from 30% to 50% are commonly observed between NBD’s from 
evolutionarily diverse sources, much of this homology lying within a 215-230 amino 
acid region that comprises the ATP-binding cassette. Some of the most highly 
conserved and intensely studied regions of the NBD are described here.
The Walker A sequence is a glycine-rich motif with the consensus sequence 
GxxGxGKS(T), where G represents glycine, x any amino acid and the final position 
being occupied by either serine or threonine (Walker et aL, 1982). Present in a variety 
of nucleotide-binding proteins, residues within the Walker A motif are key to 
stabilising interactions between the protein and the bound nucleotide. The Walker A 
residues form a loop around the tri-phosphate moiety of the nucleotide and extensive 
hydrogen bonding interactions occm* between main-chain nitrogen atoms of the 
protein and oxygen atoms in the p- and y-phosphate groups of the NTP. Alternatively 
known as the phosphate or P-loop, this structur e has been identified in a variety of 
non-transport related proteins including proto-oncogene rasP21, RecA and the F I- 
ATPase (Saraste et aL, 1990). The fine crystal structure of HisP, the NBD of the S. 
typhimurium histidine ABC transporter, indicates an identical role for the Walker A 
motif in the ABC transporters (Hrmg et aL, 1998).
The Walker B motif is always found further towards the C-terminal of the protein 
than Walker A. The consensus sequence of this motif is far less rigid than that of
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Walker A, but generally conforms to ‘ffffD’ where f  represents a hydrophobic amino 
acid and D is a highly conserved aspartic acid residue. The role of the Walker B 
motif, and the aspartic acid residue in particular, is to co-ordinate a Mg^^ ion in the 
active site of the NBD. This Mg^ "^  ion plays a vital role in catalysing ATP hydrolysis. 
Together the Walker A and B motifs constitute a nucleotide-binding fold present in 
many nucleotide-binding proteins. Mutations of the residues within these highly 
conserved sequences have differing effects, but are in general poorly tolerated and 
often lead to the loss of ATP binding and/or hydrolysis. This is particularly true of the 
lysine residue in Walker A and the aspartate of Walker B (Schneider and Hunke,
1998).
Whilst the Walker motifs are present in many different classes of proteins, the NBD’s 
of ABC transporters possess a third highly conseiwed motif that is unique to the ABC 
transporter superfamily. The so-called ‘ABC signature sequence’ or Tinker peptide’ is 
found between the Walker A and B motifs, immediately upstream of Walker B. The 
general consensus of this ABC tiansporter specific sequence is ‘LSGGQ’ and has 
proven to be of use in identifying new members of the ABC transporter superfamily 
(Higgins et aL, 1988), The residues between Walker A and B in the primary structure 
of NBD’s are thought to form a separate a-helical sub-domain that folds 
independently of the nucleotide-binding core. Recently published NBD crystal 
structures, such as that of MJ0796 ATP-binding cassette, support the presence of this 
helical domain (Yuan et aL, 2001). Specific mutations within the signatme sequence 
of CFTR have been linked to cystic fibrosis, clearly suggesting that this motif plays 
an important role in the flmction of the protein (Welsh and Smith, 1993). The exact 
role of the helical domain and the signature sequence within it have been the source of 
some controversy and will be discussed in the context of recently derived crystal 
structures.
A number of shorter regions of homology, sometimes consisting of only one or two 
highly conserved residues, have been described. One such motif is known as the 
‘switch region’. An invariant histidine residue is present at the end of this motif, 
mutation of which has been shown to destroy the transport capabilities of a vaiiety of 
ABC transporters, for example the S. typhimurium histidine permease. Mutations in
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the switch region do not affect ATP hydrolysis by the NBD, suggesting that residues 
in this region play some alternative yet vital role in the transport cycle. It has been 
proposed that the switch region may operate as a signal transduction domain, 
propagating conformational changes induced by ATP hydrolysis to different 
components of the complex (Shyamala et aL, 1991).
1. 2. 7 Biochemical properties of the NBD
Demonstration that NBD’s of ABC transporters are able to bind and hydrolyse ATP, 
concomitant with transport, was a key stage in understanding how substrate 
translocation is powered. Conformational changes occurring in the nucleotide-binding 
domains of ABC transporters during their catalytic cycle are of central importance in 
driving substrate translocation. These changes are induced by ATP-binding and 
hydrolysis and propagated to components of the translocation pathway through inter­
domain interactions. The biochemical parameters of ATP hydrolysis and the nature of 
conformational change have been studied extensively using both isolated NBD’s and 
intact transport complexes.
Studying the biochemistry of ABC transporters is dependent upon the ability of 
researchers to develop systems for their expression and purification. This has been by 
no means routine since ABC transporters are natirrally present in low abundance 
within the membrane, and recombinant systems for the overexpression of these 
proteins often result in the production of insoluble, inactive protein (Wang et aL,
1999). The production of stable, soluble protein that maintains its biological activity 
has been the limiting factor in the study of many ABC transporter systems. This is 
particularly true with respect to structural determination using biophysical techniques 
such as X-ray ciystallography and NMR which require relatively large amounts of 
highly pure protein (Duffieux et aL, 2000),
Biochemical data regarding the activity of both isolated NBD’s and intact transport 
complexes has been accumulated for a number of systems including the prokaryotic 
histidine and maltose importers, and the medically important eukaryotic systems of P- 
glycoprotein and CFTR (Schneider and Hunke, 1998). The affinity of ABC 
transporters for ATP, as measured by their Michaelis constants, vary considerably, as 
do the maximal rates of ATP hydrolysis. Expressed in the absence of their cognate
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MSD’s, purified NBD’s frequently exhibit a spontaneous, constitutive ATPase 
activity (Nikaido et aL, 1997; Morbach et al., 1993). For reasons described below, 
this constitutive activity is unlikely to be a true reflection of the behaviour of NBD’s 
in the intact transporter complex and care should be taken in inteipreting results 
derived hom experiments using isolated components.
Using the well-characterised histidine permease of Y typhimurium as an example, the 
ATPase activity the of NBD’s is under somewhat tighter control. Purified HisP has an 
intrinsic rate of ATP hydrolysis that is not exhibited by the intact transporter complex. 
This observation suggests that the membrane-spanning components of the transporter 
complex impose a negative regulation upon the ATPase activity of the NBD.
Negative regulation is only removed and ATP hydrolysis initiated when the 
transporter is able to interact with histidine, liganded by the SBP HisJ (Liu and Ames, 
1997). The necessity for such down regulation of constitutive activity becomes 
apparent in a physiological context. Unless controlled, the NBD’s of ABC 
transporters would continually hydrolyse intracellular supplies of ATP in an 
unproductive fashion. Such regulation in the intact transporter complex is indicative 
of a series of inter-domain signalling processes. Firstly, histidine-liganded HisJ is 
present in the periplasmic space, yet ATP hydrolysis is initiated by the NBD’s which 
are located at the interior face of the membrane. Interaction between the transporter 
complex and the loaded SBP must take place at the exterior face of the complex, 
implying the presence of a substrate binding site in the MSD’s of the transporter. 
Secondly this interaction must somehow be transmitted to the NBD’s which then 
hydrolyse ATP and set in motion the conformational changes required to transport the 
released histidine molecule from one side of the membrane to the other. An 
essentially analogous series of events has been proposed by Davidson and colleagues 
regarding the activity of the E. coli maltose transporter (Davidson et aL, 1992).
Induction of ATP hydrolysis tlii'ough interaction with a substrate is not restricted to 
the prokaryotic nutrient uptake ABC transporters. A similar phenomenon is also 
observed in the mammalian multi drug transporter P-glycoprotein. The rate of ATP 
hydrolysis by the NBD’s of P-glycoprotein is stimulated several times over when the 
transporter is exposed to a number of the drugs that it expels (Scarborough, 1995). 
Once again these interactions are only observed when all four domains of the
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multidomain transporter are reconstituted together. When only two of the foui* 
domains are expressed a basal level of ATPase activity can be measured, but this 
activity is not stimulated by drugs (Loo and Clarke, 1994). It seems that the ATPase 
activity of P-glycoprotein is regulated in a similar manner to that of bacterial nutrient 
importers, and that interaction between transporter and substrate occurs via the 
MSD’s.
Conflicting evidence exists as to whether the NBD’s are able to interact directly with 
the substrate of the transporter. For example, the ATPase activity of puiifîed HisP is 
largely unaffected by free histidine, the SBP HisJ, or the histidine-HisJ complex. Nor 
are the activity of P-glycoprotein NBD’s affected by the presence of drugs when they 
are expressed in isolation. However, Buche and colleagues have presented data 
showing a direct interaction between a purified NBD and its transport substrate. OleB 
constitutes the NBD of a multi-component ABC transporter fiom the antibiotic 
producing organism Streptomyces antibioticus, OleB binds directly to the transport 
substrate, oleandomycin, the antibiotic produced and secreted by S. antibioticus 
(Buche et al., 1997). Another recent example is the Pot A NBD of the E. coli 
spermidine-preferential uptake system. Kashiwagi and co-workers have shown that 
the ATPase activity of PotA decreases in the presence of the substrate, spermidine, 
and that this interaction takes place specifically with a C-teiminal region of the 
protein. This mechanism has been proposed as a form of feedback inhibition imposed 
upon the activity of the transporter, mediated via the NBD’s (Kashiwagi et aL, 2002). 
Wliilst observations of direct interactions of this kind are uncommon, they do perhaps 
suggest that different types of ABC transporter may interact with their substrates in 
differing ways. This is maybe unsurprising when it is considered that some ABC 
transporters are importers, some export molecules from the lipidic environment of the 
membrane interior, and others still export molecules directly from the cytoplasm.
Obviously the NBD must be able to bind and hydrolyse ATP. However, these 
domains also commonly exhibit an affinity for other nucleotide triphosphates 
including GTP, CTP and UTP. In general the affinity for these other molecules is 
lower than that shown towards ATP, and the accompanying rate of hydrolysis is 
usually significantly lower. Nonetheless, the ability of NBD’s to utilise alternative 
NTP’s is indicative of at least some degree of conformational flexibility within their
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highly conserved stmctiu'e. A number of inliibitors of ATP hydrolysis have been 
found to interact directly with NBD’s. Many ABC transporters are strongly inhibited 
by the presence of ortho-vanadate at micromolar concentrations. The mechanism of 
inhibition by vanadate involves the trapping of an ADP molecule in the active site of 
the NBD. Unable to exchange ADP out of the active site, all subsequent steps in the 
binding and hydrolysis cycle of the NBD are blocked (Urbatsch et aL, 1995). Another 
inliibitor known to act directly on the NBD is N-ethylmaleimide (NEM). This 
molecule covalently modifies the free sulphydril group present on cysteine residues.
A number of ABC transporters, ineluding P-glycoprotein, possess a cysteine residue 
in, or close to, the Walker A motif of the NBD. By modifying this Walker A cysteine, 
NEM is able to block the access of ATP to the catalytic active site of the protein (Al- 
Shawi et aL, 1994). Replacing the reactive cysteine by mutagenesis or preincubating 
the protein with high concentrations of ATP have both been shown to protect P- 
glycoprotein from the effects of NEM. Perhaps the most unusual inhibitor identified 
to date is the macrolide antibiotic Bafiliomycin A l. Shown to inhibit the activity of 
intact transport complexes such as P-glycoprotein and the S. typhimurium maltose 
importer, the mechanism of inhibition by this molecule is yet to be elucidated 
(Sharom et al., 1995; Hunke et al., 1995). In some instances both dinucleotides, such 
as ADP, and non-hydrolysable nucleotide analogues, such as ATPyS, will act as 
competitive inhibitors of ATP hydrolysis (Urbatsch et al., 1994).
The binding and hydrolysis of nucleotides by the NBD are thought to induce a series 
of conformational changes within the transporter complex that are central to the 
transport mechanism. A number of techniques have been used to probe these changes, 
but perhaps the most commonly used is fluorescence spectroscopy. The fluorescence 
of individual tryptophan residues within the structure of a protein are uniquely 
sensitive to the immediate environment surrounding them. Thus, as the global 
conformation of the NBD is altered through interaction with nucleotides, so the local 
environment of individual tryptophan residues changes. Typically, tryptophan 
residues exposed to the aqueous environment exhibit a lower fluorescence yield than 
those buried in the interior of the protein. This arises because buried residues are less 
susceptible to the effects of collisional quenching by surrounding water molecules. 
Additionally, the maximum wavelength of tiyptophan fluorescence may also be blue-
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shifted as residues move towards a less polar environment. This technique has been 
used to demonstrate confonnational changes in the structure of the -helical domain 
of MalK, a region of the molecule thought to be of importance in interactions with the 
MSD’s of the complex (Schneider et al,, 1994).
One of the major questions regarding the NBD’s of ABC transporters is not how they 
interact with inhibitors, transport substrates or ATP, but whether or not the two 
NBD’s present in the intact transporter complex interact with one another.
Conflicting data have emerged for different transporters, dependent upon 
whether isolated NBD’s are studied or complete transporter systems. However, the 
emerging consensus, supported by recent structural data, is that in the complete 
membrane-associated structure of the ABC transporter, the two nucleotide binding 
domains interact with one another and that this interaction is intimately linked with 
the transport mechanism. In their studies of purified HisP, Nikaido and colleagues 
proposed that the active form of this NBD was most likely to be a dimer, consistent 
with two copies of HisP being present in the functional transporter complex HisQMPa 
(Nikaido et al,, 1997). Positive cooperativity for ATP hydrolysis between the two 
NBD’s was also observed in the maltose transport complex MalFGKz (Davidson et 
al,, 1996). Further evidence supporting interaction between the two NBD was 
presented for P-glycoprotein on the basis of inlhbitor studies. Urbatsch and colleagues 
showed that vanadate-induced nucleotide trapping in the active site of one NBD 
completely inhibits transport, suggesting that neither NBD can drive transport 
independent of the other, and also that the two NBD’s are mechanistically linked 
(Urbatsch et al., 1995). Interestingly, purified MalK is insensitive to the action of 
vanadate whereas the mature transport complex is strongly inhibited. It is possible 
that the action of vanadate is dependent upon the formation of the complete 
transporter complex. The necessity for two functional NBD’s has also been 
demonstrated using genetic means. Mutations in either one of the two Walker A 
motifs present in the NBD’s of P-glycoprotein completely abrogated the biological 
activity of the protein (Azzaria et al., 1989). A similar requirement for two completely 
functional NBD’s has been demonstrated for the MalFGK2 transporter and the Ste6p 
a-pheromone transporter of yeast (Davidson and Sharma, 1997; Berkower and 
Michaelis, 1991). In addition to biochemical and genetic suggestion that the two ABC 
transporter NBD’s interact with one another mechanistically, physical interaction of
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the two domains has been demonstrated. Chemical cross-linldng agents can be used to 
identify residues in close proximity to one another. Such agents demonstrated that 
both MalK subunits of the maltose importer are in close proximity with one another 
and with the two MSD’s, MalF and MalG. Moreover, upon the addition of 
nucleotides, the relative positions of the various components were found to shift, as 
reported by a change in the pattern of chemical cross-linking. These results strongly 
support the idea that the two NBD’s of ABC transporters are closely linked, and that 
nucleotide binding/hydrolysis is accompanied by global conformational changes in all 
components of the transporter (Hunlce et al., 2000).
The stoichiometric coupling of ATP hydrolysis and substrate translocation has been 
investigated. Some estimates have suggested that as many as fifty ATP molecules 
might be necessary to drive the export of a single molecule of the dye Hoechst 33342 
by P-glycoprotein (Shapiro and Ling, 1997). However, such a high ATP requirement 
seems rather unlikely. As progress has been made in the development of artificial 
systems for reconstituting complete ABC transporters, the estimates of ATP 
requirement have steadily been revised downwards. Current best estimates place the 
number of ATP molecules hydrolysed per transport cycle at between one and two 
(e.g. see Patzlaff et al., 2003). Such estimates are far more consistent with the 
presence of two NBD’s per transporter.
All of these various biochemical and genetic data have been used to propose a number 
of models which link the events of nucleotide binding and hydrolysis to the process of 
substrate translocation. The mechanistic details of these various models are beyond 
the scope of this introduction and are reviewed elsewhere (van Veen et al., 2001; 
Senior et al., 1995). The details of the schemes differ for the various proteins for 
which models have been presented. Whilst the conserved four domain structure of the 
ABC transporters would imply a conseiwed mechanism of transport, this may not 
necessarily be the case. CFTR is a prime example of a protein that to all intents and 
purposes resembles an ATP driven transporter, yet functions as a nucleotide-gated ion 
channel. Consequently it is possible that the alternative models proposed for different 
transporters represent genuine differences in the mechanisms of these transporters, 
rather than an incomplete understanding of the processes taking place.
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1.2.8 3D Structure of the NBD
Until relatively recently, high resolution structural data for nucleotide binding 
domains has been scarce. This is perhaps a reflection o f the difficulties encountered in 
producing the large quantities o f highly purified, soluble protein required for the 
initiation o f crystallisation trials. However, exhaustive efforts by a number o f groups 
and modem techniques for high-throughput expression/purification/crystallisation 
have yielded crystals o f several isolated NBD’s. These have in turn allowed the 
structure o f the NBD’s to be solved by X-ray crystallography.
The first fully described structure o f an ABC transporter NBD was that o f the HisP 
protein from Salmonella typhimurium, published in 1998 by Kim and colleagues 
(Hung et al., 1998). The molecule was shown to adopt an overall ‘L-shape’ with two 
distinct arms. Arm-I, as it is described in the original publication, is a domain 
composed o f a mixture o f a-helices and P-sheets and contains the invariant residues 
o f the Walker A and Walker B motifs. The overall fold in this region o f the molecule 
strongly resembles the nucleotide-binding core or the FI-ATPase. Interposed between 
the Walker A and B sequences is a separate, predominantly a-helical, subdomain.
This region forms Arm-ll o f the L-shaped structure and is unique to the NBD’s o f  
ABC transporters. Furthermore, it is this region o f the molecule that contains the 
residues o f the ABC signature sequence. Crystallised in the presence o f 10 mM ATP, 
the bound nucleotide is clearly visible within the structure o f HisP, and as predicted 
interacts strongly with the residues o f the Walker A sequence. The structure o f the 
HisP monomer, showing Arm-I, Arm-II and the position o f the bound nucleotide is 
illustrated in figure 1.11 below.
Figure 1.11 - The HisP monomer
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The completion of crystal structures for a number of other ABC transporter NBD’s, 
including MalK from the archeon Thermococcus litoralis and two from 
Methanococcus jannaschii, establishes the validity of the two domain stmcture 
observed in the HisP monomer (Diederichs et al., 2000; Karpowich et al., 2001; Yuan 
et al., 2001). Comparison of nucleotide-free and ADP bound forms of the M. 
jannaschii NBD’s MJ0796 and MJ1267 with the ATP bound structure of HisP led the 
authors to propose that a series of intramolecular conformational changes occur 
during nucleotide hydrolysis. It is proposed that these changes result in movement of 
the two domains with respect to one another and that they may facilitate nucleotide 
exchange in and out of the catalytic site.
Whilst intramolecular conformational changes within the NBD may be important 
during the ATP binding/hydrolysis cycle, it is unlikely that these changes are, on their 
own, large enough to drive substrate translocation via the MSD’s of the intact 
transporter complex. Rather, it is interactions between the modules of the transporter 
that are believed to drive transport. Biochemical data has long suggested that the two 
NBD’s of ABC transporters interact not only with the MSD’s, but also with one 
another (Jones and George, 1999; Fetsch and Davidson, 2002). The publication of the 
various NBD structures has raised a number of questions regarding details of any 
interaction between the two NBD’s, and also raised the possibility that NBDiNBD 
interactions may differ between transporters.
When expressed and purified independently of the other components of an ABC 
transporter complex, NBD’s are monomeric. This is true for HisP, MalK and the MJ 
NBD’s. Even in the presence of ATP, stable NBD dimers have yet to be purified in 
the absence of MSD’s. It is against this background of either weak or transient 
interaction between isolated NBD’s that the crystal structures of the NBD’s must be 
considered. For example, the crystallographic unit cell of HisP contained a dimer, 
with the two L-shaped molecules oriented in a ‘back-to-back’ manner and the 
nucleotide-binding folds facing away from one another (sees figure 1,12 below). In 
the view of the dimer shown below, it is the upper surface of the dimer that is 
proposed to interact with the MSD’s.
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Figure 1.12-  The HisP dimer
The dimer observed in the MalK crystal structure is however very different from that 
in HisP. In the MalK dimer the two nucleotide- binding folds are facing one another, 
and the monomers contribute to a much more compact, interlocking structure. Unlike 
the HisP dimer, the two subunits o f the MalK dimer are not related by a perfect 180° 
two-fold symmetry. The MalK dimer is shown below in figure 1.13, and as with HisP, 
the dimer surface proposed to interact with the MSD’s is shown uppermost. Each 
monomer is shown in a different colour.
Figure 1 .1 3 -  The MalK dimer
The enormous amounts o f biochemical data obtained with respect to both the maltose 
transporter and the histidine transporter can be pressed into service in defence o f both 
of these possible dimérisation models. However, perhaps the best dimer model for the 
relevant physiological NBD:NBD interaction is based upon ABC domains not from a
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transporter, but from a DNA repair protein called Rad50. The structure o f the Rad50 
dimer o f Pyrococcus furiosus is illustrated below (Hopfner et al., 2000). Each 
monomer is coloured differently, and 2 bound ATP molecules are shown in green.
Figure 1 .1 4 -  The RadSOcd dimer
A n iK l l
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Note that in the Rad50 dimer structure, the bound ATP is present at the dimer 
interface. In fact ATP is not only bound by residues o f the Walker A and B motifs 
from one NBD monomer, but also by residues present in the signature sequence motif 
of the opposite NBD. This observation is consistent with the fact that unlike other 
NBD’s the Rad50 dimer forms and remains stable in the presence o f  ATP and its 
analogues (Hopffier, et al., 2000). The interlocking domain structure is more similar 
to that observed for the MalK dimer than for HisP. It has been suggested that the 
MalK and HisP dimers observed in their respective crystal structures are artifactual, 
that is they do not represent physiologically relevant dimers but form in response to 
intermolecular forces present within the crystal. As discussed in the final section o f  
this chapter, the RadSO type NBD:NBD interaction has received significant 
experimental support with the publication o f the complete structure o f the BtuCD 
transporter.
1. 2. 9 The membrane-spanning domains
The membrane-spanning domains o f ABC transporters have been far harder to study 
than their cognate N BD’s. Naturally present at low levels, significant difficulties
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surround purification of membrane proteins fi om the far more abundant and 
numerous cytoplasmic proteins. Added to this problem is the fact that genetic systems 
designed to overexpress cytoplasmic proteins are far less efficient at overexpressing 
membrane proteins. Purification of membrane proteins necessitates their removal 
from the membrane environment, a process which requires the use of mild detergents. 
Such detergents may not sufficiently stabilise the structure of the protein which can 
lead to aggregation or disruption of the protein’s native structure. Despite these 
technical challenges regarding the study of membrane proteins in general, significant 
progress has been made in understanding the contribution of the MSD’s to the 
function of the ABC transporter complex.
Primary amino acid sequence data is of little use in predicting the detailed function of 
ABC transporter MSD’s. This likely reflects the ability of many different amino acid 
combinations to support the a-helical aidiitecture of the MSD within the membrane. 
Levels of homology between MSD’s are often higher between the two MSD’s of an 
individual transport complex than between those of different transporters. This 
supports the hypothesis that the two MSD’s of a transporter have often evolved 
thi'ough gene duplication events. Despite the limited level of homology between ABC 
transporter MSD’s, it is believed that some structural constraints are imposed upon 
these domains by the nature of the substrate which they transport. This is reflected in 
the fact that the MSD’s of ABC transporters with similar substrates often cluster 
together in phylogenetic analyses.
The prokaryotic permeases, those ABC transporters involved in nutrient uptake, 
possess one moderately conserved region known as the ‘EAA-Loop’. This region 
extends over approximately twenty amino acids and conforms to the consensus
‘EAA—G I-LP’. Mutations in this motif were shown to have variable effects
when introduced individually into the MalF and MalG MSD’s of the E. coli maltose 
permease. However, simultaneous mutation of identical residues in both EAA motifs 
resulted in decreased maltose accumulation (Mourez et al., 1997). Located in a 
cytoplasmic loop of the MSD, this sequence is thought to be involved in the 
interaction of the MSD with the a-helical sub-domain of the NBD. This notion is 
supported by the observation that specific mutations in the helical domain of MalK
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can suppress the phenotypic effects of mutations in the EAA motif.
In order to transport a molecule from one side of the membrane to the other, the 
MSD’s of an ABC transporter must physically interact with their substrate. 
Interactions between substrate and MSD’s are still poorly understood for most ABC 
transporters. These interactions are probably dependent on the overall structure of the 
translocation pathway, rather than the presence of locally conserved sequence motifs. 
In this way residues distant from one another in the primary sequence of the MSD’s 
may become juxtaposed with one another in the fully folded, membrane-bound 
complex and contribute to a composite substrate binding site. A detailed 
understanding how the two MSD’s of the ABC transporter interact with one another 
and their substrate is of particular importance with regard to the multidrug 
transporters such as LmrA and P-glycoprotein. Any pharmaceutical agent aimed at 
blocking or modifying the activity of these transporters must presumably interact 
specifically with their MSD’s.
Exactly how MSD’s interact with their substrates is likely to vaiy significantly 
between different families of ABC transporters. For example P-glycoprotein is known 
to export many amphipathic substrates directly fr om the interior leaflet of the 
cytoplasmic membrane. This implies tliat the substrate binding site(s) of P- 
glycoprotein must be exposed to the interior of the lipid bilayer. Qu and Sharom have 
recently demonstrated the presence of such a lipid-exposed substrate binding site (Qu 
and Sharom, 2002). On the other hand, the substrate binding sites of the bacterial 
permeases must be exposed to the exterior of the cytoplasmic membrane in order to 
interact with their liganded SBP’s.
Lower resolution techniques have been employed to study the structure of the MSD’s 
of certain ABC transporters. 2D cryo-electron microscopy and single particle analysis 
have been used to construct projection maps for mammalian P-glycoprotein, 
mammalian MRPl, and the YvcC ABC transporter of Bacillus subtilis (Rosenberg et 
aL, 1997; Rosenberg et al., 2001; Chami et al., 2002). The map of P-glycoprotein 
indicates the presence of two arc shaped electron densities, related to one another by 
pseudo-two-fold symmetry. At the centre of the structure lies an asymmetric ‘pore’ 
that is exposed to the extracellular face of the membrane. Each of the two arc shaped
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domains consists of thiee major electron densities that are proposed by the authors to 
represent paired clusters of transmembrane helices. This observation is consistent 
with a model in which each homologous half of P-glycoprotein contributes six MSD’s 
to a translocation pathway, and the overall structure being generated by a total of 
twelve helices. It should be noted that in this structure the two arc shaped domains are 
not arranged totally symmetrically and that gaps between the domains may allow 
access to the central cavity from the interior of the lipid bilayer. Once again, these 
observations are consistent with the ability of P-glycoprotiens to extrude drugs 
directly from the inner leaflet of the membrane.
An alternative model to the ‘two-times-six’ paradigm for the arrangement of ABC 
transporter MSD’s was proposed by Jones and George (Jones and George, 1998). In 
this radically different model the authors proposed that the MSD’s interact to generate 
two membrane-embedded 16-stranded beta-barrels which form the transmembrane 
translocation pathway. However, the recent publications of the structures of the 
BtuCD ABC transporter and the MsbA transporter seem to discount this hypothesis 
and support the two-times-six-model. Indeed, these two structures, discussed in the 
final section of this chapter, have provided the greatest ever insight into how the 
various components of the ABC transporter complex interact with one another and 
even suggested possible mechanisms by which the tr ansporters may operate.
1.2,10 Structure of the ABC transporter complex
The recent publication of two complete ABC transporter structures represent major 
breakthroughs in our understanding of these proteins. The first publication was the 
structiue of the E. coli MsbA transporter, a lipid ‘flippase’ that catalyses the transport 
of lipid A from the cytoplasmic side of the bacterial cell membrane to the outer leaflet 
(Chang and Roth, 2001). The extreme difficulties encoimtered when trying to 
crystallise membrane transport proteins are well illustrated by the work leading up to 
the publication of the MsbA structure. A total of 20 different proteins from 14 
organisms were tested for expression and purification before the authors conducted an 
astonishing 96,000 crystallisation trials! Initial screens produced MsbA crystals 
diffracting to just 6.5 A, insufficient to trace the complete backbone of the protein. 
After a further round of refinement produced ciystals diffracting to 4.5 A resolution 
which were then used to solve the structure.
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The MsbA structure confirmed such fundamental hypotheses as the a-helical nature o f 
the membrane-spanning domain, and that the MSD forms the translocation pathway 
across the membrane. Although less well resolved than the MSD’s, electron densities 
corresponding to the NBD’s could be seen at positions near to the cytoplasmic face o f  
the membrane. Furthermore, two MsbA subunits were required to generate the 
complete 4 domain transporter, consistent with predictions, and the fact that the MsbA 
protein is a half-transporter. The crystal structure o f the MsbA dimer is shown in 
figure 1.15. It illustrates that the two a-helical MSD’s are tilted towards one another 
at an angle o f  30-40° with respect to the plane o f  the membrane generating an overall 
cone shape. The dimer interface occurs primarily between transmembrane helices 2 
and 5 o f each monomer at a position corresponding to the outer leaflet o f the 
membrane. No crystal contacts between monomers are observed at the base o f the 
cone shaped structure, the NBD’s apparently separated by a distance o f  approximately 
50 Â. As a consequence o f their tilted orientations, the MSD’s o f the two monomers 
form a conical chamber within the inner leaflet o f the membrane bilayer. A 
concentration o f positively charged residues in this region suggests that the interior o f  
the chamber may be a relatively polar environment.
Figure 1.15 -  The MsbA homodimer 
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An unexpected feature o f the crystal structure is the presence o f a bulky ‘intracellular 
domain (ICD)’ folded between the MSD and NBD o f each monomer. The ICD is
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formed from extended loops that connect the a -helical segments of the MSD at the 
intracellular side of the membrane. The ICD forms extensive crystal contacts with 
both the NBD below and the MSD above, and packs directly above the ABC 
signatui'e-sequence motif of the NBD. This raises the possibility that the ICD plays a 
part in signal transduction within the dimer, comiecting the molecular events of ATP 
binding and hydrolysis to structural rearrangements within the MSD. The presence of 
the ICD’s causes the NBD’s to project away from the cytoplasmic surface of the 
membrane, rather than packing directly against it. The ICD’s effectively extend the 
cone shaped chamber formed by the MSD’s well into the cytoplasam. At its base the 
conical cavity is now wide enough to allow access of lipid A to the interior chamber 
of the transporter.
Chang and Roth have suggested a possible transport mechanism based upon the 
structure of MsbA. They propose that lipid A enters the base of the conical cavity 
from the inner leaflet of the bilayer, triggering ATP binding/hydrolysis by the NBD’s. 
This process drives structural rearrangements within the dimer, possibly involving 
association of the NBD’s, eventually allowing lipid A access to the outer leaflet of the 
membrane. The final proposed stage involves nucleotide exchange at the NBD’s and a 
‘resetting’ of the dimer complex to its initial state. The autliors even propose that a 
similar mechanism may drive multidrug transporters. Such a mechanism would be 
consistent with the ability of MDR pumps such as P-glycoprotein and LmrA to 
extrude drugs directly from the inner leaflet of the cytoplasmic membrane. 
Additionally, the presence of a relatively large chamber able to accommodate 
molecules of varying sizes and shapes may account for the observed broad substrate 
range of the MDR pumps.
The second complete ABC transporter structure to be published was that of the E. coli 
vitamin B 12 transporter, BtuCD (Locher et al., 2002). Unlike MsbA, which is a 
homodimeric exporter/fiippase, BtuCD is a SBP-dependent importer. The transport 
complex consists of two molecules of BtuC (forming the MSD’s) in association with 
two molecules of BtuD, the ABC protein. Once again the crystallisation process was a 
tour-de-force effort involving 28 different ABC transporters, the BtuCD complex 
eventually yielding the best results. The published structure of BtuCD is resolved to 
3.2 Â with all important regions of the molecule clearly visible within the structure.
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Shown in figure 1.16 below, the BtuCD structure is somewhat different from that o f 
MsbA.
Figure 1 .1 6 -  The BtuCD transporter 
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The first immediate difference o f note is that the BtuC subunits each traverse the 
membrane 10 times, rather than the 6 times more commonly predicted for ABC 
transporter MSD’s. In common with MsbA, the membrane-spanning regions are a- 
helices. The 10 helices o f each BtuC protein are not all oriented in the same direction, 
as is the case in MsbA, and pack together in a rather intricate manner. Each BtuC 
monomer forms contacts with the opposite monomer, thereby contributing to the 
presumed translocation pathway, and also with the BtuD subunit below. In the 
structure o f BtuCD it should be noted that there is no region analagous to the ICD 
observed in the structure o f MsbA. Each BtuD subunit packs directly against the MSD 
above it, close to the plane o f the membrane.
Perhaps the most significant difference between the two structures regards the nature 
of the association between the NBD ’s in the BtuCD structure. In MsbA, the two 
NBD’s are separated by as much as 50 A whereas in BtuCD the two BtuD monomers 
are packed in direct contact with one another. Moreover, the nature o f the association 
between the two NBD’s is very similar to that observed in the Rad50cd
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ciystaliographic dimer. In both structures, the ABC signature motif of one monomer 
is juxtaposed with the Walker A motif of the second monomer. This results in the 
formation of a ‘composite’ nucleotide-binding site which likely stabilises the dimer 
structure. Crystal contacts between the two monomers include a number of 
moderately conserved motifs, including residues of the so-called D-loop and switch 
regions. Such contacts involving conserved residues suggest that all ABC transporter 
NBD’s may interact in this manner. The dimer interface between the two BtuD 
subunits is relatively small when compared with other dimeric complexes, just 740 
Â .^ However, the association of both NBD’s with the MSD above is likely to further 
stabilise the interaction. The authors also suggest that the small dimer interface may 
be the reason why isolated, purified NBD’s do not purify as dimers. In the absence of 
their MSD’s, the weak forces holding the dimers together may be insufficient to 
maintain the dimer structure and explain the different crystal forms of the MalK and 
HisP dimers.
The interface between each BtuD monomer and the BtuC subunit above is an 
interaction worthy of note. A relatively long cytoplasmic loop between 
transmembrane helices 6 and 7 of BtuC folds into two short a-helices called LI and 
L2 (yellow in figur e 1.16). LI and L2 contribute the bulk of the interfacial area 
between the two proteins. Interestingly, the LI and L2 regions align with the 
conserved ‘EAA’ sequence motif present in the MSD’s of the bacterial importers, as 
well as residues that are known to be important in the function of P-glycoprotein and 
CFTR. Locher and co-workers hypothesise that regions of other MSD’s 
corresponding to the position of LI and L2 helices may be important mediators of 
inter-subunit interactions.
The most likely region of the complex to form the translocation pathway is a V- 
shaped cleft between the two BtuC subunits (see figure 1.16). The cleft spans 
approximately two-thirds of the width of the membrane, and is formed by an anti­
parallel association of helices 5 and 10 of each monomer (4 helices in total). It should 
be noted that this is only a putative potential binding site since the crystals were 
generated in the absence of bound substrate. The cleft is however exposed to the 
periplasmic side of the membrane, facilitating interaction with the substrate-loaded
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SBP. The cleft is closed at its base by two serine residues and two threonine residues, 
a pair of each contributed by each monomer. This ‘gate region’ is believed by the 
authors to control access of the substrate to a large hydrophilic cavity at the interface 
of all foui' subunits.
Once again, the authors propose a perfectly plausible transport mechanism based upon 
a series of binding and structui'al rearrangements coupled to ATP hydrolysis by BtuD. 
The differences in the structures of BtuCD and MsbA highlight one of the limitations 
of X-ray crystallograpliic techniques as mechanistic tools. Each crystal structure is 
essentially a snap-shot in time of one of the structures that the complex adopts during 
the catalytic cycle. So, whilst the two structures presented may look very dissimilar at 
certain points during transport, they may also adopt similar structures at other times. 
As such, crystallography may provide clues to the molecular events occurring during 
the transport cycle, but it is the more traditional biochemical and biophysical 
techniques that will eventually complete the mechanistic picture.
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Chapter 2 
Materials and Methods
2.1 Laboratory reagents and equipment
2 .1 .1  Sources of reagents
General laboratoiy reagents such as salts and buffers were purchased in the highest 
available grade from Sigma (UK) Ltd. Microbiological growth media were variously 
sourced from Oxoid, Difco and Melford Laboratories. Except where otherwise stated 
enzymes used in molecular biology protocols were purchased from Promga (UK) Ltd.
The sources of additional reagents used in specialised applications are detailed in 
association with specific protocols.
2.1. 2 Preparation of solutions
All solutions, including microbiological growth media and molecular biology reagents, 
were prepared using high quality distilled, deionized water. Gross quantities of reagents 
were weighed out on a Sartorius digital balance whilst smaller quantities were measured 
using a Mettler Toledo digital analytical balance.
2.1. 3 Sterilisation techniques
Where possible materials were sterilised by autoclaving. A typical protocol, such as that 
used for the sterilisation of growth media, involved heating to 121 °C for 15 minutes at 4 
atmospheres pressure in a Priorclave electrically heated autoclave set on liquid cycle. 
Solutions of heat labile reagents, such as antibiotics, were sterilised by filtration through 
0.22pm syringe filters. Certain plasticware unsuitable for autoclaving was sterilised by 
washing thoroughly in 100% ethanol before drying in a laminar flow hood.
2.1. 4 Centrifugation
Standard room temperature centrifugation of 1.5 ml microcentrifuge tubes was performed 
in a Sigma benchtop microfuge fitted with a 24 place fixed angle rotor. Where there was 
a requirement for cooling a Jouan CR3 refrigerated benchtop centrifuge was used. Larger
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volumes of liquids were processed in a Beckman-Coulter Avanti J-E refrigerated 
centrifuge which accommodated a several different fixed angle rotors. A Beckman JA-10 
rotor was used to process volumes up to 3 litres in 500 ml plastic containers, whilst a 
Beckman JA-21 rotor was used to process up to 400 ml in 50 ml tubes. High-speed 
ultracentrifugation was perfonned in a Beckman L8M ultracentrifuge using a Beckman 
Ti50 fixed angle rotor.
2.2 Growth and storage of bacteria
All bacterial strains used and their associated genotype are listed in table 2.1 on the next 
page.
2. 2.1 Growth media
Liquid cultures of the Escherichia coli strains listed were propagated using two main 
types of growth media: -
Luria-Bertani tLBf medium 
NaCl lOg/litre
Tryptone lOg/litre
Y east extract 5 g/litre
2x YT medium 
NaCl 
Tryptone 
Yeast extract
5g/litre 
16g/litre 
1 Og/litre
Solid growth medium was prepared by adding 1.5% w/v agar to liquid LB medium prior 
to autoclaving. LB medium was used for the growth of most bacterial strains, whilst the 
richer 2x YT medium was used in expression cultures because of its ability to support 
higher cell densities.
2. 2 . 2 Growth conditions
Liquid cultures were initiated by inoculation of a suitable volume of sterile medium with 
a single bacterial colony transfeired from solid medium. Except where otherwise 
indicated, liquid E. coli cultures were grown at 37 °C with rotary shaking between 170 
and 225 ipm. Incubation times varied from several hours to overnight. Solid cultures of
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Table 2.1 -  Bacterial strains used in these studies
Strain Genotype Origin Application
E. co//NovaBiue endAX /?54R17(rKi2’mKi2') 
supE<^ A
thi—\ recK  g)/rA96 relKX 
lac [FhproAB /acUZAMlS 
TnlO(Tet'*)]
Novabiochem General cloning
E. coli JM109 endAX /fa'(/R17(rKi2' 
supE^A
thi recKX gyrA96 relAl X-
A{lac-proAB) [ F’, ^raD36, 
proAB, lacl^ZAMlS ]
Promega General cloning
Site directed 
mutagenesis
E. coli TO? 10 F' mcrA isQmr-hsd^MS-mcrEC) 
L80 /rtcZAM15 A/flcX74 deoK 
endAX recAX nupG
flraD139 A{ara-leii)l691 galU 
gain  rpsE
Invitrogen General cloning 
Protein expression
E. coli BL21 
(DE3)
E. coli B F' ompT hadS (ib' ms") 
dcm^ TgPgal endA
Stratagene Protein expression
E. coli LMG194 F* A/«cX74 gaîE thi rpsL 
AphoA (pvu II) Aara714 
leir.'.TnXO
Invitrogen Protein expression
E. CO//BMH71- 
18 miitS
thi siipE A{lac-proAB) 
[mi//S::TnlO] [F’,praAB, 
/acUZAM15 ]
Promega Site directed 
mutagenesis
E. coli WD2 msbA mutant Gift ofW.T 
Doerrler
Complementation
studies
E. coli N43 AacrA mutant E. coli 
Genetic 
Stock Centre
Complementation
studies
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E. coli were prepared by spreading or streaking organisms onto the surface of the 
solidified medium using disposable plastic microbiological loops or spreaders. Plates 
were allowed to dry in a laminar flow hood before being covered and incubated at 37 °C 
in an inverted position overnight.
2. 2. 3 Storage of bacterial strains
Stock cultures of each bacterial strain used were prepai'ed in order to maintain their long 
tenn integrity and viability. Stocks were typically prepared by mixing SOOpl of an 
overnight liquid culture with 200pl of sterile 80% glycerol. The mixture was then 
transferred to a sterile cryovial for storage at -80 °C. Strains stored in this manner were 
retrieved by scraping a small amount of the frozen stock from the cryovial using a sterile 
loop, and then streaking this material onto solid growth medium for overnight incubation 
at 37 °C.
2. 2. 4 Use and preparation of antibiotics
Many bacterial strains, particularly those bearing recombinant vectors, required the 
presence of antibiotics in their growth media in order to retain their genetic integrity and 
prevent contamination by extraneous microorganisms. Antibiotic stocks were routinely 
prepared at 1000 times concentration in water or ethanol as required and filter sterilised 
before use. Such stocks were stored in aliquots at -20 °C. Stock concentrations: 
ampicillin lOOmg/ml, carbenicilHn lOOmg/ml, kanamycin 1 OOmg/ml, tetracycline 
25mg/ml (50% ethanol), doxorubicin 2mg/ml (DMSO).
2. 3 Nucleic acid purification and analysis
2. 3.1 Agarose gel electrophoresis
The results of nucleic acid manipulations were routinely analysed by agarose gel 
electrophoresis. High purity agarose (Roche Molecular Biochemicals) was dissolved in 
TAB buffer* at an appropriate concentration (typically in the range 0.8-2% w/v) by 
heating the mixture in a microwave. The molten agarose solution was allowed to cool 
slightly before the addition of the DNA staining reagent ethidium bromide at a final 
concentration of 0.1 pg/ml. The solution was then poured into a horizontal gel-tray and
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allowed to set solid by cooling. Wells for sample loading were set in to the agarose slabs 
by fitting a comb into one end of the molten agarose solution. Once set, the agarose slabs 
were placed into electrophoresis tanks and submerged in TAB buffer prior to sample 
loading. Each DNA sample to be analysed was mixed with 6x loading buffer* and loaded 
into a separate well in the agarose gel. A sample of a commercially available DNA 
marker was usually loaded into one well of the gel. Comparison of experimental samples 
with such markers facilitates estimation of size and quantity of DNA present. Application 
of an approximately 1OOV potential difference across the gel promotes migration of the 
DNA in the samples towards the anode pole of the electrophoresis tank. Progress of DNA 
through the gel was monitored by the migiation of the xylene cyanol and bromophenol 
blue dyes present in the loading buffer. Once the samples had migrated a sufficient 
distance, DNA was visualised by exposure to a UV light trans-illuminator. In those 
instances where a pemianent record of the experiment was required the entire gel was 
photogiaphed using a Polaroid MP4 camera fitted with UV filters and Polaroid 677 black 
and white film.
* Buffer compositions 
IxTAE
4.84g Tris base 
1.142ml glacial acetic acid 
2ml 0.5M EDTA (pH 8.0)
Made up to IL with distilled water
6x DNA loading buffer 
lOOmM EDTA (pH 8.0)
1% w/v SDS
0.1% w/v bromophenol blue 
0.1% w/v xylene cyanol 
50% glycerol
2, 3. 2 Purification of plasmid DNA
Small-scale purification of plasmid DNA from E. coU host strains was performed using 
the QIAprep Spin Miniprep Kit (Qiagen) according to the protocols provided. A 
modification of the well known alkaline lysis procedure, the technique is summarised 
below.
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Cells from a 5ml overnight liquid culture are harvested by centrifugation and the culture 
medium decanted away from the cell pellet. The cell pellet is resuspended in 250pl of 
buffer PI supplied with the kit and transferred to a 1.5ml microcentrifuge tube. The cells 
are then lysed by the addition of 250pl of buffer P2 containing SDS and NaOH. The 
suspension is thoroughly mixed by inverting the tube several times, thereby ensuring 
complete lysis. The mixture is then neutralised by the addition of 350pl of buffer N3.
The addition of this solution causes cellular proteins and genomic DNA to precipitate out 
of solution, whilst plasmid DNA remains soluble. Insoluble and soluble components are 
separated by centrifugation of the mixture at 12,000 rpm for 10 minutes. The supernatant 
fraction, containing the soluble plasmid DNA, is next loaded onto a spin miniprep
column mounted in a 2ml collection tube. The mini-columns contain a positively charged
silica-based matrix upon which plasmid DNA becomes immobilised. The supernatant is 
spun through the resin bed and into the collection tube by centrifugation at 12,000 rpm 
for 1 minute. The immobilised plasmid DNA is then washed with 750pl of buffer PE 
(buffered 80% ethanol) by repeating the loading and centrifugation steps. Excess 
remaining ethanol buffer is removed from the immobilised plasmid by decanting the 
contents of the collection tube and performing a further 1 minute centrifugation step. 
Finally, the immobilised plasmid is eluted by transfening the spin column to a clean 
1.5ml microcentrifuge tube and adding 50pl of molecular biology grade water. The 
column is allowed to sit at room temperature for 5 minutes before a final 1 minute 
centrifugation. The eluted plasmid collects in the microfuge tube whilst the spin column 
discarded. Purified plasmid DNA is then analysed by agarose gel electrophoresis or used 
in subsequent procedures. Plasmid DNA purified in this manner is stable for long periods 
of time if stored frozen at —20 °C.
2. 3. 3 Extraction of DNA from agarose gels
A number of common molecular biology procedures, e.g. cloning reactions, require the 
extraction of DNA fragments from agarose gels after their analysis. Extraction was 
commonly performed using the QlAquick Gel Extraction Kit (Qiagen). Once again the 
manufacturer’s protocols were adopted as summarised below.
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DNA bands to be extracted were visualised by exposing the gel on a UV transilluminator. 
Slices of the gel containing a desired DNA fragment were excised using a clean scalpel 
blade, weighed, and transferred to a microfuge tube for extraction. The QlAquick Kit 
allows for processing of gel slices of up to 400mg in weight. The gel slice is mixed with 
a solubilisation buffer (buffer QG), with 30pi of buffer added per lOmg of gel. The slice 
is then dissolved in the QG buffer by incubation in a 50 °C water bath for 10 minutes 
with occasional mixing. Next, the DNA/buffer mixture is applied to a spin column 
containing a silica matrix upon which the dissolved DNA becomes immobilised. The 
column, in a 2ml collection tube, is subjected to 1 minute of centrifugation at 12,000 
rpm. The DNA becomes immobilised whilst the buffer passes through to the eollection 
tube. The DNA is treated with a fiirther 500pl of QG buffer to remove any remaining 
traces of agarose which may interfere with subsequent steps. The immobilised DNA is 
washed with 500pl of an ethanol wash buffer (buffer PE) by applying this to the column 
and repeating the centrifrigation process. The eollection tube is emptied and the column 
centrifuged for 2 minutes more in order to remove traces of ethanol from the immobilised 
DNA. Finally, the DNA is eluted by the addition of 50pl of high purity water to the spin 
column. The column is incubated at room temperature for 5 minutes before being 
transferred to a clean 1.5ml mierofuge tube. The column is centrifuged for 1 minute to 
collect the purified DNA solution. Once again, for the majority of subsequent 
applications, DNA purified in this manner is stable if stored frozen at —20 °C.
2. 4 DNA amplification, cloning and sequencing
2. 4.1 The Polymerase Chain Reaction (PCR)
PCR was used extensively throughout this work as a means of amplifying and modifying 
specific genes from M  tuberculosis genome. The technique requires the use of oligo- 
deoxynucleotides as a means of priming PCR amplification. All oligonucleotides used 
were obtained from a commercial source (Invitrogen Custom Primers) and supplied on a 
50nmol scale. Stock solutions of oligonucleotides, supplied in a desalted, lyophilised 
form, were prepared by resuspending the DNA in high purity water at a concentration of 
60pmol/pl. Working solutions of primers were prepared from stocks by dilution to a 
concentration of 12pmol/pl. Both stocks and working solutions were stored frozen at —20
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^C. All possible care was taken to avoid cross-contamination of primer solutions. Primers 
were generally designed to be between 18 and 27 nucleotides in length and have melting 
temperatures in the range 55-70 °C.
The names and sequenees of all oUgonueleotides used in this work are presented in table
2.2 on the next page.
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Table 2. 2 -  Oligonucleotides
Primer Name Sequence (5’ to 3’) Use (reference)
dnAF CAT ATG CGC AAC GAC GAC ATG 
GCG GTG
PCR (chapter 3)
drrAR AAG CTT TCG CGC GGA CCC CGA 
CAC CAG
PCR (chapter 3)
diTBF CAT ATG AGC GGC CCG GCC ATA 
GAT GCG
PCR (chapter 3)
dirBR AAG CTT TGG CCG CCT AGC CAA 
AAC AAT
PCR (chapter 3)
drrCF CAT ATG ATC ACG ACG ACA AGT 
CAG GAA
PCR (chapter 3)
dn-CR AAG CTT ATG CGT GCT GGC CCG 
TCG GTA
PCR (chapter 3)
K48E GGG CCC CAA CGG GGC CGG CGA 
GAC GAC CAT G
Mutagenesis 
(chapter 6)
G47S GGG CCC CAA CGG GGC CAG CAA 
GAC GAC CAT G
Mutagenesis 
(chapter 6)
Y17W TTA ACG GGG TTC GCA AAG CCT 
GGG GCA AGG A
Mutagenesis 
(chapter 6)
WllOG CCG CGG ACT TGC TCA GTC CCC 
CCA GAC GAC C
Mutagenesis 
(chapter 6)
W180G CGG CAA GCT ATT GGG GAT CTG 
GTG
Mutagenesis 
(chapter 6)
Y141W GTG GGC ACC TGG TCC GGC GGA 
ATG CGC
Mutagenesis 
(chapter 6)
Trx2W CTG GTT GAT TTC GGG GCA CAC 
GGG TGC GGT CCG
Mutagenesis 
(chapter 6)
Oligonucleotide names ending with ‘F’ and ‘R’ represent pairs of PCR primers,Towar^/ and reverse, used 
for the amplification of specific M. tuberculosis d ir  genes. The underlined sequences' ‘CAT ATG’ and 
‘AAQ CTT’ coiTespond to Ndel and M ndlll restriction enzyme sites that were incoiporated into amplicons 
in order to facilitate downstream manipulation o f the amplified sequences.
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2. 4, 2 Preparation of PCR experiments
PCR reactions were performed using HotStar Taq™ DNA polymerase, a recombinant, 
thermostable, derivative of Thennus aquaticus DNA polymerase (Qiagen). The enzyme 
is supplied with buffers and additional reagents optimised for use with HotStar Taq. The 
enzyme requires a 15 minute incubation performed at 95 °C before it becomes active. 
This feature of HotStar Taq minimises the chances of non-specific priming and extension 
during the preparation of PCR reactions. Cycling parameters used in PCR reactions were 
variable depending upon the primer pairs used and the nature of the template DNA. 
However, the examples of reaction mixture preparation and cycling parameters detailed 
below are typical of those used tluoughout this work.
All PCR reactions were perfonned in sterile, thin walled, 0.5ml capacity PCR tubes free 
of DNase and RNase contamination (Axygen). Where stocks and dilutions were prepared 
water of the highest available quality was used.
PCR reaction component Volume Stock concentration
lOx PCR Buffer (Qiagen) lOpl /
dNTP’s* 2pl 1 OmM each
Primer 1 5 pi 12pmol/pl
Primer 2 5 pi 12pmol/pl
HotStar Taq 0.5pl 5 units/pl
Template DNA^ Variable Variable
Water Up to 100 pi /
*deoxyi'ibonucleotides dATP, dTTP, dCTP and dGTP were obtained from Promega 
(UK) Ltd. as lOOmM stock solutions. A mixture of the 4 dNTP’s was prepared with each 
one at a concentration of lOmM.
^A typical PCR reaction used less than Ipg of template DNA.
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In certain instances the proprietary reagent Q-Solution (supplied with HotStar Taq DNA 
polymerase) was added to reaction mixtures at a concentration of 20% v/v. This reagent 
alters the melting properties of duplex DNA and was found to be useful when PCR 
amplification using standard reaction conditions was poor or failed altogether.
Typical Cycling Parameters
Step 1 1 cycle 95 °C 15 minutes (activation)
Step 2 30 cycles 94 °C 
50-65 °C* 
72 °C
45 seconds 
45 seconds 
1-3 minutes
Step 3 1 cycle 94 °C 45 seconds
50-65 “C 45 seconds
72 °C 10 minutes
*The temperature at which the annealing phase of the PCR was perfonned was the most 
highly variable parameter since it was dependent upon the particular primer pair in use. 
Wherever possible primer pairs with similar melting temperatures (Tm) were designed 
and used. In initial experiments with any given primer pair an annealing temperature was 
chosen at 5 °C below that of the primer Tm’s.
Thermal cycling was performed in either an Eppendorf Gradient Thermocycler or a 
Teclme Cyclogene Thermocycler. Both of these PCR machines were fitted with heated 
lids to prevent evaporation of the reaction mixture during the cycling process. The lids 
are pre-heated to 105 "^ C before cycling commences. Exact details of reaction parameters 
are provided in the text associated with specific experiments.
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2. 4. 3 Cloning of PCR products
The success of PCR reactions was analysed directly by agarose gel electrophoresis. In the 
event that a PCR product of the desired size was obtained, the product was purified by 
gel extraction in order to produce a solution of DNA free of interfering substances (such 
as protein and free nucleotides). The purified DNA was then cloned into a multi-copy 
vector, allowing the amplified gene sequence to be maintained in a stable form in a 
heterologous host {E. coli).
The vector of choice for the initial cloning of PCR products was the pGEM-T Easy 
system (Promega). Taq DNA polymerase exhibits a non-template directed activity that 
results in all PCR products having a single base overhang at the 3 ’ end. This additional 
base is virtually always an adenine residue. As such, PCR products readily ligate into 
linearised vectors possessing complimentary 3’ single base thymidine overhangs. The 
pGEM-T Easy vector used here is just one of many such commercially available vectors. 
Reactions were performed in 0.5ml microfuge tubes and contained the following 
components
Linear pGEM-T Easy vector DNA 1 pi (=5Ong)
2x Rapid Ligation Buffer 5 pi
Purified PCR amplicon 3pi
T4 DNA Ligase 1 pi (5 Units)
Ligation is highly efficient in this particular type of cloning reaction and a large number
of recombinant vector molecules are often produced after incubation of the reaction 
mixture at room temperature for just 1 hour. Alternatively, ligation reactions were 
allowed to proceed overnight at 16 °C.
2. 4. 4 DNA sequencing
DNA sequencing of recombinant vectors was performed by BaseClear (Leiden, The 
Netherlands). Sequencing reactions were performed on ABI377 or LiCor automated
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DNA sequencers. Sequence data were returned as both text files and chromatogram files. 
Data was analysed using Vector NTI 6.0 bioinfonnatics software (InforMax Inc.).
2. 5 Enzymatic DNA manipulation
2. 5.1 Use of restriction endonucleases
The use of restriction endonucleases was central to the production and analysis of 
recombinant DNA molecules. Except where otherwise indicated, DNA digestion was 
performed in sterile 0.5ml microfuge tubes at a temperature of 37 °C. Enzymes and their 
appropriate reaction buffers were obtained from Promega (UK) Ltd.
Typically, single enzyme restriction digests were perfonned in a total volume of 20pl and 
contained the components listed below: -
1 Ox restriction enzyme buffer 2 pi
Experimental DNA sample 2-5 pi (up to 1.5 pg)
Restriction enzyme 1 pi (2-10 Units)
MilliQ water Up to 20 pi
Digestion reactions were allowed to proceed for variable lengths of time depending upon 
downstream processes. For example, mapping of plasmids by restriction digestion (to 
verify the presence of a recombinant fragment) could typically be achieved with 
digestion times of 1 hour. However, where DNA was to be sub-cloned from one vector to 
another, digestion times of up to 4 hours were used in order to ensure that the reaction 
had proceeded to completion. Additionally, directional sub-cloning of DNA fragments 
often required the use of two restriction enzymes simultaneously. Such reactions were 
also allowed to proceed for longer periods of time, once again up to 4 hours. Reactions 
were terminated by the addition of DNA loading buffer and subsequently analysed by 
agarose gel electrophoresis.
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2. 5. 2 5’-Dephosphorylation of vector DNA ends
5’-Dephosphorylation of vector DNA ends has been shown to reduce the background of 
false positives in cohesive end cloning reactions. To this end, pre-digested vector DNA 
to be used in cohesive end cloning was routinely treated with shrimp alkaline 
phosphatase (SAP). Appropriate quantities of enzyme and associated buffer were added 
to gel purified vector DNA solutions and incubated for 10 minutes at 37 °C. The enzyme 
was then inactivated by incubating the solution for a fiirther 15 minutes at the elevated 
temperature of 65 °C. This second incubation prevents carry-over of phosphatase activity 
into the subsequent ligation reaction.
2. 5. 3 Cohesive end DNA cloning
The production of recombinant vectors for heterologous protein expression required that 
PCR amplifed M, tuberculosis DNA be cut out of the pGEM-T Easy vector and ligated 
into several different E. coli expression vectors. DNA excised fiom pGEM-T Easy by 
restriction enzyme digestion was ligated into linearised, dephosphorylated expression 
vectors that had been digested with the same enzyme(s) such that the two DNA 
fragments possessed complimentaiy ends. The ligation of the two fragments was 
performed using T4 DNA ligase (Promega, 10 Units/pl). Reactions in a total volume of 
lOpl contained the following components: -
1 Ox Ligase buffer 1 pi
T4 DNA ligase 1 pi
Vector DNA . Ipl
Insert DNA 3 pi
MilliQ water 4pl
The relative proportion of vector and insert DNA’s used in ligation reactions is known to 
affect efficiency of the reaction. Whilst the exact amounts of DNA used in ligation 
reactions were rarely fonnally quantified, a 3:1 molar excess of insert over vector was 
approximated and generally found to be sufficient. Cohesive end cloning reactions were
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incubated at 16 °C overnight to maximise the number of recombinant DNA molecules 
generated.
2. 5. 4 5’-Phosphorylation of oligonucleotides
5’-Phosphoiylated oligonucleotides were generated for use in site-directed mutagenesis 
protocols since they are known to improve the efficiency of mutagenesis (see chapter 6). 
Unphosphoiylated mutagenic oligonucleotides were purchased from Invitrogen Custom 
Primers and then modified using T4 polynucleotide kinase (Promega). Reactions were 
performed in 0.5ml thin-walled PCR tubes at 37 °C for 30 minutes. The reaction 
mixtures contained the following components: -
Unphosphorylated oligonucleotide lOOpmol
1 Ox T4 kinase buffer 2.5 pi
T4 polynucleotide kinase 2.5pl (5 Units)
lOmM ATP 2.5pl
MilliQ water Up to 25 pi
After incubation, the T4 polynucleotide kinase was inactivated by heating the reaction to 
mixture to 70 °C for 10 minutes. Phosphorylated oligonucleotides were used immediately 
for the mutagenesis reaction.
2. 6 Use of chemically competent E. coli
2. 6.1 Sources and production of chemically competent E. coli
Recombinant plasmids used for both maintenance of heterologous DNA and the 
expression of heterologous protein were transformed into chemically competent E. coli 
strains. In many instances these strains were obtained ftom commercial sources in single 
use aliquots (see table 2.1). However, in other instances it was necessary to produce 
chemically competent cells in the laboratoiy. The chemical treatment procedure used to 
induce competence is outlined below: -
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Cells of the desired strain were grown in 50ml liquid LB medium at 37 °C in a baffled 
conical flask with rotary shaking at approximately 225rpm. When the cell suspension 
reached an ODeoo of 0.5 they were immediately transferred to an ice bath and left to cool 
for two hours. During the cooling period a fresh 50ml preparation of competence 
solution"  ^was made, filter sterilised and allowed to cool in the same ice bath. After two 
hours the cooled cells were pelleted in a refrigerated centrifuge and the culture medium 
discarded. The cell pellet was then resuspended in 45ml of the ice cold competence 
solution and returned to ice for a frirther 45 minutes. After this final incubation period the 
cells pelleted once more in a refrigerated centrifuge and the excess solution poured off 
The final stage of the procedure entailed resuspending the cells in 3ml of ice cold 
competence solution plus 2ml of sterile 80% glycerol. This mixture was then split into 
50pl aliquots (in thin-walled 500pl PCR tubes) and individual aliquots flash-frozen in a 
dry ice/ethanol bath. Competent cells produced in this manner were stored at -80 °C.
^Competence solution -  lOOmM calcium chloride, 7OmM manganese chloride, 40mM 
sodium acetate, pH 5.5.
2. 6. 2 Transformation of chemically competent E. coli
Recombinant plasmids were generally transfonned into competent cells according to the 
manufacturer’s protocols. Whilst each protocol differs slightly, an outline of the general 
procedure used is given below. Competent cells produced in the laboratory by the 
previously described procedure were also transformed according to this protocol.
Aliquots of cells were removed from storage at -80 °C and allowed to thaw on ice. 50- 
500ng of plasmid DNA (or ligation mixture) was then added to the cells which were 
gently stirred with the tip of a pipette. The mixture was incubated on ice for 30 minutes. 
After the incubation period the cells were subjected to heat-shock in a 42 °C water bath 
for a period of exactly 45 seconds. After heat-shock the cells were returned to ice for 2 
minutes. 300pl of liquid LB growth medium was then added to the cell suspension and 
the newly transformed cells incubated at 37 °C in a rotaiy incubator shaking at 
approximately 225rpm for a period of 1 hour. Subsequently various volumes of cells
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were spread onto solid gi'owth medium containing appropriate selection 
antibiotics/reagents and incubated in an inverted position overnight at 37 ‘^ C.
2. 6. 3 Selective screening for recombinant bacterial clones
All plasmid vectors used in these studies carried antibiotic resistance determinants as a 
means of screening for transfonned clones. Only successfully transfonned bacterial 
clones carry these detenninants, confening upon them the ability to grow in the presence 
of the selective antibiotics, whereas non-transfonned cells are unable to do so. After this 
initial screening stage plasmids were isolated from the cells and analysed by restriction 
digestion and/or DNA sequencing to confinn the presence of the recombinant insert. The 
most commonly used vectors canied the gene for ampicillin resistance and transfonned 
cells were selected on LB-agar medium containing 50-100pg/ml of the antibiotic.
Blue/white screening for recombinant pGEM-T Easv bearing clones
One of the advantages of using the pGEM-T Easy system for the cloning of PCR 
products was the ability to screen for recombinant plasmids on the basis of insertional 
inactivation of the (3-galactosidase gene. Cells bearing recombinant plasmids are unable 
to hydrolyse the artificial lactose analogue X-Gal (5-bromo~4-chloro-3-indolyl- (3-D- 
galactoside), whereas those cells with non-recombinant plasmids (where the 
galactosidase gene has not been disrupted) are able to do so. Cells metabolising X-Gal 
contain a blue pigment, a by-product of the metabolic process, whilst cells with a 
disrupted (3-galactosidase gene remain white in colour. E. coli transformed with pGEM-T 
Easy constructs were plated onto solid media, the surface of which had been spread with 
40pi of 2% w/v X-Gal. Ampicillin (lOOpg/ml) was added to the medium to select for 
successful transformants, whilst IPTG was included at a concentration of linM to induce 
expression of (3-galactosidase. After 16 hours of growth cells bearing recombinant 
plasmids remained white in colour and were selected for frirther analysis.
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2, 7 Topoisomerase mediated T-A cloning
The pTrx-DrrA expression construct (see chapter 5) was generated using the 
‘pBAD/TOPO ThioFusion Expression Kit’ (Invitrogen). This kit allows rapid generation 
of expression constructs through topoisomerase mediated T-A cloning of Taq- 
polymerase-amplified PCR products. Briefly, a fresh PCR reaction was used to amplify 
the M  tuberculosis drrK gene from a plasmid template. The approximately 1 Kb PCR 
amplicon isolated from an agarose gel slice by standard techniques following 
electrophoretic separation. The amplified gene was then cloned into the pBAD/TOPO 
ThioFusion vector in a 5 minute, room temperature reaction perfonned according to the 
manufacturer’s protocol:-
TOPO cloning reaction components 
Fresh PCR product {drrK gene) 3 pi
Salt solution* 1 pi
TOPO vector 1 pi
dHzO Ipl
*Salt solution = 1.2M NaCl, 60mM MgCh
After completion of the TOPO cloning reaction 2 pi of the reaction mixture was used to 
transform chemically competent & coli TOP 10 cells according to standard protocols. 
Recombinant colonies were isolated by plating the transformation reaction on to solid 
LB-agar medium supplemented with lOOpg/ml carbenicillin. Transfoimation plates were 
incubated overnight at 37 °C.
77
2. 8 Site-directed mutagenesis
The ‘GeneEditor in vitro Site-Directed Mutagenesis System’ (Invitrogen) was used to 
perform all sited directed mutagenesis experiments described in this work. There follows 
a brief summary of the mutagenesis protocol :-
A -  Preparation of template DNA
Single stranded plasmid DNA was the template for all mutagenesis reactions. This was 
produced by alkaline dénaturation of double stranded plasmid. The dénaturation reaction 
contained the following components
Plasmid DNA 5 pi (approx. 2pg)
2M NaOH, 2mM EDTA 2pl
dHzO 13pl
This mixture was incubated at room temperature for 5 minutes before single stranded
DNA was precipitated by the addition of 2pl of 2M ammonium acetate (pH 4.6) and 75pl 
of 100% ethanol. The mixture was then incubated at —80 °C for 30 minutes. Precipitated 
DNA was collected by centrifugation at 13,000rpm in a bench-top centrifuge for 15 
minutes. The ssDNA pellet was washed in 200pl of 70% ethanol, re-collected by 
centrifugation and then air-dried. The pellet was dissolved in lOOpl of dPHO and a lOpl 
aliquot was analysed by agarose gel electrophoresis in order to estimate yields.
B -  Annealing of mutagenic oligonucleotides
Up to 4 mutagenic oligonucleotides could be annealed to the single stranded plasmid 
DNA simultaneously. All mutagenic oligonucleotides were 5’-phosphorylated as 
described in section 2.5.4. Each annealing reaction contained a ‘Selection 
oligonucleotide’ provided in the kit which introduces specific mutations into the vector 
encoded p-lactamase gene. These mutations alter the substrate range of the P-lactamase 
enzyme and allow selection of clones carrying mutated plasmids on the basis of
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resistance to a proprietary antibiotic mixture. The annealing reactions were prepared as 
follows
Template DNA 1 Opl
Selection oligonucleotide 1 pi
Mutagenic oligonucleotide xpl (1.25pmol each)
1 Ox annealing buffer 2 pi
dHaO up to 2Opl
The annealing reaction was heated to 75 °C and then allowed to cool to room 
temperature slowly. During this period the oligonucleotides anneal to the template DNA.
C -  Mutant strand synthesis and ligation
Various components were added to the annealing mixture in the order shown below. 
These reagents completed synthesis and ligation of the mutated plasmid DNA.
dHiO 5pl
1 Ox synthesis buffer 3 pi
T4 DNA polymerase Ipl (10 Units)
T4 DNA ligase 1 pi (3 Units)
The reaction mixture was incubated at 37 °C for 90 minutes to allow mutant strand 
synthesis.
D — Transformation of BMH 71-18 miitS E. coli
This E. coli strain, provided with the kit, has a mutation in the miit^ DNA repair gene 
which allows the cells to tolerate plasmids with small double strand mismatches. The 
cells were transformed with 3 pi of the mutant plasmid mixture prepared in second C
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above. Transformation was perfonned by a standard heat-shock protocol. Rather than 
plating the transformed cells onto solid medium, the entire mixture was incubated in 4ml 
of LB medium containing the proprietary selection antibiotic overnight (37 °C). This 
allows time for plasmid replication and segregation in such a way as to enliance the 
number of cells canying the mutated plasmid.
E — Plasmid Minipren and selection of mutants
The final stage of the selection procedure was to prepare total plasmids from the 
overnight culture. This was done by standard plasmid mini-prep (see section 2.3,2). 
Mutant plasmids were transformed into chemically competent JM109 E. coli and cells 
carrying mutated plasmids were selected on solid LB-agar medium containing the 
selection antibiotic (overnight incubation, 37 °C).
JM109 clones resistant to the antibiotic selection mixture were used to prepare plasmids 
by mini-prep. The successful introduction of specific mutations was detemiined by DNA 
sequencing.
2. 9 Recombinant Protein Expression
2. 9. 1 Expression of recombinant proteins from pET series plasmids
A number of experiments were performed to express recombinant M  tuberculosis 
proteins in the heterologous host E. coli using the pET series expression plasmids 
(Novagen). pET expression constructs were typically transformed into the host strain 
BL21(DE3), the DE3 lysogen encoding an IPTG-inducible bacteriophage T7 RNA 
polymerase required for transcription from the pET-series plasmids. A single 
recombinant clone, from either a fresh transfonnation or streaked from a glycerol stock, 
was selected after overnight incubation at 37 °C on solid LB-agar medium supplemented 
with the appropriate selection antibiotic. The clone was used to inoculate a liquid starter 
culture (typically 5ml in LB medium) which was grown overnight at 37 °C with vigorous 
shaking. Starter cultures were used to inoculate larger expression cultures grown at a 
variety of temperatures depending upon the experiment in question (16-37 °C). All 
expression cultures were grown in baffled flasks with rotary shaking between 170-
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220rpm to promote aeration. Cultures were supplemented with the appropriate antibiotics 
required for maintenance of pET expression plasmids. Growth of all expression cultures 
was monitored spectroscopically by changes in optical density at 600nm.
When each culture reached an OD^oo of approximately 0.6 (corresponding to mid-log 
phase), expression of recombinant protein was initiated by the addition of IPTG to a final 
concentration ranging between lOOpM and ImM. The addition of IPTG to E. coli 
BL21(DE3) initially results in expression of the chi'omosomally encoded bacteriophage 
T7 RNA polymerase. This enzyme then drives expression of heterologous genes cloned 
in front of the T7 promoter sequence present in the recombinant pET plasmid. Where 
necessaiy, for example during time-course experiments, 1ml samples were removed 
aseptically from expression cultures and heterologous protein expression analysed by 
SDS-PAGE.
2. 9. 2 Expression of recombinant protein from pBAD plasmids
Recombinant expression constructs based upon the pBAD-TOPO ThioFusion vector 
(Invitrogen) were transfonned into one of the two host strains recommended by the 
manufacturer, E. coli TOP 10 or E. coli LMG194. Recombinant clones were isolated by 
plating onto solid LB-agar medium supplemented with carbenicillin at lOOpg/ml. Single 
clones were used to inoculate overnight starter cultures in 5ml of LB medium. Starter 
cultures were again grown at 37 °C with vigorous shaking. These cultures were then used 
to inoculate large-scale expression cultures in either LB or 2x YT medium supplemented 
with lOOpg/ml carbenicillin. Cultures were grown at a variety of temperatures between 
17 and 37 °C in baffled flasks with rotary shaking at 170-220rpm. As with the pET 
expression cultures, growth was monitored by an increase in O D ôoo-
Expression of recombinant protein from pBAD plasmids was initiated by the addition of 
a filter-sterilised arabinose solution. Various arabinose concentrations between 0.0002% 
and 2% (w/v) were tested in order to identify the optimal concentration required for 
expression of soluble protein. Protein expression was induced when the cells reached 
mid-log phase (ODeoo approx. 0.6). Once again expression of recombinant protein was
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monitored by withdrawing 1ml samples from the cultures at various time-points before 
and after induction. Samples were then analysed by SDS-PAGE.
2.10 Analysis of recombinant expression
2.10.1 Preparation of total cell protein for analysis by SDS-PAGE
In order to monitor expression of recombinant proteins 1ml samples of culture were 
removed both prior to induction and at various time points thereafter. Cells were 
harvested by centrifugation at 13,000rpm in a bench-top microcentrifuge and the 
supernatant discarded. Pelleted cells were solubilised directly in an appropriate volume 
of SDS-PAGE sample buffer (typically 100-300pl). Each sample was boiled for 5 
minutes in a water bath to ensure complete solubilisation. Samples were loaded into 
separate wells of an SDS-PAGE gel and analysed as described below.
2.10. 2 SDS-PAGE
SDS-PAGE was used extensively as a means of monitoring both recombinant protein 
expression and the efficacy of protein purification procedures. All SDS-PAGE 
experiments were perfoimed using pre-cast Bis-Tris polyacrylamide gels obtained from a 
commercial source (NuPage gels, Invitrogen). Two different gel types were used 
dependent upon the protein samples under analysis; 4-20% polyacrylamide gradient gels 
for samples containing proteins of widely variant molecular weights, and uniform 12% 
polyacrylamide gels for less complex samples.
Protein samples were mixed with an appropriate volume of lOx sample buffer (see 
below) and loaded into the wells of a vertically mounted gel. Pre-stained molecular 
weight standards were loaded into one well of each gel to allow estimation of protein 
sizes and to allow visualisation of protein separation (SeeBlue Markers, Invitrogen). The 
entire gel, once loaded, was clamped vertically into an electrophoresis apparatus and both 
the inner and outer buffer chambers filled with Ix NuPage MOPS running buffer (see 
below). Samples were separated by the application of a 200V cun-ent for approximately 
45 minutes.
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After completion of the electrophoresis procedure each gel was removed ft om the 
apparatus and rinsed gently for 10 minutes in de-ionised water to remove the running 
buffer. Separated proteins were visualised by staining with ‘Gelcode Blue’ protein stain 
(Pierce). After rinsing each gel was immersed in 20ml of Gelcode Blue contained in a 
10cm square petri dish. The gel was placed on a rocker-table for approximately Ihr to 
allow staining to reach completion. After Ihr the stain was discarded and the gel re­
immersed in 20ml of de-ionised water for destaining. Following the destaining procedure 
protein bands could be clearly visualised and photographed.
10 X Sample Buffer 20 x NuPAGE MOPS Running Buffer
4 ml dHzO IMMOPS (104.6g)
1ml 0.5M Tris-HCl (pH 8.6) IM Tris base (60.6g)
1.6ml 10% SDS (w/v) 69.3mM SDS (lO.Og)
0.4ml p-mercaptoethanol 20.5mM EDTA (3.0g)
0.05% bromophenol blue (w/v) dH20 up to 500ml
2.10. 3 Western blotting
A number of Western blots were performed during this work in order to detect the 
expression of recombinant proteins. Firstly, the protein sample under analysis was 
separated by SDS-PAGE as described above. Following electrophoresis the gel was 
washed extensively in several aliquots of dHiO to remove traces of running buffer. The 
gel was then soaked in 1 x NuPAGE transfer buffer prepared according to the 
manufacturer’s protocol:-
1 X NuPAGE transfer buffer
Bicine 4.08g Methanol 100ml
Bis-Tris 5.23g dHiO 900ml
EDTA 0.29g
Whilst the gel was soaking several pieces of Whatman 3M filter paper were cut to the 
same size as the separating gel (8cm x 10cm). A similar sized piece of PVDF blotting
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membrane (Amersham) was also prepared. Both the membrane and filter papers were 
soaked in transfer buffer.
The blotting apparatus was assembled as follows. Firstly two abrasive nylon fibre pads 
were soaked in transfer buffer and placed into the cathode chamber of the blotting tank. 
Two pieces of pre-soaked filter paper were layered on top of the blotting pads. Next the 
SDS-PAGE gel was placed on top of the filter papers and all air bubbles removed. The 
gel was then covered with the PVDF blotting membrane followed by two further pieces 
of filter paper. Finally two more nylon fibre blotting pads were placed on the 
gel/membrane sandwich. The blotting cassette was sealed and placed into an empty 
electrophoresis tank. Both the anode and cathode chambers of the blotting apparatus were 
filled with 1X transfer buffer and transfer of proteins from the gel to the membrane was 
achieved by the application of a 30V cun-ent for a period of 1 hour. After transfer the 
apparatus was disassembled and ti'ansfer of proteins to the membrane verified by the 
effective transfer of the pre-stained SeeBlue molecular weight standards.
Following transfer of separated proteins to PVDF membrane all blots were processed 
using the Tmmun-Star Chemiluminescent Protein Detection System’ (Bio-Rad) and 
associated protocols. The membrane was first washed at room temperature with 25ml of 
Tris-buffered saline (TBS; 20mM Tris base, 500mM NaCl, pH 7.5). After 10 minutes the 
wash solution was decanted and the washing procedure repeated with a second 25ml 
aliquot of TBS. After washing the membrane was ‘blocked’ with 25ml of 0.2% w/v non­
fat dried milk in TBS. Blocking was performed over a period of 1 hour at room 
temperature with gentle agitation provided by a rocker table. After the blocking stage of 
the procedure the membrane was washed twice with 25ml of TBS for ten minutes at 
room temperature to remove unbound protein.
All blots performed in this work were designed to detect the presence of the His-Tag 
sequence. This was achieved tlnough the use of a commercially available mouse 
monoclonal antibody raised against the His-Tag (Sigma). The primary antibody was 
diluted 1 in 3000 into 25 ml of blocking solution and incubated with the transfer 
membrane for 2 hours. This period was generally long enough to allow efficient binding
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of the mouse monoclonal antibody to His-Tagged proteins. After binding the primary 
antibody solution was decanted and the membrane washed thiee times with separate 
25ml aliquots of TBS. The second stage of the detection procedure used a goat anti­
mouse IgG secondary antibody conjugate to amplify the signal from the primaiy 
antibody. The secondary antibody conjugate was diluted 3 parts in 10 in blocking buffer 
and incubated with the membrane for up to 2 hours. Finally the membrane was washed 
with three more 25ml aliquots of TBS.
Blot development was performed as follows. The membrane was removed fi’om the TBS 
wash buffer and placed on a flat surface. The surface of the blot was covered with 3ml of 
a chemiluminescent substrate solution and incubated for 5 minutes. The membrane was 
then drained of excess liquid and sealed in a heat-sealable plastic bag. The bag was fixed 
to the interior of an X-ray film cassette and a piece of film placed over the blot under 
darkroom conditions. Finally, the film was exposed for time periods of between 1 and 10 
minutes until a suitably strong signal was observed.
2.11 Protein purification and miscellaneous methods
2.11 .1 Cell lysis and sub-cellular fractionation by differential centrifugation
Sub-cellular fractionation was frequently performed as an initial erode purification 
procedure and also as a means of identifying the cellular location of particular proteins. 
Bacterial cells from expression cultures were initially separated from the growth medium 
by centrifugation at 4000-6000rpm (Beckman JA-10 rotor). The bacterial pellet was then 
re-suspended in an isotonic buffer to prevent osmotic lysis of the cells. Such re­
suspension buffers typically contained 100-400mM NaCl, 10% glycerol and a buffering 
salt (e.g. Tris-HCl) at 5OmM. The pH of such solutions was generally maintained at pH 
8.0 so as to inhibit the action of cellular acid proteases. Protease activity was further 
prevented by the addition of EDTA-free protease inhibitor tablets to the re-suspension 
buffer (Roche Molecular Biochemicals, 1 tablet/50ml of buffer). Cell pellets were 
typically resuspended with 5ml of ice-cold buffer per gram (wet weight) of cells.
Once re-suspended, cells were lysed by mechanical disruption in a Constant Systems Cell 
Disroption apparatus. This device uses a hydraulic ram to force bacterial cells through a 
veiy small aperture at high pressure (20-30 KPa). Upon passing through the aperture the
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cells impact upon a fixed target which is believed to cause lysis. The cell lysate then 
drains by gravity flow into a separate chamber where it is collected. At all stages after 
disruption cell lysates was kept on ice to reduce proteolysis.
The initial crude lysate thus generated consists of thi'ee basic components that can be 
separated by differential centrifugation; dense insoluble material such as fragments of the 
cell wall, soluble cytosolic components of the cell, and an emulsion of small hydrophobic 
lipid/protein/carbohydrate vesicles derived from cellular membranes. Cell wall material 
was not required in any of the studies presented here and was removed from lysates by 
centrifugation at 4000-6000ipm in a Beckman JA-10 rotor. The supernatant liquid, 
containing soluble proteins and membrane vesicles, was carefully decanted so as not to 
disturb the pelleted material. The supernatant was frirther fractionated where necessaiy 
into membrane and soluble components by high-speed ultracentrifugation at 100,000x g 
for 1.5 hrs (43,000rpm, Beckman Ti-50 rotor). This procedure resulted in the generation 
of a supernatant containing cytosolic proteins and small molecules and a pellet of 
membraneous material. The supernatant was decanted off and analysed by SDS-PAGE or 
used as the starting material for protein purification. The membrane pellet could be 
emulsified in a small volume of buffer by repeated passage tlnrough a syringe needle. At 
this point integral membrane proteins could be extracted from membrane lipids through 
the addition of buffer containing a biological detergent (e.g. DDM). The detergent 
solubilised membrane proteins were then used as the starting material for purification 
procedures. Alternatively, total membrane protein was analysed by SDS-PAGE after 
solubilisation in SDS-PAGE sample buffer.
2.11. 2 Purification of His-Tagged proteins by IMAC chromatography
Throughout this work IMAC chromatography was used as the primary means of protein 
purification. All heterologous expression constracts were designed in such a way as to 
encode a string of six consecutive histidine residues at either the N- or C-terminus of the 
recombinant protein. This so-called ‘His-Tag’ sequence exhibits a high affinity for 
immobilised divalent cations and fonns the basis of the IMAC purification procedure 
(Porath e/a/., 1975).
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The basic IMAC purification protocol relies upon the specific binding of recombinant 
His-Tagged proteins to a metal affinity resin loaded with Ni^ "*” ions, hi this work two 
different metal affinity resins were used, Ni-NTA agarose resin (Qiagen), and Ni-IDA 
sepharose resin (Amersham-Pharmacia), The vast majority of non-tagged proteins do not 
interact with these materials and thus pass straight through the resin bed. Non- 
specifically bound proteins can be removed by washing the resin with buffers containing 
low concentrations of imidazole, a structural analogue of the histidine residues that 
constitute the affinity tag. Finally, His-Tagged proteins are eluted from the resin material 
by the addition of buffers containing a much higher imidazole concentration.
An enomious number of variations on the basic IMAC procedure are possible and 
include the use of different affinity resins, binding methods, washing protocols and 
buffer compositions, hi fact, all of these factors were found to be important variables in 
the optimisation of the piuification procedures used here. The exact experimental details 
of the various purification protocols used in this work are described in association with 
individual experiments (see chapters 4 and 5). The results of the various protein 
purification experiments were analysed by SDS-PAGE.
2.11. 3 Protein dialysis and concentration
In a number of instances, particularly following IMAC chroniatogi’aphy, dialysis was 
used to remove small molecules from protein preparations. This was necessary because 
even low levels of contaminants were found to have a significant bearing on the outcome 
of downstream experiments. For example the presence of even tiny amounts of inorganic 
phosphate ions was found to interfere with ATP as e assays, and imidazole molecules gave 
rise to high background readings in measurements of intrinsic protein fluorescence. 
Purified proteins were dialysed in ‘Slidalyzer’ dialysis cassettes (Pierce, 10 kDa 
MWCO). The loaded cassettes were generally dialysed against approximately 3 litres of 
dialysis buffer cooled to 4 °C. Dialysis was continued for 3 hours in a cold room with 
continuous stirring of the buffer to promote rapid equilibration. Following dialysis, 
protein solutions were either concentrated (see below), used directly for biochemical 
experiments, or snap-frozen in dry-ice/ethanol and stored at -80 °C.
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Concentrated protein stocks were prepared using ‘Centricon’ centrifugal filter devices 
(Millipore). Protein concentration in these devices is achieved by ultrafiltration of the 
protein sample tlirough a membrane that allows the passage of only low molecular 
weight solutes. In this way solvents and small molecules pass through the membrane, 
whilst high molecular weight molecules such as proteins are retained in a much reduced 
volume. The ultrafiltration process is driven by centrifugal force. Generally up to 2ml of 
dilute protein solution was transferred into the upper chamber of a device and subjected 
to centrifugation at 5000 x g in a Beckman JA-21 fixed angle rotor. Centrifugation times 
were varied depending upon the desired protein concentration and the ability of the 
protein to remain in solution. At 4 °C 2ml of the initial solution could be reduced to 
approximately 200pl in a period of 1 hour. After the concentration procedure protein 
concentration was detennined using the BCA protein assay (see next section) or frozen at 
-80 ‘^ C.
2.11, 4 Protein concentration measurements -  The BCA protein assay
All protein concentration detenninations were perfonned using the ‘BCA Protein Assay 
Kit’ (Pierce). This is a colorimetric assay in which proteins react quantitatively with a 
reagent solution to produce an increase in absorbance at 562mn. The assay maintains 
linearity over a wide range of protein concentrations from 20-2000pg/ml. Briefly, lOOpl 
of the protein sample under investigation is transferred to a 2.5ml plastic cuvette and 
mixed with 2ml of the BCA working reagent. The reaction is then incubated at 37 °C for 
30 minutes to allow colour development. After the incubation period reactions were 
cooled to room temperature and Absseinm measured against a dHzO blank. Protein 
concentrations were determined by comparison with a series of standard reactions 
containing known concentrations of BSA (0-2mg/ml). This allowed the generation of a 
calibration cuiwe of protein concentration vs. Abs5 6 2nm- All standard and experimental 
reactions were perfonned in duplicate and corrected for background absorbance.
2.12 Biochemical Assays
2.12.1 ATPase assay -  EnzChek Phosphate Assay System
The EnzChek Phosphate Assay System (Molecular Probes) was used to conduct a 
number of ATPase activity assays (see chapter 6). The system relies on the
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spectrophotometric detection of inorganic phosphate (PJ released in to the assay medium 
by the activity of ATPase enzymes. P, release is enzymatically coupled to phosphorolysis 
of an artificial substrate (MESG). The phosphorolysis reaction generates a molecule with 
a strong absorption at 360nm, the production of which can be monitored in real-time. The 
components of the reaction mixture (see next page) were prepared in 1.5ml plastic 
cuvettes. Generally, ATPase activity was initiated by the addition of MgClito the 
reaction mixture. ATPase activity was monitored as an increase in absorbance of the 
reaction mixture at 360nm over time (using a dH2 0  blank as the reference sample).
ATPase reaction components
MESG substrate solution 200j.il
Purine nucleotide phosphorylase lOpl (1 Unit)
ATP X jul
MgCl2 y jil
Experimental enzyme z jul
MOPS buffer (5OmM) 7 9 0 - x - y - z p l
It is the purine nucleotide phosphorylase component of the reaction mixture which 
couples release of Pi by the ATPase enzyme to phosphorolysis of the MESG substrate.
2.12. 2 The ‘Malachite green’ Pi release assay
This assay was used extensively throughout this work. The methodology described below 
is essentially a modification of the ATPase assay developed by Harder and colleagues 
(Harder et a i, 1994). The technique once again relies on the spectrophotometric 
detection of P, released by ATPase enzyme activity. Inorganic phosphate is found to react 
quantitatively with an acidified mixture of ammonium molybdate and the dye malachite 
green to produce a phosphomolybdate-malachite gieen complex which absorbs light 
strongly in the range 600-63Onm.
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ATPase reaction mixtures were prepared in SOOpl volumes containing the following 
components at appropriate concentrations (see chapter 6): ATP, buffer, experimental 
ATPase enzyme, MgC^. Typically each reaction would be prepared in the absence of 
MgCri and pre-incubated for 10 minutes at 37 °C in a thermostatically controlled heating 
block. ATPase activity would then be initiated by the addition of Mg^ "^  to the reaction 
mixture. Immediately after induction of ATPase activity, and at various time points 
thereafter, 45 pi samples of the reaction mixture were withdrawn and mixed with 5 pi of 
500mM EDTA in a separate well of a microtitre plate. The purpose of the high EDTA 
concentration is to rapidly chelate Mg^ "^  ions and immediately halt further ATPase 
activity.
After collection of a complete set of samples (typically 12 samples collected over a 10 
minute period) the amount of inorganic phosphate in each sample was analysed by the 
addition of lOOpl of malachite green detection reagent (components shown below).
Malachite green PMetection reagent 
3 parts 0.045% w/v malachite green (in dHiO)
1 part 4.2% w/v ammonium molybdate (in 6N HCl)
0.01% v/v Tween 20
The addition of detection reagent to Pi-containing samples resulted in the rapid formation 
of a green coloured malachite green-phosphomolybdate complex. The absorbance of 
each sample was measured at 61 Omn in a plate reader. Measurement of absorbance was 
performed as rapidly as possible after the addition of the detection reagent since the low 
pH of this reagent might cause acid hydrolysis of un-hydrolysed ATP. The absorbance of 
the zero time point sample was subtracted from all subsequent absorbance readings to 
correct for non-enzymatic Pi release and Pi contamination in reagents.
Pi in each sample was accurately quantified by the use of standard curves prepai'ed in 
parallel with each set of ATPase reactions. Various known quantities of Pj were mixed 
with 5pi of 50OmM EDTA in a separate well of a microtiter plate and the total volume
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brought up to 50pl with MOPS reaction buffer (5OmM MOPS, lOOmM NaCl, pH 7.4). 
The amount of P; in the standards was typically 0-1500 picomoles. lOOpl of detection 
reagent was added to each standard sample and the absorbance at 61 Onm measured at the 
same time as the experimental samples derived from the ATPase assay reaction mixture. 
A typical standard curve produced by this teclmiqiie is shown in figure 6.1.
The amount of phosphate present in the various experimental samples was used to 
calculate the enzymatic ATPase activity in temis of nanomoles of Pj released/minute/mg 
of protein.
2.12. 3 Steady-state protein fluorescence measurements
Measurements of intrinsic protein fluorescence were performed at room temperature in a 
Jasco FP-750 fluorescence spectrophotometer. Excitation light at 285nm was selected via 
a series of chromating mirrors and fluorescence of the sample measured at right-angles to 
the direction of incident light using a photomultiplier tube to amplify the signal.
For the purpose of the experiments described here reaction mixtures were prepared in a 
total volume of 200pl and transferred to a Hellma Suprasil quartz fluorescence cuvette. 
Protein fluorescence spectra were collected at wavelengths between 295 and 400nni.
Both the excitation and emission band-widths were set to 5nm. The detection sensitivity 
of the photomultiplier tube was set to medium.
The effects of ligand binding to proteins were measured as changes in protein 
fluorescence spectra resulting from the addition of small volumes of concentrated ligand 
to the protein solution. The ligands used during the studies were ATP (lOOmM stock 
solution in dHaO) and MgCh (lOOmM stock solution in dH2 Û). ATP is Icnown to absorb 
both incident light and emitted light and can cause a significant decrease in the intensity 
of fluorescence emission spectra. This phenomenon, known as an inner filter effect, was 
a complicating factor in measuring the effect of ATP binding on intrinsic protein 
fluorescence. The magnitude of the inner filter effect caused by various concentrations of 
ATP was determined by placing a second fluorescence cuvette in the excitation beam
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between the light source and the protein sample. This cuvette was filled with reaction 
buffer and an emission spectrum collected in the absence of ligand. ATP was then added 
at various concentrations to the control cuvette and the effect on emission spectra 
determined as a percentage decrease in fluorescence. Such data was used to correct the 
fluorescence spectra observed when ATP was mixed with protein directly.
2.12. 4 Stopped-fiow fluorescence spectroscopy
Stopped-flow fluorescence data were collected in an Applied Photophysiscs stopped-flow 
device. Experiments were designed to measure transient changes in protein fluorescence 
caused by the binding of ligands such as ATP and magnesium ions. Interactions between 
protein and ligand occurred in a mixing chamber maintained at 22 °C. Delivery of 
protein and ligand to the mixing chamber was achieved by forcing equal volumes of each 
solution (approx. lOOgl) in to the chamber from external reservoirs using nitrogen-driven 
hydraulic plungers. Excitation light at 285nm was provided to the mixing chamber by 
means of an argon lamp and two serially connected monochromators. A photomultiplier 
tube was used to collect and measure the intensity of emission light at right-angles to the 
incident excitation beam. Cut-off filters placed over the window of the detection 
photomultiplier tube were used to select the wavelengths above which fluorescence data 
were collected. When measuring changes in tryptophan fluorescence a 32Onm cut-off 
filter was used. When measuring changes in the fluorescence of the external probe 
MANT-ATP a 42Onm filter was chosen. Changes in fluorescence were observed as an 
alteration in the output signal from the photomultiplier tube. Fluorescence data following 
mixing of protein with ligand were collected over logarithmic time-bases ranging from 
10 seconds to 1000 seconds.
92
Chapter 3
Initia! cloning and sequence analysis of the Mycobacterium tuberculosis dvr ABC 
operon
The JrrABC operon was initially identified by Cole and colleagues during the M. 
tuberculosis genome sequencing project (Cole et aL, 1998). During the annotation phase 
of the project all gene sequences, and the proteins encoded therein, were scanned for 
homology to sequences of known function. The genes of the drr operon were identified 
as being likely components of a transmembrane efflux system, with clrrK bearing 
sequence motifs typical of ABC transporters, and the drrE and C genes exhibiting 
characteristics typical of transmembrane proteins. Moreover, the genes seemed to encode 
proteins homologous to those of a known efflux transporter, the DrrAB system of 
Streptomyces peucetius. In this organism two genes, drr A  and B, encode the ATP- 
binding and transmembrane domains of an ABC transporter mediating producer self­
protection against the antibiotic molecules daunorubicin and doxorubicin (Kaur, 1997).
These obseiwations raise a number of interesting questions with regard to the biology of 
M  tuberculosis. For example, is it possible thatM  tubercidosis is producing and 
secreting one or more as yet unidentified bio active secondary metabolites? Is it possible 
that ABC transporter efflux systems contribute to the high level of intrinsic drug 
resistance exhibited by M  tubercidosisl Could it be that the dirABC system has some 
alternate but uncharacterised physiological function?
This chapter reports the initial stages of an investigation into the function of the M. 
tubercidosis <7rrABC genes. The genes were first amplified ûom M  tuberculosis 
genomic DNA, cloned, re-sequenced and then compared with the published sequence 
data from the M  tuberculosis genome sequencing project. An in silico analysis of the 
protein sequences encoded by the drr ABC genes was used to identify homologous 
systems in related mycobacterial pathogens and suggest possible physiological roles for 
the transporter. Finally, the amplified drr genes were used to generate recombinant 
expression vectors suitable for the production of Drr proteins in the heterologous host 
Escherichia coli.
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3.1 PCR amplification of the drr A, B, and C genes from M, tuberculosis
genomic DNA
The published sequences of the drrA, B and C genes were used to design oligonucleotide 
PCR primers for the specific amplification of the genes from genomic DNA. The thi ee 
genes constituting the rirrABC operon are located on segment 129 of the M. tubercidosis 
genome, deposited in the GenBank database under accession number Z83857. The 
operon occupies a total of 2689bp of the genome {drrA = 996bp, drrB = 870bp, drrC = 
831 bp). M  tuberculosis (strain H37Rv) genomic DNA was a kind gift from Dr. S. Ali 
(Dept, of Biochemistry, University of Glasgow).
The PCR primers used for amplification, detailed in table 2.2, were also used to introduce 
additional nucleotides at the 5’ and 3’ ends of each gene. These additional sequences 
encoded restriction enzyme recognition sites to allow excision of the sequences from the 
initial cloning vector. This was done in order to simplify the process of sub-cloning the 
amplified sequences fr om the initial cloning vector into expression vectors. Each of the 3 ’ 
primers were designed to eliminate the native stop codon of the gene and introduce a 3’ 
HinéWl recognition site. The 5’ primers maintained the native ATG start codon of each 
gene as part of an Ndel site.
Figure 3.1a shows the successftil amplification of three genomic sequences with sizes 
consistent with those published for drr A, B and C. Figure 3.1b shows the amplification of 
the complete region of the M  tuberculosis genome predicted to contain all three drr 
genes. Once again, the approximately 2.7Kb amplicon is consistent with the predicted 
size of the <7rrABC operon.
In order to maintain and propagate the amplified sequences, each one was extracted from 
the agarose gel and ligated into the commercially available T-A cloning vector pGEM-T 
Easy. The ligation reaction was then used to transfoim competent E. coli NovaBlue cells. 
Transfonned cells were selected on the basis of ampicillin resistance, and recombinant 
clones identified by blue/white screening. For each of the four sequences cloned, up to 
six recombinant colonies were selected for further analysis.
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Figurere 3. la PCR amplification of the drr A., B and C genes
B
0.5Kb
Lane A = drr A  amplified using primers 
AF/AR
Lane B = drrB amplified using primers 
BF/BR
Lane C = drrC amplified using primers 
CF/CR
94°C 1 min -  dénaturation 
54°C 1 min -  annealing 
72°C 1 min - extension
30 Cycles
Figure 3.1b PCR Amplification of the drrXBC operon 
Operon
Operon amplified using primers AF/CR
94°C 1 min -  dénaturation 4
54°C 1 min — annealing 30 Cycles
72°C 2.5 min -  extension ▼
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Plasmids were recovered from recombinant clones by mini-prep and further analysed by 
restriction digest to check for the presence of the inserted sequence. Digestion of isolated 
pGEM-T Easy plasmids with EcoK.\ allowed for simple identification of recombinant 
clones due to the presence of EcoK.\ sites either side of the T-A cloning site. Figure 3.2a 
illustrates the analysis of 6 pGEM-T Easy plasmids digested with E'coRl, all of which 
contain the inserted drr A  amplicon. The slightly increased size of the excised fragment 
compared with the amplified sequence is due to the presence of small amounts of vector 
DNA between the T-A cloning site and the EcoRl sites. Figure 3.2b shows isolated 
recombinant plasmids bearing the drrB and C amplicons and the complete drr ABC 
genomic region. Plasmids were submitted for automated DNA sequencing using standard 
vector directed sequencing primers (M l3 Forward and Reverse). The data generated was 
fiirther analysed to confinn the identity of the cloned sequences.
3. 2 Sequence analysis of the cloned drr genes
The nucleotide sequences of the four cloned PCR amplicons were entirely consistent with 
those of the published drr genes (with the exception of the 5’ and 3’ mutations introduced 
by oligonucleotide directed mutagenesis). These data confirmed the success of the initial 
genomic PCR reaction and allowed the amplified sequences to be maintained as E. coli 
glycerol stock cultures. A detailed in silico analysis of each cloned sequence was 
perfonned and used to test the hypothesis of Cole and colleagues that the M. tuberculosis 
genome encodes a daunorubicin/doxorubicin efflux ABC transporter.
Sequence analvsis of drr A
The drr A  gene, in its native form, is 996bp long encoding a protein of 331 amino acids. 
There is a marked G+C bias in the coding sequence of drr A  of 63%. This is close to the 
overall GC-bias in the M  tuberculosis genome of 65% (Cole et al., 1998). The translated 
sequence of drr A  contains a number of highly conseiwed protein motifs strongly 
suggesting that the protein is the ATP-binding subunit of an ABC transporter (see figure 
3.3a). The first major indicator that DrrA is a nucleotide-binding protein is the presence 
of the Walker A motif (PROSITE entry; PS00017). This glycine-rich motif has been 
identified in a large number of ATP/GTP binding proteins fi'om such evolutionarily 
diverse species as bacteria and man.
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Figure 3. 2a Restriction analysis of 6 pGEM IdrrX plasmids
pGEM-T Easy 
vector DNA
Inserted drr A 
PCR 
fragment
Figure 3. 2b Restriction analysis of i/rrB, drrC and drr ABC clones
pGEM/ pGEM/
drrh drrC pGEM/rfrMBC
pGEM-T Easy
drrB amplicon 
drrC amplicon
3 K b -
2 K b -
- 1 K b
pGEM-T Easy
drr ABC 
operon
The EcoRl digests above were performed in a total volume o f 20|il using lOU of  
enzyme. Digests were incubated at 37 °C for 1 hour.
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Crystallographic studies of proteins containing the Walker A sequence show that the 
residues of the motif form a flexible loop that interacts extensively with bound NTP’s 
through a network of hydrogen bonds (e.g. Hung et aL, 1998), The Walker A motif, 
highlighted in red in figure 3.3a, is found towards the N~terminus of the M  tuberculosis 
DrrA protein. The most highly conserved residues of the motif include the invariant 
glycines at positions 42 and 47 and the lysine at position 48. The second part of the ATP- 
binding site is formed by the Walker B motif, always found down-sequence from Walker 
A. Walker B includes an invariant aspartic acid residue (D172 in DrrA) that is believed to 
co-ordinate a Mg^^ ion in the active site of the protein. The magnesium ion bound at this 
site is a vital component catalytic complex and must be present for ATP hydrolysis to 
occur. The Walker A and B motifs have been identified in a variety of non-transport 
related proteins, e.g. the E. coli DNA repair enzyme UvrA, and are not necessarily 
definitive markers of ABC transporters (Thiagalingam and Grossman, 1991). However, 
located between the Walker A and B sites of M  tuberculosis DrrA, approximately 100 
residues downstream of Walker A, is the so-called ‘ABC transporter signature sequence’ 
(PROSITE entry: PS00211). The presence of this motif in DrrA, combined with the 
presence of Walker A and B sites, is a very strong indication that DrrA is the ATP- 
hydrolysing subunit of an ABC transporter complex. The ABC transporter signature 
sequence is often described in the literature as the ‘LSGGQ’ motif since these five amino 
acids are most commonly found at the start of the sequence. It should be noted however 
that a degree of degeneracy is observed at all positions of the motif, except for a 
conserved glycine residue at position four. This glycine residue is conserved in DrrA as 
part of the sequence ‘YSGGM’ (see figure 3.3a). As described in chapter 1.2, the exact 
function of the signature sequence is a matter of some debate. Some studies suggest that 
it may fonn part of a composite ATP-binding site in a dimeric model of the ABC 
transporter NBD’s, whilst others suggest a role in inter-domain communication. ABC 
transporter NBD’s often exhibit 30-40% sequence homology to one another, irrespective 
of their substrates, due to the highly conserved nature of the Walker A, B and signature 
sequence motifs. However, much higher degrees of sequence homology that extend 
outwith the core ATP-binding region can be a good indication that NBD’s share a similar 
function. A BLAST search was used to screen protein sequence databases for 
homologues of the M. tuberculosis DrrA protein in order to identify proteins that may be 
evolutionarily or functionally related (Altschul et aL, 1997).
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3. 3a Translation of the M. tuberculosis drr A  gene showing conserved sequence
motifs.
(1) MRNDDMAVVV NGVRKTYGKG KIVALDDVSF KVRRGEVIGL (40)
(41) LGPNGAGKTT MVDÏLSTLTR PDAGSAIIAG YDVVSEPAGV (80)
(81) RRSIMVTGQQ VAVDDALSGE QNLVLFGRLW GLSKSAARKR (120)
(121) AAELLEQFSL VHAGKRRVGT YSGGMRRRID lACGLVVQPQ (160)
(161) VAFLDÎ3PTTG LDPRSRQAIW DLVASFKKLG lATLLTTQYL (200)
(201) EEADALSDRI ILIDHGIIIA EGTANELKHR AGDTFCEIVP (240)
(241) RDLKDLDAIV AALGSLLPEH HRAMLTPDSD RITMPAPDGI (280)
(2 8 1 )
(321)
RMLVEAARRI
SLTHLVSGSA
DEARIELADI
R
ALRRPSLDHV FLAMTTDPTE (320)
(331:
Walker A Walker B ABC transporter signature sequence
3 .3 b Blast? search results using M. tuberculosis DrrA as the query sequence.
Accession # Descrintioii Organism P-Value
gi|2145829 Daunorubicin resistance protein drr A* M leprae le -146
gil4416482 Daunorubicin resistance protein A* M. avium 3e-74
gi|4808357 ABC tiansporter ATP-binding component* S. coelicolor 7e-66
gil29831196 ABC transporter ATP-binding protein* S. avermltilis 9e-60
gi|11346307 Probable ABC-type transport protein* S. coelicolor le-59
gi] 10129760 ABC transport system ATP-binding protein* S. coelicolor le-59
gi|20520964 ABC transporter ATP-binding protein* S. coelicolor 2e-59
gl|11141834 Putative ATP binding protein* S. vhidochromo 2e-59
gi|29832484 ABC transporter ATP-binding component* S. avermltilis 4e-59
gi|399405 Daunorubicin resistance ATP-binding protein S, peucetius 2e-57
Putative functional assignment
99
A search of the NCBI non-redundant sequence database using the Blast? algoritlim 
produced hits to a large number of putative ABC transporter NBD’s. A modified version 
of the Blast? output showing the top ten database hits is shown in figure 3.3b. In common 
with M  tuberculosis DrrA, the vast majority of the hits were uncharacterised proteins 
identified during genome sequencing projects. As such, these data cannot be used to infer 
an unambiguous function for the M. tuberculosis Dn A protein. The top hit was to a 
Mycobacterium leprae protein which exhibited an astonishing 85% identical residues, the 
overall homology rising to 90% when conservative amino acid substitutions were taken 
into account. The second most homologous protein was also from a pathogenic 
mycobacterial species, M. avium. This protein shared 51% identity to M. tuberculosis 
Dn A and 63% similarity. These levels of homology would suggest that the proteins 
almost certainly perform a similar ftinction in all three species of mycobacteria. The 
remainder of the top ten database hits were all proteins from various Streptomyces 
species, including a number of antibiotic producing organisms. One of these hits, the S. 
peucetius DrrA protein, is the only homologue which has been experimentally 
characterised. This protein, known to energise the transmembrane efflux of the 
daunorubicin and doxorubicin antibiotics, is 42% identical to the M. tuberculosis DrrA 
protein. A gapped sequence alignment of the M. tuberculosis and S. peucetius Dn A 
proteins is shown in figure 3.4. From these data it is difficult to draw firm conclusions as 
to whether the sequence homology between the mycobacterial and streptomycete proteins 
is a genuine reflection of conserved function, i.e. antibiotic transport. The homology may 
equally well reflect the common evolutionary roots of the streptomycetes and the 
mycobacteria. It is entirely possible that the ABC transporters with which these NBD’s 
are associated may have evolved different functions after divergence of the two genera.
Sequence analvsis of the drrB and drrC genes
The drrB and drrC genes are 870 and 83 Ibp in length respectively. Each of the open 
reading frames display a positive GC-bias {drrB -  59%, drrC - 57%) that is just slightly 
lower than that of the complete M. tubercidosis genome (65%). The proteins encoded by 
the drrB and drrC genes are predicted to be 289 and 276 amino acids long. Both proteins 
contain more than 50% hydrophobic amino acids (A, I, L, F, W, V) strongly suggesting 
that they are associated with the cell membrane. This observation is consistent with a 
potential role for the DrrB and DrrC proteins as the MSD’s of an ABC
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Figure 3. 4 Sequence alignment of the S, peucetius and M. tuberculosis 
DrrA proteins
s . peu DrrA (1)M .tb DrrA (1)C onserved (1)
S .peu DrrA (49 )
M .tb DrrA (50)
C onsensus (51 )
S .peu DrrA (99 )
M .tb DrrA (1 0 0 )
C onsensus (1 0 1 )
S .peu DrrA (1 4 9 )
M .tb  DrrA (1 5 0 )
C onsensus (1 5 1 )
S .peu DrrA (1 9 9 )
M .tb DrrA (2 0 0 )
C onsensus ( 2 0 1 )
S .peu DrrA ( 2 4 9 )
M .tb DrrA ( 2 5 0 )
C onsensus ( 2 5 1 )
S .peu DrrA (296)
M .tb  DrrA ( 3 0 0 )
C onsensus (3 0 1 )
MNTQPTRftlETSÊLV«VfNG--TRJ|v!PGLDLNVPAgL^YGl»È®BfêS^S 
-MRNDDMfiVVVNGVRKTiGKGKIV*LBDVSFKyRR@E«lSL^SP»Élip2HT 
A G K Y  A D  V G V G  LGPNGAGK
tT  I RMWà^L#gBG#T#RVE#Hj#T##DT##Rgsg^YASm3EG^Tq 
$MVDIÊS!ggËT##A#S#IIAj6Y#V##^AG#SS3Mlg!fGGQVAVÜDAl^S6 
T L TL RPD G A G DV SEP VRR I VTGQ VD L G
T E K # M M ^ O @ Y S W A R # E # # # I DGKG$,GD&RDRLLK#%0%mgL 
E0m atLF##W GL8KSA#K#W #LEQ#SEVHglGKRRVG###M ##(l 
NLV GRL G S AR RAAEL F L A R TYSGGMRRR
W a s :  
ü!0Icg]
DIA VV P FLDEPTTGLDPRSR WD V LLTTQY
LD|^QLABRÎAVflg|RV^alGTTG|ÜgSSLSSNVLRLRLHlE|AQSRAEA &E@|0Am,SDmiIL#0BlI#AEGTAN#^HRA#DTFCEIVPRQLKDLDAI 
L EAD L DRI IDHG lAEGT ELK G D
ERLhSAE|*GVTIHRDSDfTALSARIDD? ^QGMR#LAELSRTHL#VRS
VAAiGSLiPEHHRAMLTlDSDRITMPAiPDGIÜMLVE^RRIDEARlfiLAD 
L L P P R A E
FSfiGQSS|ieE\Rl^LfGH^DDRSTEEAAEEEKVA
IAÎ.RRPÎSSî3H5^P^iMÏTDgTESLTHLVSGSAR----
L SLD VFLA T P
The sequence alignment above shows the degree o f amino acid homology between the 
DrrA proteins o f M tuberculosis and Streptomyces peucetius. Conserved residues are 
shown in red. The regions o f  highest homology include the Walker A nucleotide-binding 
motif, the Walker B region and the ABC transporter signature-sequence. The overall 
homology between the two proteins is 42% identieal residues rising to 57% when 
eonservative substitutions are taken into aceount
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transporter complex. The original ‘two-times-six’ model of ABC transporter MSD’s 
predicted that the proteins possess multiple, hydrophobic, membrane-spanning a-helices. 
This model was recently confirmed by the high resolution structures of the MsbA and 
BtuCD ABC transporters. In order to assess whether the DitB and C proteins might 
possess similar structural features, their sequences were submitted for analysis by the 
TopPred sequence analysis program. This web-based sequence analysis seiwer makes 
predictions of membrane protein topology based upon primary amino acid sequence data 
(http://bioweb.pasteur.fr/cgi-bin/seqanal/toppred.pl, von Heijne, G., 1992). The output 
data for the DrrB and C proteins is summarised in figures 3.5 and 3.6. The topology 
predictions for the proteins suggest that they both have six membrane spanning helical 
segments. These data further support a model of the M  tuberculosis DrrABC transporter 
in which the DrrB and C proteins contribute to a heterodimeric transmembrane pathway.
As described in chapter 1.2, the sequence homology between ABC transporter MSD’s is 
often veiy limited, even when two transporters share a similar substrate. Despite this, a 
search of the NCBI non-redundant protein sequence database was performed in order to 
identify any potential homologues of the DrrB and Dn C proteins. The searches produced 
a relatively small number of database hits, with two or three results being of particular 
interest. The genomes of the pathogenic mycobacteria M  leprae and M. avium appear to 
encode homologues of both DrrB and DrrC. The M. leprae proteins exhibit an 
extraordinary level of sequence conservation for ABC transporter MSD’s (DrrB -  77%, 
DrrC ~ 75%). The M. avium homologues have a lower, but still significant level of 
homology, 42% for DnB and 49% for Dn*C. These results reflect those obtained when 
the database was searched using the DrrA protein sequence. It seems very likely that both 
M  avium and M  leprae encode a DrrABC transport system similar to M  tuberculosis, 
the very high level of sequence homology suggesting that all three systems perfoim a 
similar physiological function. Exactly what the function of the mycobacterial DrrABC 
systems is remains unclear. Hits to proteins with a characterised function were few, but, 
in the case of DitB, included the ORF2 protein of S. rochei and the DrrB protein of S. 
peucetius. Both of these proteins are known MSD components of ABC transporters 
associated with antibiotic resistance (Femandez-Moreno et a l, 1998; Kaur, 1997). These 
data would seem to support the hypothesis that the M  tuberculosis DrrB and C genes 
constitute the MSD’s of a novel antibiotic efflux ABC transporter.
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Due to the low level of sequence homology between the MSD’s of ABC transporters 
conseiwed sequence motifs are rare. The major exception to this rule is the so-called 
‘EAA’ motif identified in a subset of substrate-binding protein dependent nutrient uptake 
ABC transporters (Mourez et ah, 1997). However, a second motif known as the ‘ABC-2 
integral membrane protein signature’ (PROSITE entry: PS00890), has also been 
identified in a small number of bacterial ABC transporters associated with the export of 
antibiotics and cell wall components (Reizer et al., 1992). Interestingly, this motif is 
present in both the DitB and C proteins of M. tuberculosis and in the S. peucetius DitB 
protein. The motif itself is somewhat extended and has a high degree of degeneracy 
thi'oughout, the only absolutely conserved residue being a proline ten residues from the 
C-tenninal end. In the M  tuberculosis DrrB protein the ABC-2 motif spans residues 203 
to 239 inclusive, with the conserved proline at position 230. In the case of DrrC, the motif 
extends from residues 181 to 220 and the conserved proline occurs at position 211. The 
presence of this motif in DrrB and C is further evidence the DrrABC system is an efflux- 
type ABC transporter.
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Figure 3. 5 TopPred sequence analysis of M. tuberculosis DrrB
Candidate membrane-spanning segments: 6 segments found
Helix Begin End Certainitv
1 49 69 Certain
2 88 108 Certain
3 143 163 Certain
4 167 187 Certain
5 199 219 Certain
6 266 286 Certain Hvdrooathv Analvsis
3
zx>
Ü
-OoSIClOS_XJ3)JC
2
1
0
1
L o u e r  c u t o f f  
U p p e r  c u t o f f  h y d r o p h o b i c i  ty-2
0 5 0 1 00 1 5 0 200 2 5 0
Primary sequence of DrrB -  putative transmembrane helices shown in red
( 1 ) MSGPAXDASP ALTFNQSSAS IQQRRLSTGR QMWVLYRRFA ( 4 0 )
( 4 1 ) APSLLNGEVL TTVGAPIIFM V G FY IPFA IP WNQFVGGASS ( 8 0 )
( 8 1 ) GVASNLGQYI TPLVTLQAVS e a a i g s g f r a ATDSLLGVNR ( 1 2 0 )
( 1 2 1 ) RFQSMPMAPL TPLLARVWVA VDRCFTGLVI SLVCGYVIGF ( 1 6 0 )
( 1 6 1 ) RFHRGALYIV GFCLLVIAIG AVIÆEAADLV GTVTRNPDAM ( 2 0 0 )
( 2 0 1 ) L PL L SL P IL I FGLLSIGIMP LKLFPHWIHP FVRNQPISQF ( 2 4 0 )
( 2 4 1 )
( 2 8 1 )
VAALRALAGD
STIVIARRP
TTKTASQVSW PVMAPTLTWL FA FW IL A L S ( 2 8 0 )
( 2 8 9 )
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Figure 3. 6 TopPred sequence analysis of M. tuberculosis DrrC
Candidate membrane-spanning segments: 6 segments found 
Helix Begin End Certainitv
Ü
-Oo
CLo
■O
45
80
134
162
197
244
65
100
154
182
217
264
Certain
Certain
Certain
Certain
Certain
Certain
Hydropathy Analvsiss
2
1
0
1
-2 h y d r o p h o b i c ! t y
0 1 005 0 1 5 0 200 2 5 0
Primary sequence of DrrC -  putative transmembrane helices shown in red
( 1 ) M ITTT SQ EIE LAPTRLPGSQ NAARLFVAQT LLQTNRLLTR ( 4 0 )
( 4 1 ) WARDYITVIG A IV L P IL F M V  VLNIVLGNLA YVVTHDSGLY ( 8 0 )
( 8 1 ) SIVPLIALGA AITGSTPVAI DLMRERSFGL LARLWVLPVH ( 1 2 0 )
( 1 2 1 ) R A SG L ISR IL a n a i r t l v t t LVMLGTGWL GFRFRQGLIP ( 1 6 0 )
( 1 6 1 ) S M O flS V P V I LGIAIAAMVT TVALYTAQTV VVEGVELVQA ( 2 0 0 )
( 2 0 1 ) IA IF F S T 6L V PI2ÏSYPGWIQ PFVAHQPVSY AIAAMRGFAM ( 2 4 0 )
( 2 4 1 ) GGPVLSPMIG MLVWTAGICV VCAVPLAIGY RRASTH ( 2 7 6 )
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3. 3 Sub-cloning of the M. tuberculosis drr genes
With a significant amount of sequence data supporting the hypothesis that the cloned drr 
genes do indeed encode a novel efflux ABC transporter, the next stage of the 
investigation involves analysing the biochemical properties of the proteins themselves.
M tubercidosis is a particularly slow growing organism and, due to its pathogenicity, 
requires special facilities for its growth and handling. These features make working with 
live M  tuberculosis particularly undesirable. As such, it was decided that a biochemical 
study of the DitA, B, and C proteins would require their expression in a heterologous 
host. E. coli was selected as the heterologous host since it has been used to successflilly 
overexpress an enonnous number of proteins from biologically diverse species. In 
addition, genetic systems for the expression of heterologous protein in E. coli are well 
developed and characterized.
Myriad different plasmid based expression systems are available for use with E.coli. The 
commercially available pET-series plasmids (Novagen) were chosen for the expression of 
the drr A, B and C genes since these vectors possess a number of highly desirable 
features. Firstly, the transcription of the heterologous gene is under the control of the very 
strong bacteriophage T7 promotor. Since E. coli RNA polymerase does not interact with 
this promoter, background or Teaky’ expression of the target protein is minimized in the 
uninduced state. The transcription of the heterologous gene is achieved by transforming 
the expression construct into a host cell that possesses a chi'omosomal copy of the T7 
RNA polymerase, itself under control of the lacUV5 promotor. The expression of the T7 
RNA polymerase is induced by the addition of IPTG to a log phase culture. This in turn 
results in massive transcription of the target gene sequence. The manufacturers suggest 
that virtually all of the cell’s resources become involved in expression of the heterologous 
protein and that it may constitute up to 50% of the total cell protein after just a few hours 
(pET System Manual, ninth edition, Novagen). In addition to the tightly controlled and 
high level of expression achieved through use of the pET plasmids, the vectors also 
encode one or more ‘His-Tag’ sequences. This is a sequence of six consecutive histidine 
residues placed at either the N- or C-tenninus of the recombinant protein. The Hisg 
sequence acts as both an epitope-tag, enabling the expression of the recombinant protein 
to be monitored by immunogenic means, and an affinity purification tag. The six 
consecutive histidine residues bind strongly to certain divalent cations, particularly Ni^\ 
enabling efficient purification of the recombinant protein using ‘immobilised metal
106
affinity chromatography’ (IMAC). Detection and purification of the recombinant Drr 
proteins will be discussed in gieater detail in following chapters.
The basic sub-cloning strategy used for all of the cloned drr sequences is illustrated in 
figure 3.7, and the techniques involved are described in chapter 2. Unique restriction 
enzyme sites incorporated into the 5’ and 3’ ends of the drr genes during the initial PCR 
reaction enabled the genes to be precisely and selectively excised from the pGEM-T Easy 
constructs using Ndel and ifmdlll. Isolated drr gene fragments were then purified fiom 
vector DNA by agarose gel electrophoresis and isolated by gel extraction (figure 3.8a). 
The non-recombinant pET vector, with unique Ndel and Hinàlll sites forming part of the 
multiple cloning site (MCS), was treated in an identical fashion. After digestion, the ends 
of the linearised plasmid have non-complimentary, single-stranded overhangs which 
prevent the vector ends from ligating to themselves. However, incomplete digestion of 
the vector is difficult to detect. In order to reduce the chances of vector self-ligation, the 
isolated vector DNA was treated with shiimp alkaline phosphatase. The 
dephosphorylated vector DNA was then purified by electrophoresis and gel extraction 
(see figure 3.8 a).
The two isolated DNA fragments, possessing complimentary 5’ and 3’ single stranded 
overhangs, were ligated together using T4 DNA ligase. Recombinant expression vectors 
generated in this way were recovered by transfonning the ligation mixture into high 
efficiency NovaBlue cells. Transformants were selected on the basis of vector encoded 
antibiotic resistance. Recombinant expression plasmids were isolated by mini-prep and 
checked for the presence of the inserted drr gene by restriction digest (see figure 3.8b). 
Four recombinant expression vectors were generated by these reactions, one for each of 
the amplified drr sequences. They were termed pDrrA, pDrrB, pDrrC and pDrrABC. The 
details of each of these plasmid constructs are described in subsequent chapters.
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Figure 3. 7 Generalised sub-cloning strategy
drr ampliconNde\
Recombinant 
pGEM-T Easy 
plasmid
pT7
pET-series
expression
plasmid
I I
Ndel
MCS
HindlW
Restriction digest and gel extraction 
to isolate cloned drr gene
Restriction digest and gel extraction 
to isolate pET plasmid DNA
Ligation o f  
cohesive ends 
- T4 DNA ligase
Recombinant pET 
expression construct I
Recombinant pET plasmid 
with drr gene expression under 
the control o f the T7 promotor. 
Inserted sequence is fused to 
His6 purification tag
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Figure 3. 8a Gel purification of linearised pET-33b and é/rrABC insert after 
restriction digestion with Ndel and HinûlW
Linearised pET-33b vector 
DNA digested with Ndel 
and Hinàlll (5.5Kb)
2.7Kb c/rrABC operon 
fragment excised from 
pGEM vector
The fragments shown above were ligated together using T4 DNA ligase and the mixture 
was transformed into competent E. coli NovaBlue. Recombinant clones were isolated and 
checked for the presence o f the inserted fragment by restriction enzyme analysis (see 
below).
Figure 3.8b Restriction analysis of recombinant pET expression plasmids
pDrrA pDrrABC
pET-21a
(5.5Kb)
Inserted 
drr A  gene 
(1Kb)
pET-33b
(5.5Kb)
Inserted drr 
operon 
(2.7Kb)
Ndel!Hinàlll double digests above were performed in a total volume o f 20pl using lOU 
o f each enzyme. Digests were incubated at 37 °C for I hour.
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3.4  Discussion
With tuberculosis still a major threat to global public health, the completion of the M. 
tuberculosis genome sequence represents a major step forward in our understanding of 
the biology of this organism. Unsuiprisingly, given the almost ubiquitous distribution of 
these systems in nature, the M. tuberculosis genome appears to encode a significant 
number of ATP-binding cassette transporters. The active transmembrane efflux of 
chemotherapeutic agents is a known contributor to the growing levels of dmg resistance 
observed amongst pathogenic microorgamisms and human cancer cells. Wliilst active 
efflux of drugs by ABC transporters has yet to be demonstrated as a clinically relevant in 
the treatment of mycobacterial disease, the presence of such systems in the M 
tuberculosis genome is an indication that this may yet prove to be the case.
Analysis of the M  tuberculosis genome reveals the presence of three genes, drr A, B, and 
C, that bear many of the characteristics of known efflux ABC transporters. The three 
genes are arranged in an operon structure in which the stop codon of drr A  overlaps the 
start codon of drr^, and the stop codon of drrB overlaps the start codon of drrC. This 
feature of the operon, known as transcriptional-linkage^ is common amongst bacterial 
systems in which the protein products of the linked genes are fiinctionally related. The 
current models of bacterial ABC transporters comprise a minimum of four protein 
domains, two nucleotide-binding domains which energise the transport process, and two 
membrane spanning regions that comprise the translocation pathway. We propose a 
model of the M. tuberculosis Dit ABC transporter in which two copies of the DrrA 
protein function as NBD’s, whilst the drrB and C genes encode the membrane-spanning 
translocation pathway. A similar organisation of genes and proteins, in which just tliree 
genes encode all four functional domains of an ABC transporter complex, has been 
demonstrated for a number of systems including the MalFGK2 maltose pemiease of E. 
coli and the HisQMP] histidine permease of Salmonella typhimurium.
In support of this model of DitABC, and indeed its role as an ABC transporter, are a 
number of protein sequence motifs encoded by the genes. Firstly, the DrrA protein 
features the Walker A and B sequences common in a wide variety of nucleotide-binding 
proteins. Perhaps more importantly, DrrA also exhibits the characteristic ABC transporter 
signature sequence, a protein motif unique to the nucleotide-binding domains of ABC 
transporters. The drrB and C genes on the other hand appear to encode highly
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hydrophobic proteins, each of which possesses a possible six membrane-spanning a- 
helical segments. These features are consistent with the ability of DrrB and C to 
intercalate into the cell membrane and form a trans-bilayer protein complex. Additionally 
both the DrrB and C proteins contain one of the few conserved protein motifs yet 
identified amongst the MSD’s of ABC transporters, the so-called ABC-2 signature 
sequence.
hi an effort to identify functional homologues of M. tuberculosis DrrABC, database 
searches revealed the presence of highly similar systems in the genomes of both 
Mycobacterium leprae w à  Mycobacterium avium. The presence of r/rrABC genes in 
these pathogenic mycobacterial species suggests that this transporter plays a vital and 
conserved role in the biology of all tliree organisms. Sequence homologues of DrrA, B 
and C are rare outside of the mycobacteria, the most similar proteins being found 
amongst various species of Streptomyces. Whilst the exact function of the streptomycete 
homologues has yet to be unambiguously demonstrated in most cases, many are 
implicated in the role of antibiotic and secondary metabolite export. This further raises 
the possibility that the M. tuberculosis genome has retained antibiotic transport 
capabilities that were present in ancestral actinomycetes. Amongst the sequence 
homologues with known function are the Streptomyces peucetius DitA and B proteins. 
These are the NBD and MSD components respectively of an ABC transporter responsible 
for the efflux of the antibiotics daunorubicin and doxorubicin from the organism which 
produces them. Whilst the S. peucetius DrrAB system is encoded by just two genes, and 
is believed to function as a D1TA2B2 tetramer (Kaur and Russell, 1998), the homology 
between the two systems is enough to at least suggest a conserved function. In particular, 
the S. peucetius DrrB protein, in common with the M. tuberculosis DrrB and C proteins 
contains the ABC-2 signature motif.
Perhaps the greatest insight into the function of the M. tuberculosis DrrABC system 
comes from examination of its location within the genome, and additionally from gene 
knockout experiments. The 5’ end of the drr A  gene is found just 1 Ibp downstream of a 
very large biosynthetic system, the /y^^ABCDE operon. This cluster of genes occupies 
almost 50Kb, making it one of the largest opérons in the entire M. tuberculosis genome. 
The pps genes encode the components of a modular (type I) polyketide synthase that is 
involved in the biosynthesis of the molecules phenolphthiocerol and phthiocerol. These
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two diol molecules are found at the exterior face of the mycobacterial cell wall esterified 
to mycoserosic acid (Azad et a i, 1997). The very short distance between the ^ jA B C D E  
operon and the drr ABC operon, and the absence of any obvious intervening promoter 
sequence to drive the transcription of the drr ABC  genes, suggests that the two gene 
clusters may be transcribed in a single polycistronic mRNA. The clustering together of 
biosynthetic and transport fonctions has been observed in other bacterial species, 
particularly in the biosynthesis and export of cell wall components. One well 
characterised example of this type genetic linkage is the kps gene cluster of E. coli that 
encodes both the synthesis of polysialic acid, and an ABC transporter for its export to the 
cell surface (Rigg et al., 1998). A role for the DnB and C proteins in the export of cell 
wall components is supported by the presence of the ABC-2 motif. This sequence is 
primarily found in the integral membrane components of ABC transporters associated 
with the export of capsular polysaccharides and cell surface O-antigens (see PROSIE 
entiy: PS00890).
Random transposon mutagenesis experiments aimed at identifying important virulence 
gene clusters in the M  tubercidosis genome implieated the region containing the drr ABC 
and ^ .s-ABCDE opérons as an important mediator of in vivo pathogenicity. Knockouts in 
the pps promoter region and also in the drrC gene itself were shown to markedly reduce 
the growth and viability of the organism in a mouse model of pulmonary tuberculosis 
(Camacho et al., 1999, Cox et al., 1999). The knockouts in the pps promoter region were 
shown to reduce the synthesis of the phthiocerol esters that are found in the cell wall, 
suggesting that these complex lipids may be important virulence factors. It should be 
noted that knockouts in a number of other genes found in this region of the genome also 
resulted in attenuated virulence. This data suggests that the synthesis and export of 
phthiocerol esters is a complex process involving a large number of proteins, any of 
which may, in the future, represent useful targets for dmg intervention.
The fact that the DrrABC transporter may play a physiological role in the export of 
complex lipid species to the mycobacterial cell wall does not preclude the possibility that 
the transporter has a dual function. For example, much evidence suggests that the primary 
function of the human MDRl gene product, P-glycoprotein, is as a phospholipid flipase 
controlling the asymmetric distribution of phospholipids in the cell plasma membrane 
(Romsicki and Sharom, 2001). As well as its primary function, this ABC transporter is an
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important mediator of multidrug resistance because of its ability to excrete a wide variety 
of structurally diverse, amphipathic molecules. Included amongst the substrates of P- 
glycoprotein are the important anti-cancer agents doxombicin and daunorubicin. As such, 
the DrrABC transporter of M. tuberculosis may prove be of use as a prokaryotic model of 
the dual function ABC transporters that cause failure of cancer chemotherapy in humans.
This chapter reports the successful cloning of the M. tuberculosis drrAlBC genes, an 
analysis of their potential function, and finally their transfer into vectors suitable for 
overexpresion of the proteins in a heterologous host. Expression and purification of large 
quantities of these proteins are necessary in order to further our understanding of the 
biochemical, structural and physiological properties of ABC transporters in general and 
the function of the M. tubercidosis DrrAB C system in particular.
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Chapter 4
Heterologous expression of the DrrA, B and C proteins using pT7 based plasm ids
Bioinfoimatic methods have proven to be of great use in identifying potential members of 
the ABC transporter superfamily and in the assigmnent of putative fixnctions. Despite 
this, a more complete understanding of ABC transporters at a biochemical and structural 
level requires the expression and puiification of the proteins concerned. Such studies 
take on an added importance when particular ABC transporters are implicated in 
clinically and biologically significant processes such as drug resistance, microbial 
pathogenesis, and virulence. Since the completion of the M  tuberculosis genome 
sequence very little functional research has emerged regarding the role of ABC 
transporters in the biology of this pathogen. Two notable exceptions include partial 
characterisation of ABC transporters involved in phosphate and sulphur acquisition 
(Sarin et al, 2001; Wooff et a i, 2002).
The potential importance of the DrrABC transporter as a mediator of virulence and/or 
antibiotic resistance marks it out as a system worthy of further study given the urgent 
medical requirement for new anti-tubercular agents and dmg targets. This chapter reports 
a series of experiments in which recombinant expression was used as a tool to express 
and purify the individual proteins of the M  tuberculosis DrrABC transporter using the 
heterologous host E, coli. Results of these experiments were contrasting, and in many 
respects mirrored the results of other groups in their efforts to overexpress the 
components of ABC transporter complexes. The presumed ATP-binding protein, DrrA, 
was expressed at veiy high levels in E. coli, but unfortunately the vast majority of the 
protein produced was in the form of biologically inactive aggregates known as inclusion 
bodies. In contrast, successful over-expression of the membrane associated components 
of the transporter, DrrB and DrrC, proved difficult to establish and maintain. These latter 
results reflect the continuing difficulties associated with over-expression of membrane- 
bound proteins, a process which has long been a bottle-neck in research aimed at 
increasing our understanding of transmembrane transport. These results, and the 
problems encountered, are analysed in the wider context of ABC transporter research in 
general in the discussion section at the end of this chapter.
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4 .1  Properties of the pDrrA expression plasm id
The pDrrA expression plasmid was generated by sub-cloning a fragment of pGEM/t/zrA, 
containing the M  tuberculosis drrA gene bounded by Ndel and Hindlll restriction sites, 
into the MCS of a pET-21a expression plasmid. This resulted in the generation of a 
1032bp open reading frame in which the native drrA gene (lacking the 5’ termination 
codon) is fused to a short 5’ sequence encoding a His-Tag. The 3’ ATG start codon of the 
drrA gene is located downstream of a bacteriophage T7 promoter, a lac operator 
sequence and an optimised E. coli ribosome binding site. These elements together ensure 
maximal repression of protein expression in the uninduced state, whilst driving high 
levels of transcription when the plasmid is transformed into a suitable host strain and 
induced with IPTG. A schematic representation of the pDrrA expression plasmid is 
shown in figure 4.1.
The drrA open reading frame encodes a 344 amino acid fusion protein with a predicted 
molecular weight of 37.4 KDa. The vector encoded N-teiminal region of the protein adds 
an additional 13 amino acids to the native DrrA sequence, the last six residues 
constituting the His^-Tag. The protein encoded by this open reading frame is 
subsequently referred to as DixA-HiSô.
4. 2 Recombinant expression of DrrA-His^
Small-scale expression trials were initiated in order to test for expression of the 
recombinant DrrA protein. The pDrrA expression construct was first transformed in to 
the manufacturer’s recommended host strain, E. coli BL21(DE3). Certain features of the 
BL21(DE3) strain make it ideal for the expression of recombinant proteins from pET- 
based expression plasmids. Firstly, the strain lacks two major cellular proteases, Lon and 
OmpT, which may otheiwise interfere with the expression and purification of intact, full- 
length, recombinant protein. Secondly, the DE3 lysogen, stably incorporated into the E. 
coli chromosome, encodes an IPTG inducible bacteriophage T7 RNA polymerase. It is 
induction of this T7 RNA polymerase that ultimately drives transcription of the 
recombinant gene sequence. Freshly transformed BL21(DE3) cells were selected on the 
basis of carbenicillin resistance (vector encoded) and used to prepare 5ml starter cultures 
for expression trials. A similar culture of BL21(DE3) cells, transfonued with the non-
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recombinant pET-2la plasmid, was grown in order to provide an expression negative 
control. Trials were started by diluting 1ml of each overnight starter culture into 50ml of 
LB medium containing fresh selection antibiotic. Cells were gi'own at 37°C with rotary 
shaking until the cultures reached an O.D.eoo of 0.6. At this point, 1ml samples of each 
culture were withdrawn as zero time-point controls. Immediately afterward, expression of 
recombinant DitA was induced by the addition of ImM IPTG to each culture. 1ml 
samples were withdrawn from the two cultures at 1 hour intervals, up to three hours, and 
the cells harvested by centrifugation. Each sample was prepared for analysis by SDS- 
PAGE. Figure 4.2 illustrates the SDS-PAGE results for one of the first expression trials.
Cells carrying the pDrrA plasmid appear to accumulate a protein of approximately 40kDa 
over the course of the experiment that is not expressed in the control culture. This protein 
is found in neither of the cultures prior to induction and appears only in response to the 
addition of IPTG. Taking into account experimental limits, the accumulated protein is 
well within the size range of that expected for recombinant DrrA-Hise (37.4 kDa). 
Considered together, these results make a strong case for the apparent 40kDa protein 
being DrrA-His^.
4. 3 Western blot identification of DrrA-Hise
In order to further test the hypothesis that the candidate 40kDa was indeed DirA-Hise, use 
was made of the immunogenic nature of the His-Tag epitope to perform a Western blot. 
The same samples from induced pDrrA bearing cultures shown in figure 4.2 were 
separated by SDS-PAGE, transferred to a PVDF membrane by electroblotting and then 
probed using a mouse monoclonal primary antibody raised against the His-Tag epitope. 
The blot was developed using an enzyme conjugated secondaiy antibody in conjunction 
with a chemiluminescent substrate following the manufacturer’s recommended protocol 
(BioRad Immune-Star Chemiluminescent Detection Kit, see chapter 2). The results of 
this Western blot are shown in figure 4.3 and clearly indicate that the 40kDa candidate 
protein reacts sti’ongly with the anti-Hise monoclonal antibody. Moreover, the reaction 
seems to be highly specific and does not reveal the presence of any further candidate 
proteins. Taken in conjunction with the expression profile of this protein, and its absence 
from control cultures, these results strongly indicate the successfril over-expression of a 
recombinant form of the M  tuberculosis DrrA protein.
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Figure 4. 2 Expression time course of DrrA-His6 in £*. coli BL21(DE3) 
analysed by SDS-PAGE
Time after induction (hours)
1 2 3 0 1 2 3 MW (kDa)
60
50
40
30
pET-21a pDrrA
Control (pET-21a) and experimental (pDrrA) cultures were induced with ImM IPTG and 
samples withdrawn at the time points indicated. Amount o f protein in each lane was 
normalized using O.D.600 o f  the culture at the time each sample was taken. A candidate 
DrrA-Hise protein can be seen accumulating over time in the experimental culture. The 
same protein is absent in the control cells transformed with non-recombinant pET-21a 
plasmid. Molecular weight markers (right hand lane, MW) show the candidate protein to 
be approximately 40 kDa in size, similar in size to that predicted for the recombinant 
DrrA-His6 protein (37.4 kDa).
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Figure 4. 3 Anti-His6 Western blot to confirm expression of the 
recombinant DrrA protein
Time after induction (hours)
DrrA-HiSfi ►
M.W. (kDa)
60
50
40
30
The Western blot above illustrates the strong reaction between an anti-HiSô monoclonal 
antibody and an approximately 40 kDa protein that accumulates after induction of 
expression cultures bearing the pDrrA plasmid. The same reaction is not observed prior 
to induction (lane 0), nor is it observed in negative control cultures (data not shown). 
These data serve as a positive identification of the accumulated protein as recombinant 
M. tuberculosis DrrA.
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4. 4 Sub-cellular fractionation of cells expressing DrrA-HiSd
In a number of instances the overexpression of ABC transporter NBD’s, in the absence of 
their associated MSD’s, has caused large amounts of the NBD to accumulate as a soluble 
cytosolic protein (e.g. HisP, Nikaido et al., 1997; ArsA, Hsu and Rosen, 1989). This 
effect is particularly desirable since it enables efficient purification of the protein for 
further biochemical and structural studies. In order to determine the sub-cellular 
localisation of recombinant DnA-Hisg, cells expressing the protein were lysed by 
mechanical disruption and fractionated by differential centrifugation (see Chapter 2). An 
initial low-speed centrifugation step (16,000 rpm; Beckman JA-21 rotor) was used to 
pellet dense materials, such as cell wall fragments and large insoluble proteins, whilst 
retaining cytosolic proteins and membrane vesicles in the supernatant. These two initial 
‘crude’ fractions were then analysed for protein content by dissolving in SDS-PAGE 
sample buffer and subsequent electrophoresis. The results of the initial analysis are 
shown in figure 4.4. SDS-PAGE of the two fractions indicated that the vast majority of 
the overexpressed DnA-His^ protein sedimented during the low-speed centrifugation 
phase, whilst a much smaller amount may be present in either the cytosolic fraction or 
associated with membrane vesicles. This suggested that the recombinant Drr-Hiso protein 
was aggi'egating into high molecular weight complexes during expression. The formation 
of such complexes, often described as inclusion bodies, is not uncommon when 
attempting to express large quantities of a recombinant protein using strong promoters 
and multi-copy plasmid vectors. Inclusion bodies are thought to form when the host cell’s 
capacity for correctly folding proteins is overwhelmed by the very large amounts of 
recombinant protein being synthesised. The incorrectly folded proteins rarely retain any 
biological function and are therefore of little use in biochemical studies. Inclusion body 
foimation has been observed during attempts to express a number of ABC transporter 
NBD’s, e.g. the S. typhimurium MalK protein (Walter et aL, 1992).
Despite the fact that the majority of the DrrA-Hisg was found to be present as inclusion 
bodies, the SDS-PAGE analysis showed that a small amount of the protein expressed 
may have survived in a soluble, or possibly membrane associated foim (figure 4.4., left 
aiTow). This phenomenon has been observed previously, and, through further 
manipulation of the expression conditions, has allowed useful quantities of soluble 
protein to be expressed and purified.
1 2 0
Figure 4. 4 Preliminary fractionation of BL21(DE3) cells to determine sub-
cellular localisation of DrrA-Hise
CS
CS = Crude Soluble 
A 'I Fraction
^ I = Insoluble Fraction
Possible _   DrrA-His»
DrrA-Hisc (40 kDa)
Figure 4.4 illustrates an SDS-PAGE analysis of protein fractions derived from 
BL21(DE3) cells harboring the pDrrA expression plasmid. Lane CS shows proteins 
present in a crude cytosolic extract (including membrane fragments), whilst Lane I shows 
the proteins present in the ‘insoluble fraction’. The two fractions are derived from the 
supernatant and pellet fractions, respectively, following low-speed centrifugation of 
disrupted cells. DrrA-Hisô is seen to accumulate primarily in the insoluble fraction where 
it accounts for greater than 90% of the total protein present. This is a strong indication 
that the protein has formed inclusion bodies. The arrow to the left of the figure indicates 
the position of a small amount of DrrA-Hise that has potentially remained soluble in the 
cytosol or is associated with membrane vesicles.
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Since these initial results were the product of low-speed fractionation experiments, the 
possibility existed that any DirA-His^ observed in the crude soluble fraction might be an 
experimental artefact caused by cross-contamination of the fractions. In order to further 
assess this possibility, and more accurately detennine the sub-cellular localisation of 
DrrA-His6, a second round of fractionation experiments were performed.
Disrupted cells were first subjected to two rounds of low-speed fractionation in order to 
reduce the possibility of insoluble proteins mixing with the crude soluble extract. The 
soluble extract was then further fractionated into cytosolic and membranous components 
by high-speed ultracentrifugation (100,000 x g, 1 hour). This technique generated thi ee 
protein fractions; insoluble, cytosolic and membrane associated. A sample of each was 
dissolved in SDS-PAGE sample buffer and analysed by electrophoresis. A Coomassie 
blue stain of the SDS-PAGE gel once again showed the presence of large amounts of the 
Dn A-Hisg protein in the insoluble fraction. Strong bands corresponding to DrrA-Hiss 
were observed in neither the cytosolic nor membrane associated protein fractions (data 
not shown). This suggested that expression of soluble DrrA-His^ was either very low, and 
consequently masked by the protein background, or that a soluble form of the protein was 
not expressed at all. As a further stage in the analysis, a Western blot of each fraction was 
performed using an anti-Hise monoclonal antibody to detect the presence of DrrA-Hise. 
Since immuno-affinity detection techniques are significantly more sensitive and selective 
than simple protein staining, it was hoped that a Western blot might succeed in detecting 
even very low levels of soluble DrrA-His^ expression. The results of the Western blot are 
shown in figure 4.5. The results confirm that DrrA-HiSô expressed under these conditions 
accumulates almost exclusively in the insoluble fraction. Interestingly, absolutely no 
reactive protein was detected in the cytosolic fraction, whilst a small amount was found 
to be associated with the membranes. Since the experiments were perfoimed in such a 
way as to minimise cross contamination of fractions, the presence of small amounts of 
DrrA-His6 associated with the membrane was considered a genuine possibility despite the 
predicted hydrophilic nature of the protein. In fact, Kaur noticed a similar phenomenon 
when examining the sub-cellular localisation of the S. peucetius DrrA protein over­
expressed in E. coli. Whilst those experiments yielded a significant amount of soluble, 
cytosolic DrrA, as much as 60% of the total DrrA protein was found associated with the 
membrane (Kaur, 1997). Together these results suggest that the DrrA proteins retain
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Figure 4. 5 Western blot of protein fractions from BL21(DE3)/pDrrA cells 
expressing DrrA-His6
40 kDa
I = Insoluble fraction
C = Cytosolic fraction 
M = Membrane fraction
 DrrA-His6
Western blot o f the three primary sub-cellular fractions generated by differential 
centrifugation (probed using an anti-Hise monoclonal antibody). The overwhelming 
majority DrrA-Hise was detected in the insoluble fraction (lane I), whilst a small amount 
could be detected in the membrane associated protein fraction (lane M). The experiment 
indicates that, under the conditions used, expression o f soluble DrrA-Hisé cannot be 
detected, even by very sensitive techniques.
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some degree of hydrophobicity, a feature which may contribute to the association of the 
NBD with membrane embedded, hydrophobic MSD’s.
4. 5 Modulation of DrrA-Hise expression conditions to improve yield
The above experiments showed that, under standard conditions for growth and induction 
of E. coli expression cultures, insignificant quantities of soluble DrrA-Hise were 
produced. Since the ultimate aim of the expression experiments was the generation of 
stable, soluble, active DrrA-Hise suitable for biochemical and structural studies, a series 
of expression trials were performed under different conditions aimed at increasing the 
yield of soluble protein.
The documentation supplied with the pET series vectors suggested a number of routes 
that might lead to increased yield of soluble protein (pET System Manual, Ninth Edition, 
Novagen). The methods described include lowering the temperature at which expression 
cultures are grown and induced, and also lowering the concentration of inducer (IPTG) 
added to the expression cultures. Both of these methods are thought to slow down the rate 
at which the heterologous protein is synthesised, thereby allowing the protein to fold 
coiTectly and assume a stable, globular conformation.
Initial trial cultures had been grown at 37 °C, induced with ImM IPTG and grown over 
time periods of 3 hours. Optimisation experiments were performed at lowered growth 
temperatures of 30 °C (6 hours) and 20 °C (overnight). Reduced IPTG concentrations of 
300juM and 50jaM were also tested. Whilst some improvement of soluble DrrA-Hise yield 
was obseiwed, particularly when the expression cultures were grown at low temperature 
(20 °C) and induced overnight, yields did not improve to the point that even large-scale 
expression experiments might provide suitable quantities of the soluble protein (data not 
shown). Given the failure of these techniques to provide the basic material required for 
further studies, an alternative route of investigation was pursued.
4. 6 Purification of DrrA-Hise under denaturing conditions
Despite the inactive nature of proteins isolated from inclusion bodies, their formation 
does give rise to certain advantages. Firstly, inclusion bodies represent a very 
concentrated and relatively pure foim of the expressed protein (see figures 4.4 and 4.5), 
Secondly, proteins sequestered in inclusion bodies are largely protected from degradation
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and proteolytic attack, and thirdly, inclusion bodies are easily isolated from cultures in 
large quantities by low-speed differential centrifugation. Techniques for solubilisation of 
inclusion bodies, and strategies for refolding the protein into an active confonnation, 
have advanced significantly over the last decade and have been successfully employed in 
a number of instances. Perhaps the best example in the context of this work is the 
successful application of refolding techniques in the isolation of soluble, active MalK, the 
NBD component of the S. typhimurium maltose ABC-transporter (Walter et al, 1992).
The inclusion bodies isolated from DrrA-Hisg expression cultures appeared to contain 
greater than 90% of the target protein, with relatively few contaminating proteins (see 
figure 4.4). However, since the confonnation of the His-Tag sequence is not an important 
factor in determining its affinity for Ni^ "*" affinity resins, an initial purification step 
performed under denaturing conditions was tested as a means of fuither enhancing the 
purity of the initial inclusion body preparation. Inclusion bodies were prepared by 
growing a IL culture of BL21(DE3)/pDnA cells at 37 °C for 3 hours after induction 
with ImM IPTG. Cells were harvested by centrifugation and resuspended in 50ml of 
disruption buffer (50mM Tris-HCl, 300mM NaCl, 10% glycerol; pH 8.0). The cells were 
then lysed by a single round of mechanical disruption. Inclusion bodies were recovered 
from the pellet following low-speed centrifugation of the crude lysate (16,000rpm; 
Beckman JA-21 rotor). Typical yields of DrrA-His^ inclusion bodies were in the range of 
100-300mg per litre of culture.
Inclusion body solubilisation requires the use of strong dénaturants to completely 
separate and unfold the aggregated protein. Reagents employed for this purpose include 
buffered solutions of either 6M guanidine-HCl or 8M urea. In these experiments a 
solution of 8M urea in 50mM Tris-HCl, 300mM NaCl (pH 8.0) was used as the 
dénaturant. 50mg of inclusion body pellet was solubilised in 10ml of this buffer by 
stirring at room temperature for 1 hour. A further round of centrifugation at 16,000rpm 
removed material that remained insoluble. The inclusion body solution was then mixed 
with 1ml of IMAC Ni^ "^  affinity resin (Ni-NTA, Qiagen) and agitated gently for 1 hour at 
room temperature in order for the Hise-tagged protein to bind to the resin. The solution 
was then loaded into a 0.8cm diameter gravity fed chromatography column and the resin 
allowed to settle. The flow-through solution was collected for frirther analysis.
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Figure 4. 6 Purification of denatured DrrA-HiSé by IMAC column 
chromatography
W1 W2 W3 W4 W5 W6
FT
W H-W 2 
W3 + W4 
W5 +W 6 
El + E2
DrrA-Hisô («40 kDa)
Column flow-through 
20mM imidazole washes 
30mM imidazole washes 
40mM imidazole washes 
300mM imidazole elutions
Base Buffer (pH 8.0) 
50mM Tris-HCl 
300mM NaCl 
8M Urea
A Coomassie blue stained SDS-PAGE gel showing various stages in the purification o f  
DrrA-Hise by IMAC chromatography. The source material used was DrrA-Hise inclusion 
bodies, and the entire purification procedure was performed under denaturing conditions 
(8M urea). Lane FT clearly shows that a large quantity o f solubilised DrrA-Hise did not 
bind to the IMAC resin, possibly as a result o f saturation. Lanes W1-W6 show the 
removal o f background contaminants under a stepped imidazole gradient. The final two 
lanes show the elution o f DrrA-Hise from the resin using a buffer containing 300mM 
imidazole. The two elutions contained highly purified, denatured DrrA-Hise.
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The resin was washed with 10ml of the initial solubilisation buffer in order to remove any 
unbound protein. Extensive washing was performed at this and subsequent stages since 
the amount of protein loaded onto the resin (nominally 50mg) far exceeds the known 
binding capacity of 1ml of Ni-NTA resin («lOmg/ml). The resin was washed a further 3 
times using 10ml of buffers supplemented with 20mM, 30mM, and 40mM imidazole. 
These washes were aimed at removing non-specifically bound background proteins and 
loosely bound aggregates. At all stages of the washing procedure 5ml fractions were 
collected for analysis. Finally, specifically bound, denatured DrrA-Hise was eluted from 
the column using 10ml of solubilisation buffer supplemented with 300mM imidazole.
The eluate was collected in two fractions of 5ml each. At the end of the procedure all 
fractions collected were analysed for protein content by SDS-PAGE.
The results of the denaturing purification are illustrated in figure 4.6. The 
chromatography procedure was essentially successful, yielding a highly purified solution 
of denatured DrrA-Hisg ideal for use in subsequent refolding experiments. However, as 
can be judged from the SDS-PAGE analysis, significant losses in yield occurred, and 
only a small proportion of the starting material was recovered in the final elutions. The 
yield losses incurred were almost certainly due to the limited binding capacity of the 
small resin volume used.
4. 7 DrrA-HiS(j refolding experiments -  Part I - IMAC
The demonstration that inclusion body-derived DrrA-His^ was able to bind to the IMAC 
resin in a denatured form was the starting point for the first set of refolding experiments 
undertaken. Most fomis of protein refolding require a reduction in the concentration of 
dénaturant, allowing time for individual protein molecules to adopt a number of 
intermediate conformations before reaching their final, fully folded state. However, many 
of the intermediate protein confomiations are likely to be unstable. Interactions between 
these unstable folding intermediates can lead to protein aggregation and/or eventual 
precipitation. Physical separation of the molecules, for example by immobilising them on 
an IMAC resin, is thought to reduce the possibility of unfavourable protein-protein 
interactions occurring during the refolding process. This teclmique was used successfully 
during the early MalK refolding experiments, albeit using a different method of 
immobilisation (Walter et al, 1992), and has even been applied to the refolding of 
membrane proteins (Rogl et al, 1998).
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Urea solubilised DrrA-Hise inclusion bodies were prepared for refolding as described in 
section 4.5 with the exception of two changes. Firstly, the solubilisation process and all 
subsequent steps were performed at 4 °C rather than at room temperature in order to 
reduce the possibility of protein hydrolysis or damage. Secondly, the NaCl concentration 
in all buffers was raised from 300mM to 0.5M. The increase in ionic strength of the 
buffer was designed to reduce non-specific protein-protein interactions during refolding, 
particularly as the urea concentration was reduced. A batch binding procedure was once 
again used to immobilise the solubilised Dn A-Hisg, this time onto a somewhat larger 
volume of resin (4ml) in order to improve yields. After 1 hour of binding at 4 °C the 
IMAC resin was loaded into a chromatography column and the resin allowed to pack 
under gravity flow.
The refolding procedure began by washing unbound protein out of the resin using 20ml 
of solubilisation buffer. Subsequent stages involved washing the resin in 16 separate 5ml 
aliquots of buffer, the urea concentration in each buffer being reduced by 0.5M each time 
(from 8 to CM). The aim was to generate a stepped gradient that gradually reduced the 
urea concentration to zero whilst allowing the immobilised protein time to refold into a 
native confonnation. Finally, refolded, soluble DrrA-Hise was released from the column 
by washing with a number of 1ml aliquots of elution buffer (OM urea, 300mM 
imidazole).
One of the major problems encountered during the various refolding trials perfonned was 
a dramatic reduction in the flow rate of the column that occun ed as the urea 
concentration approached the 3-4M range. This was believed to be caused by protein 
aggi’egation within the matrix, sometimes manifesting itself as a white coloured 
precipitate. Despite a number of modifications to the procedure, including shallower 
gradients and allowing extended periods of time between buffer changes, yields of 
soluble protein were rarely significant. A typical result from one of these refolding 
experiments, illustrating the low yield of DrrA-Hlsg recovered, is shown in figure 4.7. 
Furthermore, whilst SDS-PAGE analysis of the elution fractions shows monomeric, 
apparently soluble DrrA-Hisg, no biological activity could be detected for the protein (for 
example in ATPase activity assays). This suggested that the elutions were merely 
releasing inactive protein aggi*egates from the column matrix which were then being re- 
solubilised by the detergent present in SDS-PAGE sample buffer.
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Figure 4. 7 IMAC-based refolding of immobilised DrrA-His6
M El E2 E3 E4
40 kDa
Eluted
DrrA-His6
Gradient Buffer: 50mM Tris-HCl 
500mM NaCl 
8-OM Urea (in 0.5M steps) 
pH 8.0
Elution Buffer: 50mM Tris-HCl 
500mM NaCl 
300mM Imidazole 
pH 8.0
Example o f a Coomassie blue stained SDS-PAGE gel showing 4 x 1ml elution fractions 
(E1-E4) recovered from a typical IMAC refolding experiment. Whilst the eluted DrrA- 
His6 runs as a monomeric protein o f high purity, it displays no detectable ATPase 
activity. This data, combined with evidence o f protein precipitation during the urea 
gradient, suggests that the eluted protein is unable to adopt a native conformation under 
the experimental conditions used.
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The IMAC based method of protein refolding described above failed to recover any 
biological activity from urea solubilised DrrA-Hise inclusion bodies. Nevertheless, only a 
single buffer system was tested during the procedure. Given that large quantities of a 
relatively pure, easily isolated starting material were available, an alternative approach 
was adopted in order to identify optimal refolding parameters.
4. 8 DrrA-Hisg refolding experiments -  Part II -  The Foldit Screen
The efficiency of protein refolding is known to be influenced by a large number of 
external conditions, as well as by the individual physico-chemical properties of the 
protein under investigation. Since there is, as yet, no rational framework for predicting 
ideal refolding conditions, it is necessary to establish the parameters empirically. A 
number of kits are commercially available that help to identify optimal refolding 
conditions. One such kit, the Foldit Screen (Hampton Research), was used in an effort to 
identify the various conditions that might affect the efficiency of DrrA-His^ refolding. 
The screen is factorial in nature, using 16 different basic buffer conditions in combination 
with a number of additives known to promote successful refolding. The identification of 
the basic parameters can then be used to further optimise the refolding process. The 
various optimisation parameters tested in the refolding of DrrA-Hisg are shown in table 
4.8 on the next page.
Inclusion bodies for use in the Foldit screen were prepared as described in section 4.5 and 
solubilised in a buffer of 8M Urea, 50mM Tris-HCl, 50mM NaCl, pH 8.0. The reduced 
salt concentration in the solubilisation buffer was deemed necessaiy because ionic 
strength is a variable in the screen. DrrA-Hise inclusion bodies were solubilised at a 
nominal concentration of 20mg/ml and insoluble material was removed from the 
preparation by centrifugation at 12,000rpm in a bench-top microfuge. In contrast to the 
IMAC based refolding protocol described in the previous section, where the 
concentration of dénaturant was reduced gradually, the Foldit screen utilises rapid 
dilution in order to reduce dénaturant concentration. Reactions were perfoimed in 1.5ml 
micro-centrifuge tubes and initiated by the addition of a small volume of the
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Table 4. 8 - DrrA-Hise refolding parameters tested
Protein concentration 0.1 mg/ml vs. l.Omg/ml
Presence of polar additive +/- 550mM L-Ai'ginine
Presence of detergent +/- 30mM Lauryl Maltoside
pH pH 6.5 vs. pH 8.2
RedOx potential lOOinM DTT vs. lOOmM GSH
Presence of chaotropic salt +/- 550mM Guanidine Flydrochloride
Ionic strength 264mM NaCl +1 ImM KCl vs. 
10.56mM NaCl + 0.44mM KCl
Presence of cations or chelator 2.2mM CaCl + 2.2mM MgCl vs. 
1.ImM EDTA
Presence of osmolyte +/- 0.055% (w/v) PEG 3350
Presence of non-polar additive +/“ 440mM Sucrose
concentrated DnA-Hisg inclusion body preparation to a much larger volume of the 
various refolding buffers. Typically either 5 or 50pl of inclusion body solution was added 
to 950pl of refolding buffer in order to achieve final DrrA-His^ concentrations of 
0.1 mg/ml and 1 mg/ml. The tubes were capped and incubated at 4 °C with gentle agitation 
for a period of 4 hours.
After 4 hours each of the 16 refolding reactions were examined visually for signs of 
protein precipitation. A degree of precipitation was observed in all cases, particularly at 
higher protein concentration. However the extent the visible precipitate varied widely 
between different tubes, suggesting that certain refolding solutions represented a more 
beneficial enviromnent for refolding than others. The polar additive L-arginine, present in 
8 of the 16 reactions, appeared to exert a particularly positive influence in terms of 
minimising the amount of visible precipitate present.
At this stage, the ideal situation would have been to remove precipitates by 
centrifugation, and then assay each solution for the predicted ATPase activity of correctly 
folded DrrA-HiSfi. Unfortunately, a number of the reagents present in the Foldit buffers, 
for example L-arginine, divalent cations and EDTA, are known to interfere with both
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spectroscopic protein quantitation teclmiques (A2 8 0 , BCA assay) and ATPase assays. This 
made a meaningful comparison of enzymatic activity in each of the 16 samples 
impossible at this stage. In order to make such a comparison possible, all 16 samples 
were transfened into separate dialysis tubing and dialysed against 2L of a buffer 
consisting of 50mM Tris-HCl (pH 8.0), 150mM NaCl, 10% glycerol (v/v). This dialysis 
procedure appeared to result in the removal of reagents that were enabling Dn*A-His6 to 
remain soluble, leading to further extensive precipitation. The Foldit screen 
documentation suggests that yields of 30-70% soluble protein after the dialysis procedure 
are typical where refolding has been successful. Unfortunately, such yields were not 
obseiwed for DrrA-Hisg and no ATPase activity could be detected in any of the 16 
samples tested (using the Molecular Probes spectroscopic Pi assay, see chapter 2). The 
failure of this screen to identify suitable refolding conditions for DrrA-Hise led to the 
abandomnent of inclusion bodies as a suitable source material for further biochemical 
studies of the recombinant M. tuberculosis DrrA protein. An alternative method for 
obtaining correctly folded, native DrrA was sought, as described in subsequent chapters.
4. 9 Heterologous expression of the M. tuberculosis DrrB and DrrC
proteins -  the pDrrB and pDrrC expression constructs
Integral membrane proteins, such as those mediating the majority of transmembrane 
transport processes, are notoriously difficult to over-express and purify. Ordinarily 
present at only low concentrations within cellular membranes, their over-expression can 
result in toxic side effects for both heterologous and homologous hosts. Another problem 
frequently encountered is the failure of heterologously expressed membrane proteins to 
be correctly targeted to the appropriate compartment, a process that may require host 
specific signal-sequences or protein factors. Furthermore, the conformation of 
transmembrane proteins is intimately linlced to the hydrophobic enviromnent of the 
membrane interior. Removal of integral membrane proteins from their lipidic 
enviromnent, for example by the use of detergents, can dramatically affect their stmcture 
and function. The difficulties associated with membrane protein over-expression and 
purification largely account for the paucity of high-resolution structural information 
available for this biologically important class of proteins. The problems are however not 
insurmountable, as demonstrated by the recent publication of 3D crystal structures for 
the E. coli MsbA and BtuCD ABC transporters (Chang and Roth, 2001; Locher et al.,
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2002), and the AcrB multidrug resistance protein (Murakami et aL, 2002). Advances in 
detergent chemistry have created whole series of molecules specifically designed for the 
gentle extraction of proteins h'om biological membranes whilst maintaining their 
functional conformation. Methods for reconstituting transport proteins into artificial 
membrane enviromnents, for example proteoliposomes, have enabled the development of 
novel membrane transport assays. Hand-in-hand with these advances have come a variety 
of new reagents used to probe the conformation and transport capabilities of membrane 
embedded proteins. With this knowledge in hand, attempts were made to over-express 
and purify the DitB and DrrC components of the M. tuberculosis DrrABC transporter.
Expression constructs for both the DrrB and DitC proteins were generated by subcloning 
NdeVHindill fragments from recombinant pGEM-T Easy plasmids into the pET-21a 
expression vector. The two plasmids thus generated, pDrrB and pDrrC, are essentially 
analogous to the pDrrA expression constmct used for the expression of DrrA. The pDnB 
plasmid encodes a 302 amino acid protein with a predicted molecular weight of 32.5 IdOa. 
The first 289 amino acids are encoded by the cloned t/?rB gene, whilst the remaining 13 
amino acids at the C-terminal end are vector encoded and include a His-Tag sequence. 
The pDrrC plasmid encodes a slightly smaller protein of 289 amino acids (M.W. 28.1 
kDa) with the same 13 amino acid extension appended to the C-terminal of the native 
drrC coding sequence.
Both the pDrrB and pDrrC plasmids were transformed in to the expression strain 
C41(DE3). This strain is an undefined mutant derived from E. coli BL21(DE3) that 
possesses certain advantages for the expression of membrane proteins. Identified by 
Miroux and Walker, C41(DE3) appears to be more resistant to the toxic effects of IPTG 
than its parent strain (Miroux and Walker, 1996). As such, C41(DE3) cultures gi'ow to 
higher cell densities in liquid media and thus generate a higher yield of recombinant 
protein per litre of culture. This is advantageous when the target protein under 
investigation expresses only at low levels, as is the case for most membrane proteins. 
Because of the lower expression levels expected for the recombinant DrrB and C 
proteins, expression experiments were perfoimed using larger culture volumes, typically 
3-6L, and cells were grown in the rich 2xYT medium to enliance gi’owth. A flow chart 
showing the progress of an expression experiment from cell culture to isolation of 
membrane material is shown on the next page.
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Phase-1 -  Starter culture
Phase-2 -  Culture gi'owth
Phase-3 -  Harvesting
Phase-4 -  Membrane 
Isolation
Single C41(DE3)/pDn*B colony used 
to inoculate a 5ml starter culture. 
Cells grown overnight at 37 °C with 
rotary shaking.
1 f
5ml of overnight starter culture used 
to inoculate 6xlL flasks of 2xYT 
medium. Cells gi’own at 30 °C with 
rotary shaking until O.D.6 0 0  reaches 
0 .6 .
Protein expression induced by the 
addition of IPTG to a concentration 
of ImM.
Cultures harvested after 3 hours by 
centrifugation at 6000rpm (Beckman 
JA-10). Culture medium discarded 
and cells resuspended in buffer of 
50mM Tris-HCl, 300mM NaCl, 20% 
(v/v) glycerol, pH 8.0.
Resuspended cells lysed by 
mechanical disruption. Cell debris 
removed by centrifugation (16,000 
rpm, Beclaiian JA-21).
Membrane vesicles sedimented by 
high-speed centrifugation 
(43,000ipm, Beckman Ti-50)
Following high-speed centrifugation the supernatant fraction (containing cytosolic 
proteins) was discarded. Membrane pellets were then resuspended in an ice-cold, 
detergent free buffer (50mM Tris-HCl, 300mM NaCl, 20% glycerol, pH 8.0) 
supplemented with EDTA-free protease inliibitor tablets. Resuspension of the 
hydrophobic membrane material in an aqueous buffer required the pellet to be broken up
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and passed through a syringe needle many times in order to generate a smooth emulsion 
of vesicles. Membranes were resuspended using 5ml of buffer per litre of culture. At this 
point membrane suspensions were either stored at -80 °C or processed immediately.
4 .1 0  Detergent extraction of membrane proteins
Purification of membrane proteins requires their extraction from the membrane 
enviromnent. This is generally performed using biological detergents at concentrations 
high enough to disrupt the membrane structure whilst not destroying protein 
conformation. Solubilisation is a complex, muti-phasic process, the end result being the 
generation of both mixed lipid/detergent micelles, and lipid/detergent/protein micelles. It 
is the hydrocarbon ‘tails’ of detergent molecules that are thought to associate with 
integral membrane proteins, thereby mimicking the hydrophobic environment of the 
membrane interior, and also preventing protein aggregation. The detergent dodecyl- 
maltoside (DDM) has been used successfully in the extraction of a number of membrane 
proteins, including human MDRl (Howard and Roepe, 2003), and was used here in 
attempts to solubilise DrrB and DrrC.
Resuspended membrane vesicles were solubilised by the addition of an equal volume of 
ice-cold resuspension buffer supplemented with 4% w/v DDM and protease inliibitors. A 
final concentration of 2% DDM was found to be more than enough to completely 
solubilise a typical membrane preparation. Solubilisation was enlianced by gentle mixing 
of the solution for a period of 1 hour at 4 °C. Low temperatures, pro tease inhibitors and 
pH of 8.0 were used at all times during protein extraction. These factors are all known to 
inliibit the action of proteases (to which solubilised membrane proteins become 
particularly susceptible). After detergent extraction any remaining insoluble material was 
removed by a further round of ultracentrifugation (100,000 x g, 1 hour). The quantity of 
sedimented material at this stage was used to judge the efficiency of the solubilisation 
process. The supernatant fraction, containing detergent-solubilised proteins, was used as 
the starting material for the purification procedure.
4.11 IMAC purification protocols for the DrrB and DrrC proteins
Both the pDrrB and pDrrC expression constmcts were designed to append a C-teiminal 
His-Tag sequence to the recombinantly expressed proteins. This provided a means of 
selectively purifying the proteins by IMAC using Ni-NTA affinity resin. The purification
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procedure was started by adding linl of Ni-NTA-agarose to the solubilised membrane 
protein solution and allowing binding to proceed for 1 hour at 4 °C with gentle stirring. 
The mixture was then loaded into a 1.5cm diameter gravity flow chromatography column 
and the resin allowed to settle. The flow-through fraction containing unbound proteins 
was collected for analysis. The following washing and elution steps, containing different 
concentrations of imidazole, were then used as a starting point to identify fractions 
containing the recombinant proteins: -
Wash 1. 20ml buffer* containing OmM imidazole to wash out unbound
protein.
Wash 2. 20ml buffer containing 25mM imidazole, removal of loosely
bound contaminants.
Wash 3. 20ml buffer containing 40mM imidazole, removal of more tightly
associated background proteins.
Elutions 5x 1ml buffer containing 300mM imidazole to elute specifically
bound His-Tagged proteins.
* A variety of Tris-based buffers were tested during purification trials. Glycerol 
concentration was maintained at 20% v/v in all buffers tested in order to promote 
membrane protein stability. NaCl concentrations tested varied between 5OmM and 
400mM. Detergent concentration and fonnulation were two further variables tested. After 
the solubilisation process, in which the majority of lipids are stripped away from 
membrane proteins, much lower concentrations of detergent (e.g. 0.1 % w/v) were used to 
maintain proteins in solution. Different detergents with alternative head groups and chain 
lengths were also tested for their ability to promote protein stability and reduce 
background contamination e.g. Octyl-glucoside and nonyl-maltoside as well as DDM.
4.12 Purification of recombinant DrrB-Hisg
Unlike recombinant DrrA-His^, induction of DrrB-Hise expression with ImM IPTG did 
not lead to the formation of inclusion bodies. In fact, simple SDS-PAGE analysis of the 
various sub-cellular fractions obtained from DrrB-Hisg expression cultures did not reveal
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the obvious presence of a protein exhibiting particularly high expression levels (data not 
shown). Attempts to demonstrate the expression of DrrB-Hise by Western blot also 
proved unsuccessful, primarily hindered by the large number of backgi'ound proteins in 
the crude fractions. Together these obseiwations led to the conclusion that DnB-Hise _ 
expression levels were far lower than those observed for the recombinant DrrA protein. 
Such a result might be predicted based upon the generally low levels of expression 
observed for integral membrane proteins. An alternative explanation was that no DnB- 
His6 was being expressed at all. Causes of such negative results might include toxicity of 
the DrrB-His6 protein. Another potential reason for a low expression might be the large 
evolutionary separation between the Gram-negative expression host E. coli and the 
Gram-positive donor organism M. tuberculosis. Such evolutionary separation can lead to 
differences in codon usage between the host and donor organisms, which in turn are 
reflected in the relative abundance of tRNA species. This may be relevant when 
attempting to express GC-rich mycobacterial genes in E. coli, an organism that possesses 
a slightly AT-biased genome.
Nonetheless, working on the hypothesis that D itB -Hise would be localised in the cell 
membrane, attempts to purify the protein from this fraction were initiated using the 
protocols described in section 4.10. After a number of different trials, a candidate DrrB- 
HiSô protein was partially purified from DDM solubilised membranes. An SDS-PAGE 
analysis of one successful procedure is shown in figure 4.8. The figure illustrates the 
absence of any obviously over-expressed protein in the solubilised membranes prior to 
purification, but also the specific elution of two major protein species in the 300mM 
imidazole fractions. The molecular weight of the smaller protein was approximately 28 
kDa (judged by comparison with molecular weight standards). This value is slightly 
lower than the calculated size for DrrB-Hise, 32.5 kDa. However, since many 
hydrophobic proteins display a greater than expected electrophoretic mobility, the 
possibility remained that this protein was indeed DrrB-His^. The larger protein present in 
the eluate fractions purified in similar quantities to the lower band, suggesting that it too 
was specifically bound to the affinity resin, rather than being present as a
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Figure 4. 8 IMAC purification of recombinant DrrB-Hise
A FT W M El E2 E3
m Possible DrrB-His6 dimer (approx. 50 
kDa)
#
«mm»
mi
  Candidate DrrB-HiSô
(approx. 28 kDa)
Coomassie blue stained SDS-PAGE gel showing partial IMAC purification o f candidate 
DrrB-Hise protein(s) from DDM solubilised membranes. Lanes A and FT show the 
samples applied to the IMAC column and flow-through collected, respectively. Lane W 
shows the fraction obtained after extensive washing o f the column to remove non- 
specifically bound protein (60ml o f buffer containing 40mM imidazole). Lanes E1-E4 
show elution fractions (4x 1 ml) generated by washing the column with buffer containing 
300mM imidazole. Arrows mark the positions o f candidate proteins.
Membrane solubilisation buffer - 50mM Tris-HCl (pH 8.0) 
150mM NaCl 
20% (v/v) glycerol 
2% (w/v) DDM
Column buffers: 50mM Tris-HCl (pH 8.0)
150mM NaCI 
20% (v/v) glycerol 
0.1% (w/v) Nonyl-maltoside 
Imidazole: 60 mM (wash), 300mM (elution)
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contaminant. The observed molecular weight of this protein, approximately 50 kDa, 
suggested that it might be a dimeric or aggregated form of the smaller protein. Since 
ABC transporter MSD’s are known to exist as dimers in the functional complex, the 
possibility remained that DrrB-Hise might fomi a stable homodimer in the absence of 
DrrC. This would account for co-purification of this higher molecular weight species.
In order to further characterise the candidate proteins, a Western blot was performed 
using an anti-HiSô monoclonal antibody. This experiment was aimed at identifying which, 
if either, of the two major protein species eluted from the IMAC column possessed a His- 
Tag. The results of this Western blot are shown in figure 4.9.
Both of the major protein species reacted strongly with the anti-Hise antibody. Similar 
positive reactions were not observed for the low abundance contaminants released from 
the IMAC column at the same time. This result provided confirmation not only of the 
identities of both protein species as DrrB-Hisg, but also of the membrane localisation of 
the recombinantly expressed DrrB protein. Such a result was consistent with the 
hypothesis that the M  tuberculosis drr'B gene encodes a membrane-spanning component 
of a novel mycobacterial ABC transporter.
Despite the successful expression and purification of DrrB-His^, further manipulation of 
the protein proved difficult. Such basic technical procedures as dialysis, necessary to 
remove imidazole from the preparation, or concentration of the protein led to 
precipitation. This suggested that the isolated DrrB-Hisg protein became unstable after its 
extraction from the cell membrane. A search for more suitable elution buffers that might 
stabilise the protein ultimately proved fruitless. Attempts were made to reconstitute the 
protein into artificial proteoHposomes in order to increase its stability. Unfortunately the 
reconstitution process required extensive dialysis of the protein preparation in order to 
remove detergent and promote incorporation of the protein into lipid vesicles. The 
dialysis procedure invariably resulted in aggi'egation and precipitation. The presence of 
imidazole in the preparations, necessary for elution of the protein fi'om the IMAC 
column, presented a further experimental problem. Imidazole exhibits strong absorbance 
and fluorescence in the same range of wavelengths as native proteins. Present at 300mM 
in a typical DrrB-Hisg preparation, imidazole would mask any of the subtle spectroscopic 
effects that might be induced by interaction of DrrB-HiS6
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Figure 4. 9 Western blot of heterologousiy expressed DrrB-HiSô
M.W. (kDa)
—  i<ii
—
Possible DrrB-HiSô ________ ^ —» $*l
dimer
DrrB-HiSft monomer
An anti-His6 monoclonal antibody was used to determine the presence o f His-Tagged 
proteins in elutions from an IMAC purification column aimed at purifying DrrB-HiSô. 
The above Western blot illustrates that the two major protein species eluted from the 
IMAC column (see figure 4.8) react strongly with the antibody. Molecular weights o f  the 
reactive proteins are consistent with monomeric and dimeric forms o f the heterologously 
expressed DrrB-HiSô protein.
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with potential substrates (such as doxombicin). Given these experimental problems, a 
further characterisation of DitB function proved impossible. It was hypothesised that 
Dn B stability might be dependent upon the co-expression and purification of its 
presumed partner, DitC.
4.13 Attempted expression and purification of DrrC-Hisg
The sequence homology between the M  tuberculosis DrrB and DitC proteins suggested 
that a similar set of experimental parameters might be of use in purifying both of the 
proteins. As such, initial DrrC-Hisô expression trials were performed using identical 
conditions to those used for the expression and purification of the DrrB protein. 
C41(DE3)/pDiTC cells were gi'own at 30 °C in 2x YT medium and induced by the 
addition of ImM IPTG. As had been the case with recombinant DrrB, no obviously over­
expressed protein could be identified by simple fractionation the cells. The decision was 
made to progress directly to a series of IMAC purification trials. E. coli membranes were 
prepared from C41(DE3)/pDrrC cells as described in section 4.8.
By using a slight modification of the DrrB-HiSg purification protocol a potential DrrC- 
His6 protein was soon identified. An SDS-PAGE analysis of the IMAC purification 
procedure is shown in figure 4.10 along with the experimental conditions. The candidate 
DrrC-HiSô protein eluted as a single species from the IMAC column exhibiting an 
apparent molecular weight of slightly less than 28 kDa. In common with the previously 
identified DrrB protein, the recombinant form of DrrC exhibited a marginally higher 
electrophoretic mobility than might be expected for a 28.1 kDa protein. Once again this 
discrepancy was put down to the likely hydrophobic nature of the DrrC-Hise protein. The 
candidate DrrC-Hisg protein was, as expected, slightly smaller than the previously 
purified DrrB-Hisô protein. Unlike the DrrB protein however, the candidate DrrC-Hisg 
showed no evidence of dimérisation or fonnation of higher order aggregates.
Additionally, the candidate protein showed a lower affinity for the Ni-NTA resin than 
DrrB-HiSô had done. Figure 4.10 illustrates how some of the target protein was lost during 
washing of the IMAC resin with buffer containing 60raM imidazole. Under similar 
washing conditions DrrB-Hisg had remained fully bound to the column matrix. The 
decreased yield of target protein compared with DrrB-Hisô was deemed an acceptable 
trade-off given the increased purity achieved and the elution of only a single protein 
species.
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Figure 4. 10 Purification and SDS-PAGE analysis of a candidate 
DrrC-HiSô protein
A FT W l W2 W3 M El E2 E3 E4
64
51
39
28
19
M.W.
(kDa)
Candidate DrrC-Hise protein
Solubilisation buffer: - 
50 mM Tris-HCl (pH 8.0) 
150mM NaCl 
20% glycerol (v/v)
2% DDM (w/v)
IMAC purification buffers 
50 mM Tris-HCl (pH 8.0)
150mM NaCl 
20% glycerol (v/v)
0.1% Nonyl-maltoside (w/v)
Imidazole (20mM, 40mM, 60mM: washes) 
Imidazole 300mM (elution buffer)
A Coomassie blue stained SDS-PAGE gel showing the purification o f a candidate DrrC- 
His6 protein. The purification shown used total cell membranes isolated from 3L of  
C41(DE3)/pDrrC cell culture. The candidate protein elutes as a single species o f high 
purity with an apparent M.W. slightly lower than the predicted 28.1 kDa. Lanes A and FT 
represent applied and flow-through fractions respectively. Lanes W1-W3 are 20ml wash 
fractions containing increasing concentrations o f imidazole (20mM, 40mM and 60mM). 
Lanes E1-E4 are 4x 1ml eluate fractions o f a buffer containing 300mM imidazole. The 
candidate protein is present in only the first eluate fraction. However a significant 
quantity o f the target protein appears to have been stripped from the IMAC column by the 
60mM imidazole wash (lane W3).
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The candidate DrrC-His^ protein proved to be considerably more stable than its 
counterpart, DrrB. The protein could be dialysed safely to remove imidazole without 
significant precipitation. This obseiwation was somewhat surprising given the highly 
unstable nature of the homologous DrrB-Hise protein. Minor modifications to the 
purification protocol produced much larger yields of the target protein. These 
modifications included processing larger quantities of isolated membranes in a single 
purification step (e.g. total membranes isolated from 6 litres of cell culture). Additionally, 
less stringent column washes were employed in an attempt to reduce target protein losses 
during the purification. The lower stringency washes only caused a minor increase in the 
levels of contaminants co-eluting with the target protein. Elution fractions from the 
enhanced purification protocol are shown in figure 4.11.
The high purity of the eluted protein and the increased quantities available enabled the 
protein to be identified by direct N-terminal amino acid sequencing. Samples of the target 
protein were sent to the University of Leicester for analysis by automated N-terminal 
Edman degradation. 10 cycles of analysis were perfoimed generating the following 
results: -
Cycle 1 2 3 4 5 6 7 8 9  10
Residue M K V A L D L V V S
Comparison of this N-teiminal sequence with that encoded by the native M. tuberculosis 
drrC gene reveals similarity at only 1 position, the initiation methionine at the extreme N- 
terminus. The predicted N-terminal sequence of DrrC-Hise should have read 
MITTTSQEIE. This data suggested that a major contaminant protein was purifying in 
preference to any DrrC-Hise that might be present, and that DrrC-His^ expression levels 
were very low. An examination of the NCBI protein database revealed the identity of the 
contaminating protein, and also provided an explanation for its high affinity for the Ni- 
NTA resin. The 10 N-terminal amino acids of the contaminant exhibited 100% homology 
with those of the native E. coli protein SlyD (GenPept accession no.P30856). This protein 
normally fmictions as apeptidylproline cis-trans-isomerase, one of a number of 
chaperone-like proteins that facilitate correct protein folding (Hottenrott et al, 1997). The 
protein has been identified as a major contaminant in a number of Ni-NTA based IMAC
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Figure 4. 11 Modification of the purification procedure enhances the yield 
of the candidate DrrC-Hisg protein
El E2 E3 E4
M.W. (kDa)
191
64
51
39
28
19
Candidate DrrC- 
His6 protein
Buffer compositions : - 
50mM Tris-HCl (pH 8.0)
ISOmM NaCl
20% (v/v) glycerol
0.1 % (w/v) Nonyl-maltoside
Imidazole (40mM in wash buffer, 300mM in elution buffer)
SDS-PAGE analysis showing elution o f increased quantities o f the candidate DrrC-Hise 
protein. Total membranes were isolated from 6L o f C41(DE3)/pDrrC, solubilised in 
buffer containing 2% DDM, and the target protein purified by IMAC. The increased yield 
shown in this preparation (c.f. figure 4.10) was also enhanced by a reduction in the 
imidazole concentration present in the column washing buffer. The 1ml IMAC resin bed 
volume was washed just once with 20ml o f a 40mM imidazole wash buffer prior to 
elution o f the target protein. Elution was achieved by the addition o f 4x 1 ml aliquots o f  
buffer containing 300mM imidazole (lanes E1-E4). The purified protein shown in this 
figure was sent for N-terminal protein sequencing.
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1999 and Mukherjee et al, 2003). SlyD exhibits a high affinity for Ni^ "^  ions based upon 
the presence of an extremely histidine rich C-teiininal region. SlyD is just 196 amino 
acids in length, yet includes 15 histidine residues amongst the last 45 amino acids. It is 
the histidine-rich region of the protein that allows SlyD to compete with His-Tagged 
proteins for chelated Ni^ "*" ions present in the Ni-NTA IMAC resin. In the event that no 
His-Tagged proteins are present in a given sample, SlyD will bind to Ni^’^ -charged IMAC 
resin preferentially.
The undesired purification of SlyD was taken as a strong indication that little or no DitC- 
His6 expression was occurring. Modification of basic cell growth and induction 
parameters, such as lowered temperature and inducer concentrations, failed to produce 
any improvement in the observed results. Potential reasons for the failure of this protein 
to express effectively include toxicity of the protein to host E. coli cells, or extreme 
instability of the protein which might prevent its extraction from the cell membrane. 
Instability within the membrane due to the absence of its heterodimeric partner DrrB is 
another potential reason for the difficulties associated with the purification of this protein.
4 ,1 4  Discussion
Sequence analysis of the M. tuberculosis drrABC operon suggests that these genes 
encode an efflux-type ABC transporter playing an essential role in mycobacterial cell 
wall biosynthesis and/or drug resistance. However, a deeper understanding of the 
structure and function of this pump requires the study of its protein components at a 
biochemical level. This chapter describes various attempts to over-express and purify the 
DrrA,B and C proteins using the heterologous host E. coli, the aim being to provide 
suitable quantities of the proteins for basic biochemical analysis. The commonly used 
pET vectors were chosen for cloning and expression of the M. tuberculosis proteins since 
they have been used to successfully over-express and purify proteins from a wide variety 
of heterologous organisms. Moreover, the pET vectors also contain features that provide 
for high levels of target protein expression combined with specific immuno-affinity and 
purification tags. Each of the three mycobacterial genes were cloned into the pET-21a 
vector downstream of the strong bacteriophage T7 promoter and upstream of a short C- 
terminal fiision sequence encoding a His-Tag. The His-Tag provides a simple and 
efficient means of detecting and purifying heterologously expressed proteins against the 
background expression of E. coli proteins.
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Expression of DrrA-Hisô, the presumed ATP-binding protein of the M  tuberculosis ABC 
transporter, was achieved at high levels in the heterologous host. The high expression 
levels occuiTed despite a large separation, in evolutionary terms, between the Gram- 
negative host organism E. coli, and source of the heterologous protein, the Gram-positive 
M. tuberculosis. This suggested that codon usage differences between the two organisms 
would not be a barrier to heterologous expression, and that E. coli would be a suitable 
host for expression and purification of all three DrrABC transporter components. In a 
number of previous studies, over-expression of both eukaryotic and prokaryotic ABC 
transporter NBD’s in isolation, that is in the absence of their cognate MSD’s, has lead to 
the stable cytosolic accumulation of the NBD protein (e.g. ArsA, the ATP-binding 
component of the E. coli arsenical transporter; Hsu and Rosen, 1989). A similar sub- 
cellular localisation might also have been expected for the heterologously expressed DrrA 
protein which, sequence analysis suggests, exhibits a predominantly hydrophilic 
character. However, upon investigation, the Dii'A-Hise fusion protein was found to 
accumulate almost exclusively in the form of insoluble protein aggregates, known in E. 
coli as inclusion bodies. The protein present in inclusion bodies, whilst relatively pure 
and easy to isolate, is believed to be incoiTectly folded, and thus devoid of biological 
activity. In their 2001 paper reporting the crystal structure of the Methanococcus janschii 
MJ0796 ATP-binding cassette, Yuan and colleagues suggest that certain structural 
features of ABC transporter NBD’s may make these protein particularly prone to 
aggregation. A key structural element present in the Fi-type ATP-binding core of the 
NBD, a conserved p-sheet element, is able to fonii non-physiological pairings with 
similar elements in other molecules, eventually leading to aggregation (Yuan et al,
2001). Such events might be favoured in a situation where the NBD, normally a 
component of a stable multisubunit complex, is expressed in isolation. Under such 
circumstances the protein could expose to the enviromnent certain cavities and structural 
elements that would nomially be sequestered away from non-physiological interactions.
It should be noted that sub-cellular localisation experiments identified a small quantity of 
DrrA-HiSô as being associated with the cell membrane, a phenomenon that was also 
obseiwed for the S. peucetius DrrA protein. This suggests that the mycobacterial DrrA 
protein may possess certain surface-exposed hydrophobic regions. These regions may be 
involved in association of the NBD with the predominantly hydrophobic MSD’s in the 
intact transporter complex. Attempts to solubilise and refold the DrrA-His^ inclusion
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body protein ultimately proved fruitless, as did attempts to modify the growth and 
expression conditions in such a way as to promote the synthesis of a soluble, active foiin 
of the protein. These experiments did however demonstrate that a C-terminal located His- 
Tag was a suitable affinity tag for the purification of the DrrA fusion protein by IMAC 
cliromatography on Ni-NTA resin. Given the failure of the pET system to provide a 
biologically active form of heterologously expressed DnA for biochemical analysis, an 
alternative route to soluble protein expression was sought. These experiments are 
described in subsequent chapters.
Analysis of the DrrB primary sequence prior to expression suggested that this 
hydrophobic protein would locate to the E. coli cell membrane, the normal location of 
ABC transporter MSD’s. Low expression levels are typical of transniembrane proteins, 
even when their expression is driven by a strong promoter such as the bacteriophage T7 
promoter of the pET system. A low expression level for the DrrB fusion protein may 
have been responsible for the difficulties associated with detecting its expression in crude 
sub-cellular fractions. Even when Western blotting was used to probe for the presence of 
the DrrB His-Tag in these fractions, definitive results were hampered by the large number 
of native E. coli proteins present in the crude fractions, leading to a high background in 
the blot results. Despite problems detecting DnB-Hise expression in crude fractions, the 
protein was eventually partially purified from detergent solubilised E. coli membranes by 
IMAC affinity chromatography. Positive identification of DrrB-Hise was achieved by 
Western blotting, using an anti-Hise monoclonal antibody to probe for the presence of the 
His-Tag sequence in IMAC column eluate fractions. The DrrB protein purified as two 
predominant species, a monomeric and dimeric form, both species being present in 
approximately equal quantities. It was unclear as to whether the dimeric species foimed 
in a response to the absence of the DitC protein. Bacterial ABC transporter MSD’s are 
believed to function as either homo- or heterodimeric complexes, each protein 
contributing six transmembrane helices to an overall twelve helix substrate translocation 
pathway. This hypothesis was confmned by the publication of the complete X-ray crystal 
structures of the BtuCD and MsbA ABC transporters (Locher et al., 2002; Chang and 
Roth, 2001). Unfortunately, further attempts to manipulate either foim of the purified 
DrrB-Hise protein proved unsuccessful due to problems with protein stability. Any 
attempt to dialyse or concentrate the protein for further experiments caused the detergent- 
solubilised DrrB-Hisô to aggregate and precipitate. This problem persisted despite a
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immbep.pf trials imwliich different.detergents and buffer conditions were used.
,Meggaj^ane been a major problem associated with ABC transporter
studie_s,..|speqjaljy.^^^  ^ expression has been the route to obtaining the
,8tarting ;n^#e(ial,Jit is: Of note dh# much of the detailed structural and biochemical data in 
the.literqW^ ^^  prokaryotic ABC transporters has been obtained using model
transp0 rte%systepis,homologously expressed in E.coli (e.g. MalFGK; Lippincott 
.and ^ %axlei\rdf997).By^n. when such conditions are met, as was the case for the A. coli 
J\4sb.A,fr'ansppi'tec number of trials were necessary in order to identify
,sui|ab+e. conditions for expression and purification of the protein for structural studies. 
.The.;dË%W%^:^.#7We.d in working with isolated DrrB-Hisg perhaps reflects the 
niultisubunitjiatiU’e of.prokaryotic ABC transporters. Expressed in the absence of the 
other domains, individual subunits may become unstable and prone to aggregation, 
making further analysis of their properties impossible. This intrinsic instability, and the 
interdependence of ABC transporter subunits on one another for correct function, was 
shown for the S. peucetius DrrAB doxorubicin efflux system. Kaur demonstrated that 
maintenance of the DrrB protein within the host cell membrane was entirely dependent 
upon the presence of the DrrA ATP-binding subunit. Additionally, the S, peucetius DrrA 
protein appeared to be unable to bind ATP in the absence of DrrB, suggesting that the 
confonnation of DrrA was linked to its association with the DrrB protein (Kaur, 1998). 
Whilst this does not appear to be the case for M  tuberculosis DrrB-Hise, as evidenced by 
the ability to purify it from the membrane, its stability once extracted seems to be 
severely impaired.
The interdependence of the DrrABC transporter subunits for stability may also account 
for the failure of experiments aimed at expressing a recombinant DrrC protein. No 
evidence was found for the expression of this protein anywhere within the E. coli host 
cell. In the absence of any His-Tagged proteins, IMAC clri’omatography led to the 
purification of a histidine rich E. coli protein called SlyD. This protein has been identified 
as a major contaminant in a number of IMAC procedures where E. coli has been used as 
the host organism for heterologous expression (e.g. see Finzi et al, 2003; Mitterauer et 
a l, 1999).
The various experimental problems described here required that alternative approaches be 
investigated as a means of purifying sufficient, active and stable forms of the M
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tuberculosis DitA, B and C proteins. These methodologies included attempts to co­
express all tlu'ee components of the transporter in order to improve expression levels and 
stability of the individual proteins. The high expression levels associated with DrrA-His^ 
were viewed as a positive sign that an alternative expression system may be of use in 
producing significant quantities of this NBD for biochemical analysis.
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Chapter 5
Soluble expression of the M  tuberculosis DrrA protein by construction of a N- 
term inal fusion to E. coli thioredoxin
The inefficiency of the pET-based expression system with regard to generating soluble, 
recombinant DrrA necessitated a search for an alternative expression system. An in vitro 
expression system was considered as a potential means of producing Dn A for further 
studies, but was eventually rejected because of the high costs and relatively low yields 
associated with the technique. A system based upon the use of a more closely related 
Gram-positive expression host, Streptomyces lividans, was also investigated.
Unfortunately a number of technical difficulties associated with the gi'owth, handling and 
genetic manipulation of these organisms, combined with a lack of expertise and 
experience within the laboratory, led to the curtailment of these experiments. Instead, a 
series of E. coli expression vectors possessing features believed to promote protein 
solubility were selected for further investigation.
Transcriptional frisions of heterologous proteins to native E. coli proteins have been used 
as a means of improving both the expression level and solubility of the heterologous 
protein. Commonly used fusion partners include glutathione S-transferase (GST), maltose 
binding protein (MBP) and thioredoxin. All of these proteins are non-toxic when 
expressed at elevated levels in E. coli and provide the additional benefit of being highly 
soluble. Moreover, certain fusion partners may act as an affinity tag to facilitate 
purification of the protein by chromatographic means (e.g. purification of MBP fusions 
by amylose affinity chi'omatography). Many proteins have been expressed and purified in 
this way but a particularly pertinent example is the OleB protein of Streptomyces 
antibioticus. This protein, the ATP-binding domain of the oleandomycin efflux ABC 
transporter, was successfully characterised when expressed as a MBP-fusion (Aparicio et 
al, 1996). A similar MBP-fusion was used to produce a soluble form of the first NBD of 
the human MDRl gene product (Wang et al, 1999).
Each of the various fusion protein vectors available differ not only in the size and nature of 
the fusion partner, but also in the promoters used to drive expression and the presence of 
additional affinity tags. Of all of the systems investigated, the “pBAD-TOPO ThioFusion” 
vector (Invitrogen) was considered to offer the largest number of positive benefits. E. coli
150
thioredoxin is able to accumulate to approximately 40% of the total cell protein whilst 
remaining soluble, improves the efficiency of translation when present at the N-terminal, 
and is also relatively small in size compared with DrrA (11.7 kDa). An additional benefit 
of using thioredoxin is that the protein has no known nucleotide/drug/lipid binding 
functions that may have interfered with subsequent biochemical assays of the fusion 
protein. A relatively small fusion partner for DrrA was preferred because of the proximity 
of the Walker A nucleotide-binding residues to the N-terminal of the protein. A large 
fusion partner, such as MBP(42 kDa), may have had the potential to interfere with con*ect 
folding of the DrrA moiety, or perhaps have caused steric effects with regard to DrrA’s 
presumed nucleotide-binding activity. The use of the pBAD-ThioFusion system also 
presented the opportunity to test a different promoter to drive DrrA expression (the 
^raBAD promoter) whilst maintaining a C-terminal His-Tag sequence for effective 
purification of the fusion protein.
5 .1  The pTrx-DrrA expression construct
The pBAD/TOPO ThioFusion vector was obtained from a commercial source 
(Invitrogen) and used to generate a recombinant expression construct for DrrA according 
to the manufacturer’s instructions (see chapter 2). The key features of this construct, 
pTrx-DrrA, are shown in figure 5.1. The vector contains a 1455bp open reading frame 
encoding a protein of 485 amino acids with a predicted molecular weight of 52.5 kDa. 
The first 110 amino acids of the fusion protein constitute the E. coli thioredoxin moiety. 
There then follows a short 13 amino acid ‘linker sequence’ before the beginning of the M. 
tuberculosis DnA moiety (334 amino acids). The remaining 28 amino acids of the 
protein are a C-terminal extension to DrrA containing the His-Tag sequence. One of the 
major differences between the new construct and those generated previously was that 
expression of the heterologous protein was under the control of a promoter native to E. 
coli, the araBAD promoter. This promoter has the advantage that it is regulated by a non­
toxic inducer, arabinose, and that levels of transcription fr om the promoter are tightly 
linked to inducer concentration (Guzman et al, 1995). It was hoped that by using this 
promoter the levels of fusion protein production could be more finely tuned than had 
been possible with the pET-2Ia construct. Under such control it may be possible to 
identify those conditions in which soluble protein expression is enhanced and inclusion 
body formation reduced or prevented altogether.
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Figure 5. 1 The pTrx-DrrA expression construct
Linearised pTrx-DrrA 
(5456bp)
1002bp drrA  gene
Restriction enzyme digestion o f the pTrx-DrrA expression construct:
The pTrx-DrrA expression plasmid totals 5456bp in size (4454bp vector, 1002bp drrA  
insert). The vector contains only a single HindlW restriction site which was introduced by 
PCR to the 3’ end o f the drrA  amplicon. Digestion o f the plasmid with this enzyme (Lane 
H above) results in linearization o f the plasmid. The plasmid contains two Nde\ 
restriction enzyme sites, one at the 5’ end o f the drrA  insert, the second within the vector 
itself. A double digestion o f the plasmid with both Nde\ and HindWl (Lane D above) 
results in the generation o f three DNA fragments, two o f which are derived from the 
vector, the third being the 1002bp drrA  amplicon. The digests above were performed in a 
total volume o f 20pl using lOU o f each enzyme. Digests were incubated at 37 °C for 
Ihour.
Schematic representation o f pTrx-DrrA
Î Î
pBAD
promoter
E. coli thioredoxin 
coding sequence
C-terminal His6-Tag
Î
M  tuberculosis 
drrA  gene
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5. 2 Expression trials using pTrx-DrrA
The newly generated expression construct was transformed into the manufacturer’s 
recommended host strain E. coli TOP 10 (see table 2.2, chapter 2 for genotype). 
Transformed colonies were selected on the basis of vector-encoded ampicillin resistance, 
and isolated plasmids screened for the presence of the inserted DrrA sequence by 
restriction digestion (see figure 5.1). A single recombinant colony was used to initiate 
expression trials and to determine those conditions leading to maximal expression of the 
Trx-DrrA fusion protein. The recombinant colony selected was used to prepare a 5ml 
liquid starter culture which was grown overnight at 37 °C in LB medium with vigorous 
shaking. The next day 0.1ml samples of the starter culture were used to inoculate four 
separate 5ml cultures, each of which was grown to an ODooo of 0.6 before induction with 
arabinose. Each culture was induced with a different concentration of arabinose ranging 
between 0.2% w/v and 0.0002% w/v. The 1000-fold difference in inducer concentration 
was designed to identify optimal induction conditions. After 3 hours of growth samples 
were withdrawn from each culture and changes in protein expression were analysed by 
SDS-PAGE and by comparison with uninduced samples. The results of this analysis are 
presented in figure 5.2.
The expression trials demonstrated the accumulation of a protein with a size consistent 
with that predicted for Trx-DrrA. The same protein was expressed in all four trial cultures 
and was apparently absent prior to induction with arabinose. The concentration of 
arabinose added to each culture had a moderate effect, the greatest level of expression 
being observed in cultures induced with either 0.02% or 0.002% arabinose. In all future 
experiments using the pTrx-DrrA expression constmct 0.02% w/v arabinose was used to 
induce expression. A Western blot against the C-terminal His-Tag was used to confinn 
the identity of the 52 kDa protein as Trx-DrrA. Samples of total cell protein taken before 
and after induction with 0.02% arabinose were separated by SDS-PAGE and transferred 
to a PVDF membrane before being probed with an anti-His^ monoclonal antibody. The 
results of the blot, shown in figure 5.3, clearly show the positive reaction of the 52 kDa 
protein, and that it is only present in the culture after induction. This result was 
interpreted as a positive indication that the expressed 52 kDa protein was indeed 
recombinant Trx-DrrA.
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Figure 5, 2 Expression trials using the pTrx-DrrA fusion protein construct
Concentration o f arabinose (% w/v) 
0.2 0.02 0.002 0.0002 M.W.
I (kDa)
191
64
51
39
28
3 0 3 0 3 0
Time after induction (hours)
A Coomassie blue stained SDS-PAGE gel showing induction o f Trx-DrrA expression. 
Each lane shows total cell protein isolated from E. coli TOP 10/pTrx-DrrA prior to 
induction, or 3 hours post induction. Amounts o f protein loaded in each lane were 
nomalised by ODôoo at the time the samples were taken. The concentration o f inducer 
(arabinose) added to each culture varied over a 1000-fold range. A protein o f  
approximately the predicted size for Trx-DrrA (52 kDa) can be seen to accumulate in all 
four cultures 3 hours after induction. Maximal levels o f Trx-DrrA synthesis were 
observed in cultures induced with 0.02% and 0.002% arabinose.
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Figure 5. 3 Western blot to show expression of Trx-DrrA
Time after induction (hours)
M.W. (kDa) Oh 3h
191 ^
64
^  ^ ___  Trx-DrrA (52.5 kDa)
39
28
Anti-Hisft Western blot to show arabinose induced expression o f the 52.5 kDa Trx-DrrA 
fusion protein. The blot was performed on total cell protein isolated from E. coli 
TOP 10/pTrx-DrrA cells immediately prior to induction with 0.02% w/v arabinose (Lane 
0), and after growth at 37 °C for three hours (Lane 3). Cells were grown in LB medium 
supplemented with 1 OOpg/ml carbenicillin and induced at ODôoo = 0.6.
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5. 3 Sub-cellular localisation of Trx-DrrA
Sub-cellular fractionation experiments, in line with those described in chapter 4, were 
used in order to determine the physical location of Trx-DrrA within the cell, A 1 litre 
culture of TOP 10/pTrx-DrrA was grown in LB medium at 37 °C with shaking. Trx-Dn*A 
expression was initiated with 0.02% arabinose when the culture reached an ODeoo of 0.6. 
1ml samples were removed from the culture prior to induction, and at hourly intervals 
thereafter, in order to monitor expression of Trx-DiTA over the course of the experiment. 
After 3 hours of growth the cells were haiwested by centrifugation and resuspended in a 
buffer of 50mM Tris-HCl, 300mM NaCl, 10% glycerol w/v, and lysed by mechanical 
disruption. Cytosolic, membrane and insoluble fractions were prepared as described 
previously and solubilised in SDS-PAGE sample buffer for analysis. The results of the 
expression time-course and fractionation experiments are shown in figures 5.4a and 5.4b.
The time-course experiment demonstrated that maximal levels of Trx-DrrA were 
achieved after just one hour (figure 5.4a). However, as the culture continued to grow over 
the entire length of the experiment, monitored by an increase in ODeoo, it was assumed 
that Trx-DrrA expression was non-toxic. As such, the overall yield of Trx-DrrA was 
believed to increase throughout the entire growth period. Fractionation experiments 
(figure 5.4b) revealed that a significant quantity of the Ti'x-DitA synthesised was once 
again present in the insoluble fraction. This result was surprising given the known 
solubility of E. coli thioredoxin, but was perhaps a consequence of the high levels of 
expression seen within the first hour of growth after induction. A small quantity of Trx- 
DrrA was found to be present in the cytosolic fraction, an indication that the N-terminal 
fusion of thioredoxin to DrrA was having a positive effect on DrrA solubility, even when 
the cells were grown at 37 °C.
Following identification of soluble Trx-Dn A a number of optimisation experiments were 
perfoimed in order to improve the yield of soluble protein. These experiments primarily 
involved induction of Trx-DrrA expression at much lower temperatures and using much 
longer periods of growth. These measures were designed to slow down the rate of Trx- 
DrrA synthesis after induction, and to allow the fusion protein to fold into a native 
conformation. At the same time the growth medium was changed fr om LB to the richer 
2x YT medium, promoting cultures to grow to greater cell densities.
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Figure 5. 4a Time-course of Trx-DrrA expression
Time after induction (hours)
0 1 2  3
Trx-DrrA 
(«52 kDa)
M.W. (kDa) 
191
64
51
39
28
Total cell protein isolated from TOP 10/pTrx-DrrA before and after induction with 0.02% 
w/v arabinose. Trx-DrrA expression is fully induced after 1 hour.
Figure 5. 4b Sub-cellular fractionation of cells expressing Trx-DrrA
I S M M.W. (kDa) 
191
Trx-DrrA
► 28
1 = Insoluble 
fraction
S = Cytosolic 
fraction
M = Membrane 
fraction
Sub-cellular fractions isolated from cells expressing Trx-DrrA at 37 °C. The majority o f  
Trx-DrrA is found in the insoluble fraction (lane I), whilst a small amount is visible in the 
soluble or cytosolic fraction (lane S).
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Optimal expression of soluble Trx-DrrA was found to occur when using the following 
gi'owth and induction scheme: -
Starter culture:
Single TOP 10/pTrx-DrrA colony used to inoculate 
20ml of fresh LB medium containing 1 OOpg/ml 
carbenicillin. Culture grown overnight at 37 °C 
with shaking.
Pre-induction gi’owth period:
5ml of starter culture used to inoculate 1 litre of 
fresh 2x YT medium containing 1 OOpg/ml 
carbenicillin. Growth continued at 37 °C until 
culture reaches an ODgoo of 0.4.
Cooling of culture and induction:
At an ODeoo of 0.4 the incubator is switched to 17 °C 
and the cultures allowed to cool for 1 hour. Shaking 
of the cultures is stopped to reduce aeration. During 
this period the growth of the culture slows rapidly. 
After 1 hour the cultures reach an ODsoo of «0.8. 
Arabinose added at 0.02% w/v and shaking switched 
back on.
Overnight growth and expression:
Cultures grown overnight («16 hours) at 17 °C with 
shaking. Growth over this longer time period and at 
low temperature allows maximal expression of 
soluble Trx-DrrA. At the end of the growth period 
cells are harvested by centrifugation before further 
processing.
Following harvesting the cells were resuspended in a buffer of 50mM Tris-HCl (pH 8.0), 
300mM NaCl, 10 % glycerol (v/v). Cells were resuspended using 40ml of buffer per litre 
of cell culture. At this point cells were either stored at -80 °C for future use, or used 
immediately for the purification of soluble Trx-DiTA (see next section).
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5. 4 Initial purification of soluble Trx-DrrA by IMAC cliromatography
The presence of the C-tenninal His-Tag on Trx-Dii'A had previously been demonstrated 
by Western blot (figure 5.3). This feature of Trx-DrrA was then used in attempts to 
isolate and purify the flision protein by IMAC chromatogiaphy. Resuspended cells were 
lysed by mechanical disruption and insoluble material removed from the lysate by 
centrifugation (16,000 rpm, Beckman JA-21 rotor). Cells and lysates were kept on ice at 
all times in order to reduce proteolysis. EDTA-fiee protease inhibitors were added to the 
cleared lysate in order to further reduce proteolytic damage to the fiision protein. 1ml of 
Ni-NTA IMAC resin was added to the lysate along with imidazole at a final 
concentration of lOmM. The addition of imidazole at this stage was designed to reduce 
non-specific binding of E. coli proteins to the IMAC resin. Trx-DnA was allowed to bind 
to the resin for a period of 2 hours at 4 °C whilst the mixture was gently agitated on a 
blood wheel. At the end of the binding period the mixture was loaded into a 1.8cm 
diameter chromatography column and the resin allowed to settle under gravity flow.
The IMAC resin was then washed with a series of buffers containing increasing 
concentrations of imidazole in order to remove non-specifically bound proteins, followed 
by elution of Trx-DrrA using a buffer containing a high concentration of imidazole. The 
washing and elution conditions used to prepare Trx-DixA are shown below:-
Buffer A (same as resuspension buffer) :- 
50 mM Tris-HCl (pH 8.0)
300mM NaCl 
10% glycerol (v/v)
Wash I 
Wash II 
Wash III 
Elution
50ml Buffer A
50ml Buffer A + 25mM imidazole 
25ml Buffer A + 50mM imidazole 
5 X Iml Buffer A + 300mM imidazole
Protein samples were collected thr oughout the purification procedure for analysis by 
SDS-PAGE. Results obtained using the purification protocol detailed above are shown in 
figure 5.5.
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Figure 5. 5 Initial purification of soluble Trx-DrrA
Fraction
FT Wl W2 W3 M El E2 E3 E4
Trx-DrrA 
(« 52 kDa)
SDS-PAGE analysis o f protein fractions obtained during initial purification trials of 
soluble Trx-DrrA. Column chromatography was performed according to the protocol 
described in section 5.4. Fractions: FT = column flow-through, W1-W3 = washes to 
remove non-specifically bound protein, E1-E4 = Elutions o f the Trx-DrrA fusion protein.
Significant quantities o f Trx-DrrA are released from the IMAC resin using the 300mM 
imidazole elution buffer (lanes E1-E4). However, despite extensive washing o f the IMAC 
resin during the early stages o f the procedure (lanes W1-W3), a large number o f  
contaminating proteins are seen to co-elute with Trx-DrrA. The contamination is 
particularly evident in the first two elution fractions where the majority o f Trx-DrrA is 
found.
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Figure 5.5 illustrates that the low temperature growth and induction protocol employed !
was sufficient to generate acceptable quantities of soluble Trx-DrrA for further 7
experiments. However, both biochemical studies and crystallisation trials require the I
availability of protein samples having purity levels in the region of 90-95%. The IMAC i
purification of Trx-DrrA shown in figure 5.5 yielded protein with a purity of little more !
than 60%, well below the level required for any meaningflil analysis of biochemical -
activity. y
A number of variations on the basic gravity-fed column chromatography procedure were 
tested as a means of enhancing Trx-DrrA purity. These variations included processing of 
increased quantities of cell lysate in a single purification experiment so as to saturate the 
IMAC resin with specifically bound Trx-DrrA, thereby reducing the availability of 
binding sites for contaminating proteins. Alternative host strains for the pTrx-DrrA 
expression plasmid were also tested in order to identify a strain capable of generating 
higher yields per litre of culture. Whilst some minor improvements in yield were 
obseiwed when E. coli LMG194 was used as the expression host, this variable had little 
effect on the purity of Trx-DrrA. Since the major problem with the procedure lay in the 
co-elution of contaminating proteins, a number of variations in the column washing 
protocols were adopted. These included washing the IMAC resin with both increased 
volumes of wash buffer and the use of more stringent buffers (containing higher 
concentrations of imidazole). Figure 5.6 illustrates how all of these factors combined led 
to significant increases in both the purity and yield of Trx-DiTA obtained by this 
methodology. Despite the observed improvements, figure 5.6 also illustrates the 
limitations of this particular fonn of IMAC. Lane W4, a sample obtained whilst washing 
the IMAC resin with a buffer containing 75mM imidazole, contains a low concentration 
of Trx-DrrA and few if any contaminants. This suggests that an imidazole concentration 
of 75mM was sufficient to cause the leaching of Trx-DrrA from the resin, whilst not 
completely removing contaminating proteins (see lanes E2 and E3).
The experiments described above served as an important ‘proof-of-principle’ for the 
purification of soluble Trx-DrrA by IMAC, yet had failed to produce protein of sufficient 
purity for further analysis. Given the problems encountered, an alternative purification 
procedure was adopted. This modified procedure, described in the next section, 
eventually led to the generation of highly purified Trx-DrrA.
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Figure 5. 6 Improved yields of Trx-DrrA generated by a modification of
the basic IMAC procedure
Fractions
FT Wl W2 W3 W4 M El E2 E3 E4
f
f
^ -----  Trx-DrrA
(«52 kDa)
Coomassie blue stained SDS-PAGE gel showing purification o f Trx-DrrA by gravity 
flow IMAC chromatography. A number o f modifications to the basic protocol were used 
in attempts to increase the purity and yield o f Trx-DrrA. The above analysis shows 
protein purified from a 6 litre culture o f  LMG194/pTrx-DrrA cells grown and induced at 
17 °C.
FT = Flow-through, W1-W4 = Wash fractions (see below), M = Molecular size markers, 
E1-E4 = Elution fractions
Basic buffer : 50mM Tris-HCl (pH 8.0), 300mM NaCl, 10% glycerol (v/v)
Wl = Buffer + 25mM Imidazole (20ml)
W2 = Buffer + 40mM Imidazole (20ml)
W3 = Buffer + 50mM Imidazole (20ml)
W4 = Buffer + 75mM Imidazole (20ml)
E1-E4 = Buffer + 300mM Imidazole (4 x 1.5ml)
162
5. 5 Effective purification of soluble Trx-DrrA using an enhanced
chromatography procedure
Up to this point all attempts to purify soluble Trx-DrrA had been performed using 
Qiagen’s ‘Ni-NTA-agarose’ IMAC resin. The purification procedure itself had involved 
two distinct phases, an initial bulk binding phase followed by gravity flow column 
chromatography. In the following series of experiments an alternative procedure was 
adopted. Purification was performed using a pre-packed IMAC matrix purchased from a 
commercial source, and all binding, washing and elution phases were perfoimed under 
positive pressure provided by a peristaltic pump.
1ml ‘HiTrap Chelating HP’ columns were purchased from Amersham Pharmacia Biotech 
and were loaded with Ni^ "^  ions according to the manufacturer’s instructions (see chapter 
2). A single 1ml column, loaded with Ni^ "^ , served as the chromatography matrix in all of 
the following experiments. The major difference between this matrix and the Ni-NTA 
matrix used previously is the nature of the ligand gi oup to which Ni^ "^  ions are bound. In 
the case of the HiTrap columns Ni^^ ions are bound to a Sepharose matrix through an 
iminodiacetic acid (IDA) ligand, rather than being bound to agarose beads via a 
nitrilotriacetic acid (NTA) ligand. The experiments described below show how this 
relatively small difference led to vastly improved yields and purity levels during the 
preparation of Trx-DnA.
A trial experiment using the Ni-IDA matrix was performed according to the following 
protocol. 1 litre culture of E. coli LMGl 94/pTrx-DrrA was grown using the low 
temperature growth and induction procedure described in section 5.3. These cells were 
resuspended in 50ml of an ice-cold buffer containing 50mM Tris-HCl (pH 8.0), 400mM 
NaCl, 10% glycerol and EDTA-free protease inhibitors. The cells were disrupted and a 
cleared lysate containing soluble Trx-DnA was prepared by centrifugation. The elevated 
NaCl concentration used in all buffers was an attempt to reduce non-specific interactions 
between the column matrix and proteins present in the cleared lysate. Trx-DnA was 
immobilised by pumping the cleared lysate (approx. 45ml) through a pre-equilibrated 
IMAC column at a constant flow-rate of O.Sml/minute. This and all subsequent stages of 
the procedure were performed at 4 °C in a cold-room. After the completion of the 
binding phase unbound protein was removed from the column matrix by passing 25ml of
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resuspension buffer through the column at the same flow-rate. Non-specifically bound 
contaminants were removed from the resin by washing with 75ml of the same buffer 
supplemented with 60mM imidazole. The final stage of the procedure involved elution of 
the bound Trx-DrrA using buffer supplemented with 250mM imidazole. 10ml of this 
elution buffer was pumped through the column at a flow rate of 0.8ml/minute and 1.5 ml 
fractions collected. The results of the experiment described above were analysed by SDS- 
PAGE as shown in figure 5.7.
The use of a pre-packed Ni-IDA column and a peristaltic pump clearly resulted in a 
vastly improved preparation of soluble Trx-DixA. Little background contamination was 
evident in the elution fractions and the protein was estimated to be approximately 90% 
pure, ideal for subsequent biochemical assays. The experiment illustrated in figure 5.7 
was performed using a clear ed lysate prepared from just 1 litr e of cell culture.
Following the success of the initial purification trials, lar ger scale purification 
experiments were initiated in order to provide the necessary quantities of Trx-DrrA 
required for subsequent studies. The purification protocols developed previously were 
simply applied to cleared lysates obtained from larger cell cultures. Figure 5.8 shows the 
large scale purification of Trx-DrrA from a 3 litre culture of LMG194/pTrx-DrrA cells. 
Exactly the same IMAC binding, washing and elution steps as had been performed in the 
smaller scale experiments were used here also. Figure 5.8 shows that the purification 
methodology developed was robust, reproducible and able to yield Trx-DrrA of the 
required purity (greater than 95%) for furtlier studies. In addition, the protein purified in 
this manner proved to be stable at 4 °C for up to a week, and could be dialysed without 
risk of precipitation.
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Figure 5. 7 Enhanced purification of Trx-DrrA using a Ni-IDA
chromatography matrix
Fractions
FT W1 W2 M El E2 E3 E4 E5
Trx-DrrA 
(=52 kDa)
A Coomassie blue stained SDS-PAGE gel showing IMAC purification o f  soluble Trx- 
DrrA. Purified protein was isolated from a 1 litre culture o f LMG 194/pTrx-DrrA grown 
and induced as described in section 5.3. Column chromatography was performed using a 
pre-packed 1ml Ni-IDA-Sepharose column loaded and developed at a flow rate o f  
0.8ml/minute. Trx-DrrA prepared by this method was estimated to be approximately 90% 
pure. This represented a significant improvement in the quality o f the Trx-DrrA protein 
preparation when compared with previous gravity-flow IMAC experiments.
Column Buffer : 50mM Tris-HCl (pH 8.0), 400mM NaCl, 10% glycerol (v/v)
W 1 = Buffer + OmM Imidazole (25ml)
W2 = Buffer + 60mM Imidazole (75ml)
E1-E5 = Buffer + 300mM Imidazole (5 x 1.5ml)
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Figure 5. 8 Large-scale purification of soluble Trx-DrrA
Elution fraction
6 M 7 8
A Coomassie blue stained SDS-PAGE gel showing purified soluble Trx-DrrA. The above 
protein was purified from 3 litres o f LMG 194/pTrx-DrrA cells grown and induced at 17 
°C. Cleared lysate from these cells was applied to a 1ml HiTrap Chelating IMAC column 
at a constant flow rate o f 0.8ml/minute using a peristaltic pump. Wash and elution buffers 
(see below) were applied to the column in the same fashion. Trx-DrrA purified by this 
technique was estimated to be greater than 95% pure, suitable for further biochemical 
analysis. Protein samples were stored at -80°C.
Purification protocol: -
Column Buffer 5OmM Tris-HCl (pH 8.0), 400mM NaCl, 10% glycerol (v/v)
Wash 1 
Wash 2 
Elutions
Buffer + OmM Imidazole (25ml)
Buffer + 60mM Imidazole (75ml)
Buffer + 300mM Imidazole (15ml, collected in 1.5ml fractions)
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5.6 Discussion
Recombinant protein over-expression and purification is a complex process, the success 
of which is influenced by a wide range of variables. Factors such as the source of the 
recombinant protein, the expression host, and the nature of the expression system 
employed may all have a significant role in detennining the outcome of experiments. All 
previous attempts to express a soluble form of recombinant M. tuberculosis DrrA using 
the pET-based expression system had failed due to the formation of inclusion bodies. 
However, as the data in this chapter demonstrates, such problems can be overcome by 
careful modulation of variables known to affect protein expression and solubility.
The eventual production of soluble M  tuberculosis DrrA was achieved through 
introduction of multiple, sequential changes to expression and purification protocols. The 
exact degree to which each variable influenced the eventual outcome is difficult to 
assess. However, modifications to the expression system, growth conditions, bacterial 
strains and chromatography techniques were all shown to contribute to the improved 
results. Perhaps the greatest improvements in DrrA expression were derived from the use 
of an alternative expression vector. The pBAD-ThioFusion system not only provided 
high levels of expression (as the pET vector had done), but also had a significant 
influence on the sub-cellular localisation of the protein. Whereas cells carrying the pDrrA 
plasmid had expressed the protein in the form of insoluble aggregates, pTrx-DrrA led to 
accumulation of the fusion protein in the E. coli cytosol. The use of fusion proteins is 
becoming an increasingly common strategy when attempting to improve the solubility of 
ABC transporter NBD’s. The technique has been applied to proteins from both 
eukaryotic and prokaryotic sources, most commonly employing MB? as the fusion 
partner (e.g. see Gartner et al, 2003; Honisch and Zumft, 2003). The data presented here 
suggests that E. coli thioredoxin may be an equally effective fusion partner for some 
bacterial NBD’s. The proximity of the structurally important Walker A nucleotide- 
binding motif to the N-teiminal of DrrA was a major factor in the choice of thioredoxin 
as the fusion partner. It was considered possible that the presence of a high molecular 
weight protein, such as MBP, near to the nucleotide-binding fold might influence the 
biochemical properties of the ATPase. This may be even more of a consideration in the 
light of structural data suggesting that important functional interactions between ABC 
transporter NBD’s are mediated by juxtaposition of two nucleotide-binding folds (Chang,
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G,, 2003). Determining whether or not this is a valid concern will require the availability 
of high resolution structural data for a NBD fusion protein.
The quantity of soluble Trx-DrrA produced was strongly influenced by the growth 
temperature of expression cultures. Rapid growth at 37 °C was shown to promote the 
fonnation of insoluble aggi'egates similar to those produced by the pET system, whilst 
growth at 17 °C generated primarily soluble, cytosolic protein. Clearly the speed at 
which heterologous proteins are synthesised in E. coli can have a major effect on the 
efficiency of protein folding, especially when so many of the cell’s resources are being 
used to this end.
Having established conditions suitable for the expression of soluble Trx-DrrA, further 
analysis required development of an efficient purification protocol. Previous experiments 
using C-terminal His-Tagged DitA had shown that IMAC was an acceptable means of 
purification. However, further iterative alterations to the basic IMAC protocol were 
required to identify optimal purification parameters. Initial experiments using a 
combination of batch-binding and gravity flow column cliromatogi aphy were only 
partially successful in the purification of Tix-DrrA. Whilst acceptable levels of Trx-DirA 
were recovered using this teclmique, the purity of the preparations was deemed to be 
insufficient for subsequent biochemical analysis. By switching to an alternative metal 
affinity resin and using larger quantities of starting material the problem of protein 
impurity was virtually eliminated (see figure 5.8). Once again a relatively small change 
in experimental methodology had produced a significant improvement in results.
The expression and purification protocols described here were used to produce Trx-DiiA 
for a range of biochemical experiments described in the next chapter. Yields of the highly 
purified protein were estimated to be 2-3mg/litre of culture, and the protein could be 
stored at -80 °C for extended periods of time without significant loss of function or 
aggi’egation.
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Chapter 6
Biochemical analysis of the Trx-DrrA fusion protein
Sequence analysis of the M  tuberculosis drrABC operon (presented in chapter 3) 
strongly suggests that DrrA constitutes the NBD of an ABC transporter complex. Having 
established a suitable means of over-expressing and purifying the protein using E. coli as 
the host organism, the next stage of analysis was to examine the biochemical properties 
of the protein.
A significant body of experimental data has accrued regarding the biochemical properties 
of ABC transporter NBD’s. Much of this data relates to the medically important 
eukaiyotic ABC transporters, CFTR and P-glycoprotein, and to model bacterial systems 
such as the nutrient uptake transporters. Despite this, a definitive picture of NBD 
behaviour has yet to emerge. Whilst certain fundamental properties of these proteins 
remain constant, for example their ability to bind and hydrolyse ATP, other properties 
show a marked degree of variation. Variables identified include the sensitivity of ATPase 
activity to a range of inhibitors, whether or not activity is stimulated by transport 
substrates, and the proposed multimeric state of these proteins. Differences in the 
experimental systems used by different gi'oups to over-express, purify and assay the 
activity of NBD’s no doubt contribute to this variability.
The data presented in this chapter show the biochemical activity of the Trx-Dn A fusion 
protein to be broadly compatible with a functional role as the NBD of a mycobacterial 
ABC transporter. A partial characterisation of the protein was achieved tlrrough the use of 
traditional biochemical assays to determine features of the protein such as its enzymatic 
activity and substrate preference. Efforts to describe more detailed features of Trx-Dn A 
behaviour using sophisticated techniques such as stopped-flow fluorescence spectroscopy 
were essentially unsuccessful. Possible reasons for the failure of these experiments are 
described at the end of the chapter.
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6.1 Trx-DrrA exhibits cation dependent ATPase activity
The ability to bind and hydrolyse ATP is a flxndamental property of all ABC transporter 
NBD proteins identified to date; the phosphate bond energy released being used to drive 
the substrate translocation process. Many ABC transporter NBD’s have been shown to 
retain their ATP-binding/hydrolysing properties even when expressed and assayed in 
isolation, i.e. in the absence of associated membrane-spanning components of the 
transporter complex (e.g. see Nikaido et al., 1997). The high level of sequence homology 
between M  tuberculosis DitA and other NBD proteins suggested that this protein should 
demonstrate a similar ATPase activity. In fact, establishing such activity was considered 
to be a vital first step in demonstrating not only the efficacy of the expression and 
purification protocol developed, but also in confimiing the hypothesis that DrrA does 
indeed constitute the NBD of a novel mycobacterial ABC transporter.
The ATPase activity of recombinant Trx-DrrA was initially assayed using a modification 
of the protocol developed by Harder and colleagues. The technique relies upon the use of 
a chromogenic reagent in order to detect inorganic phosphate (Pi) released into the assay 
medium through the activity of the ATPase enzyme. The detection reagent, a mixture of 
malachite green and acidified ammonium molybdate, reacts quantitatively with Pj to form 
a green coloured complex absorbing strongly at 610nm (see chapter 2 and Harder et al., 
1994). Perfonned in 96-well microtitre plates, the assay provides excellent sensitivity and 
linearity of response when testing samples containing a range of P, concentrations from 1 
to 30 pM (50 to 1500 picomoles of PJ. Standard curves were prepared in parallel with 
each ATPase assay in order to quantify the amount of Pi released. Figure 6.1 shows the 
data generated for a typical standard curve.
To date, the ATPase activity of virtually all ABC transporter NBD’s has been shown to 
be dependent upon the presence of a divalent cation, most usually magnesium. Indeed, 
the function of the highly conserved aspartate residue in the Walker B ATP-binding motif 
is believed to be co-ordination of the divalent cation. The presence of this cation is 
thought to be absolutely vital to the mechanism of ATP hydrolysis and a number of ABC 
transporter NBD’s show dramatically reduced ATPase activities when the conserved 
aspartate is removed by site directed mutagenesis (e.g. see Zhou and Rosen, 1999).
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Figure 6.1
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The standard curve above shows the response of the malachite gi-een Pi assay over the 
range 50 to 1500 picomoles of Pj. Standard samples containing various amounts of 
phosphate were prepared by diluting a ImM stock of NaH2 P0 4  into assay buffer (5OmM 
MOPS, lOOmM NaCl; pH 7.4). A 45pi aliquot of each standard sample was then mixed 
with 5pi of 500mM EDTA in a separate well of a 96-well microtitre plate. The assay was 
developed by the addition of lOOpl of malachite green detection reagent to each well and 
the absorbance of samples at 610nm measured in a plate reader.
Detection reagent: 3 parts 0.045% w/v malachite green 
1 part 4.2% w/v ammonium molybdate in 6N HCl 
0.01% v/v Tween 20
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The first ATPase assays perfonned were designed to identify whether or not the Trx- 
DrrA fiision protein was capable of ATP hydrolysis, and also whether such activity was 
dependent upon the presence of Mg^’*’ ions. Two identical reaction mixtures, detailed in 
figure 6.2, were prepared and incubated at 37 °C for 10 minutes in a thennostatically 
controlled heating block. After this initial equilibration period the reaction in one of the 
two tubes was initiated by the addition of MgClz to a final concentration of ImM. A 
similar volume of water was added to the second reaction mixture (the negative control). 
Over the ensuing ten minutes 45 pi samples of each reaction mixture were withdrawn at 
various time points and mixed with 5pi of 500mM EDTA in a separate well of a 
microtitre plate. The role of the high concentration EDTA was to rapidly chelate Mg^ "^  
ions, thereby immediately halting cation-dependent ATP hydrolysis in each sample. After 
a complete set of samples had been collected for both the experimental and control tubes, 
the phosphate content of each withdrawn sample was analysed by the addition of lOOpl 
of malachite gi een detection reagent. The results were analysed immediately after the 
addition of the detection reagent by measuring absorbance at 61 Onm. This was done as 
quickly as possible in order to reduce the interfering effect of acid-hydrolysis of ATP 
caused by the low pH of the detection reagent.
The results of these initial experiments are shown in figure 6.2. The Ti'x-DrrA fusion 
protein clearly shows ATPase activity, as measured by an increase in P; content of the 
assay mixture over time. A similar level of ATPase activity is absent fi'om the control 
sample indicating that activity is, as expected, dependent upon the presence of a divalent 
cation. Whilst a small increase in phosphate content is observed in the negative control 
reaction over the course of the experiment, it is many times lower than that observed for 
the magnesium-containing sample. This small increase can perhaps be attributed to 
spontaneous ATP hydrolysis occurring over the total 20 minute period of the experiment. 
The assay was performed under ‘steady-state’ conditions, i.e. the concentration of 
substi'ate (5mM ATP) was far in excess of that of the enzyme (1.2pM, based upon a 
calculated M.W. of 52 kDa for Trx-DnA). Under such conditions the enzyme would be 
expected to display linear ATPase activity. Although some deviation from linearity was 
observed in the earliest time-points, overall the activity was a good fit to a straight line 
(R  ^= 0.98).
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Figure 6. 2 Magnesium-dependent ATP hydrolysis by Trx-DrrA
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Two identical reaction mixtures (see below) were incubated at 37 °C for ten minutes prior 
to the addition of ImM MgClz (filled circles), or H2 O (open circles). 45 pi samples were 
withdrawn from the reaction mixtures at the time points indicated and ATPase activity 
quenched by mixing with 5pi of 500mM EDTA. Samples were analysed for ?i content by 
measuring absorbance at 61 Onm after the addition of lOOpl of malachite gi'een detection 
reagent. Absolute quantities of Pi in each sample were calculated by comparison with a 
standard curve.
Reaction conditions
Assay buffer = 50mM MOPS (pH 7.4), lOOmM NaCl 
[ATP] = 5mM 
[Trx-DrrA] = 1.2pM
[MgCli] = ImM (filled circles), OmM (open circles)
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The gradient of the activity curve indicated that Pi was being released into the reaction 
mixture at a rate of 209 picomoles/min/45pi sample analysed. By subtracting the 
apparent rate of spontaneous ATP hydrolysis obseiwed in the control reaction (11 
picomoles/min/45 pi) a coiTected figure of 198 picomoles/min/45 pi was derived. ATPase 
data is more commonly presented in tenns of activity/minute/mg protein. In order to 
allow effective comparison of Trx-DrrA with other NBD proteins the activity data was 
converted to these alternative units using the calculated M.W of the protein and the fact 
that the assay was carried out in a total volume of SOOpl. On this basis, the ATPase 
activity of Trx-DrrA, under the conditions described, was found to be 56.41 nmoles 
Pi/minute/mg protein. The only other mycobacterial NBD protein for which ATPase 
activity data is available is PstB, the ATPase domain of the phosphate-specific transporter 
(Sarin et aL, 2001). The activity of this protein was found to be 122 mnoles P;/min/mg, 
approximately twice that observed for Trx-DrrA. The significance of this and other 
comparisons are considered in the discussion section at the end of this chapter.
A second means of measuring the ATPase activity of Trx-DnA was also tested in order 
to confirm the results of the malachite green Pi release assay. This second assay, the 
EnzChek Phosphate Assay system (Molecular Probes, see chapter 2), had the advantage 
that Pi accumulation could be monitored in real-time by spectroscopic means. This feature 
of the assay allowed both the stimulatory effect of Mg^ "^  ions and the quenching effect of 
EDTA to be shown directly. It also provided a frirther demonstration that the steady-state 
hydrolysis of ATP by Trx-DrrA was indeed linear, and that the deviations from linearity 
obseiwed in the early time-point samples of the malachite green Pi assay were artefactual. 
Figure 6.3 shows that virtually no ATP hydrolysis is observed in the sample prior to the 
addition of ImM MgCB (0-60sec, blue line). Thereafter, the Pi content of the sample 
increased linearly over the period 77-387sec (red line) as measured by the increase in 
absorbance of the sample at 360nm. Finally, EDTA was shown to completely halt the 
ATPase activity of Trx-DrrA when added to the reaction mixture at a final concentration 
of 5mM (green line). The data produced by this assay were not directly quantified 
because of the need to use large quantities of the expensive assay reagents in order to 
generate Pi standard curves.
174
Figure 6. 3 Direct observation of ATP hydrolysis by Trx-DrrA using a 
continuous spectroscopic assay
Abs. 360nm
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The EnzCheck Phosphate Assay system (Molecular Probes) was used to monitor the 
continuous hydrolysis o f ATP by Trx-DrrA in a spectroscopic assay. The assay mixture 
was prepared according to the manufacturers directions and the generation o f P; 
monitored as an increase in absorbance o f  the sample at 360nm (see below and chapter 
2). ATPase activity was induced by the addition o f 1 mM MgClz to the sample cuvette, 
left hand arrow, and stopped by the addition o f  the chelator EDTA, right hand arrow. 
Between these points the rate o f  ATP hydrolysis by Trx-DrrA was essentially linear and 
entirely dependent upon the availability o f free Mg^  ^ions. The assay was performed at 22 
°C in a 1.5ml cuvette with a 1cm path length. Increase in absorbance o f the experimental 
sample was calculated with respect to an identical cuvette containing dHiO.
Assav Component
MOPS (pH 7.4), lOOmM NaCl
PNP
ATP (lOOmM stock)
MESG
Trx-DrrA (300pg/ml)
MgCb (lOOmM stock)
Volume (total 1 ml)
720pl
lOpl
lOpl
200pl
50pl
lOpl
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6. 2 Dependence of Trx-DrrA ATPase activity on ATP concentration -
Determination of V,„ax and K„,
Having established that the purified Trx-DrrA fiision protein was indeed a functional 
ATPase, a series of experiments were performed in order to deteimine some of the basic 
kinetic parameters of the enzyme’s activity, thereby allowing meaningful comparison 
with other NBD proteins. The malachite green P, release assay was used to determine the 
rate-dependence of ATP hydrolysis upon ATP concentration (under steady-state 
conditions). ATPase activity data was collected over a 150-fold range of ATP 
concentrations from lOpM to 1.5mM. The Trx-DrrA concentration used in all assays was 
1 pM (52pg/ml). Figure 6.4 shows that the rate of ATP hydrolysis varied in a hyperbolic 
manner with increasing ATP concentration, indicative of simple Michaelis-Menten type 
kinetics. Non-linear regression analysis (Sigma Plot 4.01, SPSS) showed that the data 
was a good fit to a single hyperbolic function indicating that Trx-DrrA had a V,„ax of 52.4 
± 2.3 nmoles Pj/min/mg and a of 84.8 ± 6.3 pM.
Whilst regression analysis of this kind is undoubtedly the best way of accurately 
determining kinetic parameters from untransfonned rate data, indirect, graphical means 
are also available. The same rate data illustrated in figure 6.4 were re-plotted in a straight 
line form according to the method of Hanes and Woolf. The values of the gradient and x- 
intercept were used to calculate V,„ax and K,„ respectively (see figure 6.5). Using this 
graphical means Trx-DrrA was shown to have a U»».? of 52.4 nmoles Pi/min/mg and a K„i 
of 85.5pM, both figures showing excellent correlation with those derived by non-linear 
regression. This calculated Vmax value of 52.4 ± 2.3 nmoles Pi/min/mg for Trx-DrrA also 
shows good conelation with the earlier ATPase data described in section 6.1. This 
previous assay, perfonned using a veiy high ATP concentration of 5mM (% 60 times K,n), 
suggested an activity of 56.4 mnoles P|/minute/mg protein, a figure that is in good overall 
agreement with the calculated value described here. Comparison of these data with those 
obtained for other prokaryotic ABC transporter NBD’s is discussed in section 6.11 at the 
end of this chapter.
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Figure 6. 4 ATPase activity of Trx-DrrA as a function of [ATP]
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The malachite gi een Pi release assay was used to determine die rate of ATP hydrolysis by 
1 |iM (52 jig/ml) Trx-DrrA in the presence of various ATP concentrations ranging from 
lOpM to ISOOpM. ATPase assays were performed at 37 °C in a thermostatically 
controlled heating block and initiated by the addition of MgCl2  to a final concentration of 
ImM. All assays were conducted in a total volume of SOOpl with 45pl samples analysed 
for Pi content at 1 minute time intervals over a time course of 10 minutes. A Pi standard 
curve was used to convert Pi accumulation data to rate data in the format nmoles 
Pi/min/mg protein.
The rate data were fitted to a single hyperbolic (Michaelis-Menten) function of the type:
V = a . X
b  +  X
where the co-efficients a and b correspond to kinetic parameters V,nax and K„i^  and x and y 
refer to the substrate concentration and measured rates respectively. The values for V,„ax 
and K,n returned by the Sigma Plot 4.01 non-linear regression software are shown on the 
gi'aph.
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Figure 6. 5 Hanes-Woolf determination of K,,„v and K„, for Trx-DrrA
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The ATPase activity data shown in figure 6.4 were re-plotted according to Hanes and 
Woolf (above). The data were an excellent fit to a straight line with the equation: - 
y = 0.01907x T 1.63 (R  ^= 0.998). The Hanes-Woolf plot is a re-arrangement of the 
hyperbolic Michaelis-Menten plot and can be used to determine the kinetic parameters 
V,nax and Km by graphical means. The gradient of the straight line fit corresponds to the 
value If Vmax, whilst solving the linear equation for y = 0 provides the - Km value.
Evaluated by this means, the ATPase activity of Trx-DrrA was shown to have a Vmax o f 
52.4 mnoles Pj/min/mg of protein and a K,,, of 85.4pM. Both of these figures are in 
excellent agreement with those calculated for the same parameters by non-linear 
regression analysis of the untransfonned data.
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6. 3 The Trx-DrrA fusion protein does not display positive cooperativity
with regard to ATP hydrolysis
The fact that Trx-DnA appeared to hydrolyse ATP according to simple Michaelis- 
Menten kinetics suggested the absence of any physical or mechanistic interaction 
between protein sub-units during the ATP hydrolysis cycle. Indeed, a Hill plot of the 
kinetic data indicated that individual Trx-DrrA molecules behave completely 
independently of one another (Hill coefficient = 1.01, see figure 6.6). However, 
interaction between NBD’s has become an increasingly central feature of models 
regarding ABC transporter function (e.g. see Locher et aL, 2002 ). It was considered that 
up to this point all ATPase activity had been measured at low enzyme concentrations, 
conditions which reduce the likelihood of protein/protein interactions, particularly if the 
affinity of sub-units for one another is weak. In order to investigate whether protein 
concentration might be a factor in the foimation of Trx-DrrA dimers (or higher order 
multimers), a series of ATPase assays were conducted using increasing concentrations of 
protein whilst maintaining a constant ATP concentration. Protein concentration in the 
ATPase assays was varied over a 50-fold range from 1 to 50 pM. This upper limit was 
largely determined by the ability to produce solutions of Ti'x-DrrA up to a maximum 
concentration of approximately 3mg/ml (before incurring protein precipitation and loss of 
activity). The EnzChek phosphate assay system, rather than malachite green Pi assay, was 
used to measure ATPase activity for a number of reasons. Firstly, the continuous assay 
retains linearity of response over a wider range of Pi concentrations (0-1 OOmnoles), and 
secondly, the rate of reaction could be inferred directly from the continuously monitored 
absorbance at 360mn with out the need to transform the data.
The results of these experiments are illustrated in figure 6.7. The plot of ATPase activity 
vs. Trx-DrrA concentration is essentially linear, once again suggesting that Trx-DrrA 
molecules hydrolyse ATP independently of one another, i.e. ATP hydrolysis by T i -x -D itA  
is a non-cooperative process. These results initially appear to be at odds with a significant 
amount of experimental data concerning the behaviour of both eukaiyotic and prokaiyotic 
ABC transporters. For example, the MalFGKi and H1SQMP2 transporters, from E. coli 
and S. typhimurium respectively, were both shown to display
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Figure 6. 6 Trx-DrrA hydrolyses ATP in a non-cooperative manner
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The Hill plot of Ti'x-DrrA ATPase activity shown above indicates that ATP hydrolysis 
occurs with a Hill coefficient of 1, i.e. it is a non-cooperative process. This data suggests 
that each Trx-DixA molecule binds and hydrolyses ATP independently of all others and 
that increasing concentrations of ATP do not drive the fonnation of Trx-DrrA dimers or 
multimers that behave differently from the monomeric species.
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Figure 6. 7 Dependence of ATPase activity on protein concentration
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The rate o f ATP hydrolysis by Trx-DrrA was shown to vary linearly with increasing 
protein concentration (top). Assays were performed using the EnzChek phosphate assay 
system in which the hydrolysis o f ATP (and hence the accumulation o f P j )  is monitored 
by a change in absorbance at 360nm (bottom). All assays were pre-incubated at room 
temperature with 1 mM ATP before the reaction was initiated by the addition o f 1 mM 
MgCb. The fact that the top plot does not pass through the origin suggests a small 
amount o f spontaneous ATP hydrolysis occurred over the 10 minute time-course o f the 
assay.
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positive cooperativity with regard to ATP hydrolysis when the activity of the intact 
transporter complex was measured (Davidson et aL, 1996; Liu et aL, 1997). Cooperative 
interaction between NBD’s has also been demonstrated for the human multidrug ABC 
transporter P-glycoprotein/MDRl (Qu and Sharom, 2001). However, in some cases, the 
behaviour of purified NBD’s assayed in dilute solution appears to vary from that 
displayed by the same proteins when they are present as part of an intact (four domain) 
ABC transporter complex. For example, neither the MalK nor HisP NBD’s show strong 
evidence of cooperative ATP hydrolysis when their activity is assayed in solution 
(Nikaido et aL, 1997; Morbach et aL, 1993). In response to this apparent contradiction 
Nikaido and colleagues proposed that removal of HisP from the ABC transporter 
complex may result in structural rearrangements that affect the enzymatic properties of 
the protein.
Only recently has direct evidence of ATP-driven dimérisation of isolated NBD’s been 
presented. Moody and colleagues used very high resolution gel filtration chi'omatography 
to demonstrate that the soluble M. jannaschii ATP-binding cassette, MJ0796, fonns 
stable dimers specifically in response to ATP-binding (Moody et aL, 2002). The 
formation of NBD dimers was shown to be highly dependent upon the ionic strength of 
the assay medium, a factor which suggests electrostatic interactions are important 
mediators of NBD-NBD association. The authors go on to propose a model of ABC 
transporter function in which ATP-driven association of NBD’s is a vital first stage in 
coupling the event of ATP binding to the stmctural changes in the transporter complex 
necessaiy for substrate transloeation. Upon ATP hydrolysis subtle electrostatic and 
structural effects result in dissociation of the dimer and the transporter returns to its initial 
state.
The biochemical behaviour of the Trx-DrrA fiision protein appears to mirror that of the 
isolated HisP and MalK NBD’s, rather than that of MJ0796. However, the data presented 
here does not preclude the possibility that the native mycobacterial Dn*A NBD behaves 
differently when it is part of a complete ABC transporter. Indeed, it illustrates rather well 
that subtle effects such as enzymatic cooperativity may be difficult to identify when the 
components of multi-protein complexes are treated in isolation. Whilst in some instances 
simple biochemical data may hint at the underlying mechanism of an enzymatic reaction, 
in others a more sophisticated analysis may be necessary. Increasingly, both biochemical
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and structurai data aie beginning to suggest that ABC transporter function is liighly 
dependent upon interactions between the various domains of the complex. As such, a 
complete understanding of their flinction may require researchers to adopt a ‘systems- 
approach’ to their analysis, rather than more traditional techniques.
6. 4 The Walker A structural motif in Trx-DrrA is vital for efficient ATP
hydrolysis
The presence of the Walker A and B nucleotide-binding motifs in the mycobacterial DrrA 
protein is one of the key indicators that the enzyme is an ATPase, and possibly the energy 
transducing sub-unit of a novel mycobacterial ABC transporter. Crystallographic studies 
have shown that the amino acid residues of the Walker A motif in particular mediate vital 
hydrogen bonding interactions between the NBD and associated nucleotide (e.g. see 
Hung et aL, 1998). Mutations to residues within this motif are usually veiy poorly 
tolerated and can lead to complete loss of catalytic activity of ABC transporter NBD 
proteins (e.g. Saveanu et aL, 2001). In order to ascertain whether the Walker A residues 
of M  tuberculosis DrrA are similarly vital in the obseiwed ATPase activity of protein, 
two different amino acid mutations were introduced into the motif by site directed 
mutagenesis (see chapter 2). The mutations introduced at key positions in the motif are 
illustrated below (most highly conserved residues are bold): -
Mutant 1 (G47S) 42- G P N G A S K T -49t
Native DrrA Walker A motif 42- G P N G A G K T -49
Mutant 2 (K48E) 42- G P N G A G E T -49
Each mutation introduced was designed to significantly alter the chemical nature of the 
amino acid present at a given location in the motif. In the first mutant the small, apolar, 
glycine residue at position 47 is changed to the larger hydroxyl-containing amino acid 
serine. The second mutation introduced changes the positively charged lysine residue at 
position 48 to a negatively charged glutamate.
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native Ti'x-DrrA fusion protein. The mutations appeared to have no significant effect on 
the expression levels, solubility or purity of the protein.
The biochemical effect of the Walker A mutations was assessed in terms of the ATPase 
activity displayed by the mutant proteins. Under conditions similar to those used for the 
initial characterisation of the native Trx-Dn A protein, i.e. ImM ATP, ImM MgCh, 1 M 
protein, no cation stimulated ATPase activity was detectable for either mutant using the 
malachite green P, release assay. However, when the ATP concentration in the assay was 
increased to 5mM, a limited degree of Mg^^ stimulated activity could be detected for both 
proteins. The results of these assays and an analysis of the data are presented in figure 
6 . 8 .
Similarly to the native protein, both the G47S and K48E mutants were shown to 
hydrolyse ATP in a linear maimer, ATPase activity being dependent upon the presence of 
Mg^^ ions. When the rate of ATP hydrolysis by each mutant protein was calculated in 
terms of a specific activity, significant differences emerged both between the mutants, 
and in comparison with native Trx-DrrA. The K48E mutant showed the lowest level of 
activity, 2.86 nmoles Pj/min/mg. This represents just 5% of the activity of the native Ti'x- 
DrrA protein assayed under the same conditions. The G47S mutant was a little more 
active, displaying a specific activity of 7.96 nmoles Pj/min/mg. Nonetheless, this activity 
still represented just 14% of that of the native protein. The very low activity of the two 
mutant proteins precluded a rigorous analysis of the kinetic properties of these enzymes 
e.g. detennination oiK„i and V,nax values. However, it is apparent from these empirical 
data that both the G47S and K48E mutations result in dramatically reduced enzymatic 
activity.
The experiments provided important confirmation that the ATPase activity of Trx-DrrA 
was at least 95% attributable to the mycobacterial DrrA moiety of the fusion protein. 
Furthermore, ATP-binding appears to be dependent on the same nucleotide/protein 
interactions as occur in other well-characterised ABC transporter NBD’s. The dramatic 
decreases in ATPase activity of the mutant proteins almost certainly reflect a reduced 
affinity for ATP caused by structural distortion or physico-chemical alteration of the 
nucleotide binding fold.
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Figure 6. 8 Mutations in the Walker A motif of Trx-DrrA result in reduced
ATPase activity
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* see section 6.1
The malachite green Pi release assay was used to calculate the ATPase activity of mutant 
Trx-DrrA proteins. Assays were performed at 37 °C in a total volume of SOOpl.
Each assay contained 1 pM mutant protein, 5mM ATP and was initiated by the addition of 
MgCl2 to a final concentration of ImM. 45 pi samples of the assay mixtures were 
withdrawn at the time-points indicated and mixed with 5 pi of 500mM EDTA to quench 
the reaction. Phosphate content of each sample was analysed by Abseionm after mixing 
with 1 OOpl of malachite green detection reagent. Reaction rates measured in teims of 
ÔAbSôio (see figure) were converted to specific activities using a Pi standard curve.
Neither protein exhibited activity in the absence of Mg^ "^  (data not shown).
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6, 5 Neither Doxorubicin nor Daunorubiein activate the rate of
ATP hydrolysis by the Trx-DrrA fusion protein
A number of ABC transporters exhibit significantly enhanced ATPase activities when 
exposed to their transport substrates, e.g. mammalian P-glycoproteins, and the ArsAB 
arsenite/antimonite efflux transporter of E. coli (Scarborough, 1995; Kaui', P., 1999). 
However, as with so many other featui'es of ABC transporter research, this propeify is by 
no means universal and the mechanism by which it occur s is a matter of some 
controversy. For example the ArsA ATPase was shown by X-ray crystallography to 
possess three metalloid binding sites, occupancy of which can be correlated with 
increases in the rate of ATP binding and hydr olysis by tlris protein (Zhou et aL, 2000).
On the other hand, only scant evidence exists to suggest that the NBD s of P- 
glycoproteiris possess similar substrate binding sites. To add further complexity to the 
picture, neither free histidine nor the liganded soluble receptor HisJ, affect the ATPase 
activity of purified HisP, whilst spermidine, the substrate of the PotA ABC transporter, 
actively inhibits the ATPase activity of this NBD (Nikaido et al,, 1997; Kashiwagi et aL, 
2002). Despite this apparent complexity of regulation, which may involve the presence of 
substrate binding sites in either the NBD or MSD components of a transporter, it was 
decided to analyse whether or not the ATPase activity of the Trx-DrrA fusion protein was 
affected by the presence of the potential transport substrates doxorubicin and 
daunorubiein. An obvious stimulatory effect caused by the presence of these antibiotic 
molecules might be interpreted as an indication that the DrrABC transporter is indeed an 
antibiotic efflux system, and that M  tuberculosis retains some of the antibiotic transport 
capabilities widely distributed amongst other members of the actinomycetaeles.
ATPase assays were performed using the EnzChek phosphate assay system. 40pM Trx- 
DrrA was pre-incubated in the presence of ImM ATP and doxombicin or daunorubiein at 
varying concentrations between 0 and lOOpM. Afrer a five minute incubation period 
ATPase activity was initiated by the addition of ImM MgCl]. ATPase activity was 
monitored spectroscopically by a change in absorbance of the assay mixture at 360nm 
over a period of five minutes.
Figure 6.9 shows the results of two such ATPase assays, one conducted in the absence of 
antibiotic (blue line), and the second in the presence of lOOpM daunorubiein (gieen line).
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Figure 6. 9 The ATPase activity of Trx-DrrA is unaffected by 
anthracycline antibiotics
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The ATPase activity o f Trx-DrrA monitored in the presence and absence o f the 
potential transport substrate daunorubiein (Dnr). ATPase assays were performed at 
room temperature using 40pM Trx-DrrA (approx. 2mg/ml) and ImM ATP. Assays 
were prepared in a total volume o f  1ml according to the manufacturers instructions (see 
chapter 2). Dnr was added to the assay by microdilution o f a concentrated stock solution 
prepared in DMSO. After a five minute pre-incubation period ATP hydrolysis was 
initiated by the addition o f MgClz to a final concentration o f ImM. The rate o f  ATP 
hydrolysis was monitored by the increase in absorbance o f the assay mixture at 360nm.
The gradients o f the two activity curves above were used as a direct measure o f  ATPase 
activity. In the first assay, conducted in the absence o f daunorubiein, the ATPase 
activity corresponded to a ÔAbsg o^ o f 0.0182 units/minute (blue line). The second assay, 
conducted in the presence o f lOOpM daunorubiein, showed a ÔAbssôo o f 0.0192 
units/minute (green line). The difference between these two figures represents that a less 
than 5% increase in ATPase activity occurring in response to the presence o f the 
antibiotic. This very small figure suggests that anthracycline antibiotics have little or no 
effect on the ATPase activity o f Trx-DrrA.
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Clearly, the presence of the antibiotic has no significant effect on the rate of ATP 
hydrolysis by Trx-DrrA, even at this highest concentration tested. One possible 
interpretation of these results is that the Trx-DrrA fusion protem does not possess a 
binding site(s) for doxorubicin/daunorubiein. Alternatively the results may simply 
suggest that any interaction between the NBD and the anthracycline antibiotics has no 
stimulatory effect on the rate of ATP binding or hydrolysis. However, two interesting 
counterpoints to these data are have been presented in the literature. In her initial studies 
on the S. peucetius DrrAB antibiotic efflux system Kaur was able to demonstrate that 
35pM doxorubicin significantly enhanced the binding of radiolabelled ATP to DrrA 
(Kaur, P., 1997). In this experimental system radiolabelling was perfonned using whole 
cell membranes from a recombinant E. coli strain expressing both the DrrA and B 
proteins, rather than using the purified NBD. Kaur suggests that the data can be 
interpreted in two alternative ways. The first, simplest, interpretation is that the NBD 
protein DrrA is an allosteric enzyme with binding sites for doxorubicin that, when 
occupied, directly enhance ATP binding. The second interpretation proposes that 
binding of doxorubicin to the MSD component of the transporter, DrrB, enhances ATP 
binding to DrrA through conformational changes transmitted from one domain to the 
other.
A second, and perhaps more significant contradiction to the ATPase activity data 
presented here was published by Choudhuri and colleagues in 2002. This group, also 
working on the M  tuberculosis Drr proteins, developed an artificial operon for 
simultaneous recombinant expression of both DrrA and DrrB in E.coli (Choudhuri et 
ah, 2002). Much of the research published by this group is discussed in the next chapter 
which considers the possible physiological roles of the M  tuberculosis DrrABC system. 
However, in a series of experiments essentially similar to those performed by Kaur, this 
gi’oup were able to demonstrate that ATP binding to DrrA was again enhanced by both 
doxorubicin and daunorubiein (40pM) when binding activity was measured in whole 
cell membranes. Choudhuri uses these, and other data presented in the same work, to 
argue that the mycobacterial DrrA and B proteins together constitute a functional 
daunorubicin/doxorubicin efflux transporter. It should be noted however that they chose 
to express only two of the three genes present in the transcriptionally linked M 
tuberculosis JrrABC operon.
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Nonetheless, both the experiments of Kaur and Choudhuri hirther suggest the potential 
importance of inter-domain interactions between the various components of prokaiyotic 
ABC transporters. The fact that the ATPase activity of the soluble Trx-DrrA fusion 
protein is independent of daunorubicin concentration would seem to suggest that any 
enhancement of ATP-binding must be the product of antibiotic binding to a component of 
the transporter other than DrrA.
6. 6 Trx-DrrA displays a marked preference for purine nucleotides
The ability to bind substrates other than Mg^’^ ATP has been demonstrated for a number of 
ABC transporter NBD’s (e.g. see Buche et al,, 1997). Whilst this ability is unlikely to be 
of physiological significance, it is indicative of a degree of conformational flexibility 
within the NED core. In order to ascertain whether Trx-DrrA possesses a similar degree 
of confomiational flexibility the malachite green P; release assay was used to test 
alternative nucleotide-triphosphates as potential substrates. GTP, CTP and TTP were all 
tested at ImM concentrations and their rate of hydrolysis compared with that of ATP (see 
figure 6.10).
The results indicated that Trx-DrrA was capable of hydrolysing the purine nucleotide 
GTP, whilst displaying virtually no activity towards the pyrimidine substrates CTP and 
TTP. The rate of hydrolysis of GTP was approximately 40% of that observed for the 
same concentration of ATP, suggestive of a lower affinity for this substrate. A similar 
ability to bind GTP was demonstrated for the S. peiicetiiis DrrA protein (Kaur, P. 1997). 
The only other mycobacterial NBD protein for which similar data is available is PstB, the 
NBD subunit of the phosphate specific uptake transporter (Sarin et at., 2001). This 
protein was able to hydrolyse not only ATP and GTP, but also the pyrimidine CTP. In 
fact the affinity of this protein for CTP was higher than that for GTP (K,„[CTP] = 130pM, 
K,„[GTP] = 21 IpM). Generally speaking there is very little consistency in the literature 
regarding the ability of different ABC transporter NBD’s to bind and hydrolyse 
alternative NTP’s. Differences appear to be case specific although GTP is by far the most 
common alternative substrate. Whilst the F i-type ATP-binding core of all NBD proteins 
is thought to adopt a highly conserved structure, it is possible that minor differences in 
the amino acid residues in and around the ATP-binding fold affect the ability of different 
NBD’s to utilise alternative substrates.
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Figure 6. 10 Hydrolysis of alternative NTP substrates by Trx-DrrA
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ATP 42.08 100
GTP 16.66 39.6
CTP 0.29 0.7
TTP 0.35 0.8
* nmoles Pi/min/mg Trx-DrrA
NTPase assays were performed at 37 °C in a total volume o f 800pl using IpM Trx-DrrA 
and ImM NTP. Reactions were initiated by the addition o f ImM MgCh. 45pl samples 
were withdrawn from each reaction at 1 minute intervals over a 10 minute period and 
analysed for P| content as described in chapter 2 and elsewhere in this chapter. Specific 
activities with regard to each substrate were calculated and normalised by comparison to 
ATP. Whilst ATP is clearly the preferred substrate, Trx-DrrA is also able to bind and 
hydrolyse the structurally similar molecule GTP. The fact that neither CTP nor TTP are 
effective substrates indicates there is only a limited degree o f conformational flexibility 
in the ATP-binding core o f the mycobacterial DrrA protein.
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Confonnational flexibility of secondaiy structural elements in the region of the ATP- 
binding fold may also have a significant effect. These experiments suggest that the Trx- 
DrrA NBD has only a limited ability to bind and utilise alternative substrates.
6. 7 Both and Co^^ions will support ATP hydrolysis by Trx-DrrA
The data presented in section 6.1 demonstrated that the catalytic activity of Trx-DrrA was 
entirely dependent upon the presence of Mg^^ ions. In order to ascertain whether 
alternative divalent cations might substitute for Mg^'^in the reaction mechanism of Trx- 
DrrA a series of ATPase assays were perfonned in the presence of different salts. The 
same series of experiments were also used to detennine the rate dependency of the 
ATPase reaction upon the concentration of the various ions tested. The dichloride salts of 
manganese, cobalt, zinc and calcium were all tested for their ability to support ATP 
hydrolysis. The concentration of each salt was varied over a range from lOOpM to 3mM 
and rate data presented as percentage of the maximum rate of ATPase activity supported 
by Mg '^  ^(see figure 6.11). All ATPase assays were conducted at 37 °C using the 
malachite green Pi release assay and constant concentrations of Ti'x-DrrA and ATP of 
IpM and ImM respectively.
The data shown in figure 6.11 clearly indicate that Mg^^ ions support the highest level of 
ATPase activity across all concentrations tested. The optimal concentration for Mg^ "^  ions 
appears to lie in a broad range between 0.5mM and 2mM. Only at the highest 
concentrations tested do Mg^ "^  become inhibitory to the ATPase activity of Trx-DrrA. On 
the basis of this data ImM MgCb was used in all further ATPase assays. The next best 
stimulator of ATPase activity was cobalt dichloride. Co^  ^ions produced 53% maximal 
ATPase activity at a concentration of 0.5mM with stimulatoiy activity dropping-off 
shaiply above this concentration. Manganese ions were also able to support ATP 
hydrolysis hy Trx-DrrA, a maximal stimulation of 42% occurring at a concentration of 
ImM. Neither Zn^  ^nor Ca^ "^  ions were able to support ATPase activity.
The physical and mechanistic implications of the fact that a range of divalent cations can 
support ATP hydrolysis by ABC transporter NBD’s are unclear. Structural and 
biochemical data suggest that the divalent cation is liganded by the highly conserved 
aspartate residue of the Walker B motif (e.g. see Hung et al., 1998). The presence of a 
divalent cation at this site is clearly central to the catalytic mechanism of ABC
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Figure 6. 11 Cation dependency of ATP hydrolysis by Trx-DrrA
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The divalent cations Mg^*, Mn^ % Co^\ Ca^* and were all tested for their ability to 
Stimulate the ATPase activity o f Trx-DrrA. All assays were performed at 37 °C in a total 
volume o f  SOOpl. The ATP concentration in each assay was constant at ImM and Trx- 
DrrA concentration was maintained at IpM. ATPase activity was initiated by the addition 
o f dichloride metal salts at the concentrations indicated. The malachite green Pj release 
assay was used to calculate the rate o f ATP hydrolysis in each experiment and all data is 
presented as a percentage o f the maximal rate o f ATP hydrolysis observed.
Mg^  ^ions were the most effective stimulators o f ATP hydrolysis (100% at ImM), whilst 
both Mn^  ^and Co^  ^produced a moderate stimulatory effect at concentrations between 
0.5 and 1 mM. Neither Zn^  ^nor Ca^  ^produced any stimulatory effect at any o f the 
concentrations tested (data for Zn^  ^not shown as it overlaps with that o f Ca^ )^.
192
transporters since mutations to the Walker B aspartate are poorly tolerated and 
frequently lead to complete loss of ATPase activity. The behaviour of Trx-DixA with 
respect to the different cations tested is broadly similar to that observed for model NBD 
proteins such as HisP. Optimal concentrations of cation lie in the range l-2mM with 
Mn^ "^  and Co^  ^ions all supporting ATP hydrolysis to a greater or lesser extent 
(Nikaido et aL, 1997). It should perhaps be noted that the mycobacterial PstB NBD 
exhibits some highly unusual properties with regard to its use of cations. Mg^ "^  ions over 
a range of concentration lOpM to lOOmM were reported to have absolutely no effect on 
ATPase activity of the enzyme. ATPase activity could even be detected in the complete 
absence of Mg^^ ions. Even more strangely Mn^ "^  ions appeared to actively inhibit the 
ATPase activity of the enzyme. At the same time, mutation of residue Aspl 18, the 
Walker B aspartic acid, to lysine, dramatically decreased the observed ATPase activity 
(Sarin et ah, 2001). These two groups of data are very difficult to reconcile with one 
another and with what is known about the activity of ABC transporter NBD’s in 
general. The highly unusual behaviour of this mycobacterial protein awaits clarification.
6. 8 Intrinsic tryptophan fluorescence studies of Trx-DrrA
Tiyptophan fluorescence spectroscopy has proven to be a powerful tool for investigating 
the properties of both ABC transporter NBD’s and complete transporter complexes (see 
Borges-Walmsley et aL, 2003). The technique relies upon the observation that the 
fluorescence properties of individual tryptophan residues within a protein are uniquely 
responsive to even small changes in their microenvironment. Consequently, 
conformational changes in a protein, induced by events such as ligand binding, can 
fi*equently be correlated with a change in the measured tryptophan fluorescence.
Collected under steady-state conditions, protein fluorescence data can be used to 
calculate important biochemical parameters such as the equilibrium dissociation constant 
of a particular protein-substrate interaction. The rate o f change of tryptophan 
fluorescence linked to a particular event can also be used to determine similarly important 
reaction parameters. Walmsley and colleagues have successfully used a combination of 
these techniques to develop a detailed kinetic mechanism describing the activity of the of 
the E. coli ArsA ATPase. Confonnational changes associated with ATP binding, 
metalloid binding, ATP hydrolysis and product release were all detected thi‘ough changes 
in the tryptophan fluorescence of the protein (Walmsley et aL, 2001).
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In order to ascertain whether similar conformational changes might be detected during 
the ATP binding and hydrolysis cycle of Trx-DrrA, steady-state tryptophan emission 
spectra were collected for the protein both in the presence and absence of nucleotide. The 
resulting spectra are shown in figure 6.12.
In the absence of nucleotides Trx-DrrA exhibits an emission maximum of 109 Units at a 
wavelength of 334nm. The addition of ImM ATP to the protein resulted in a large 
quench in the measured fluorescence (64% decrease), and the subsequent addition of 
ImM MgCli to the mixture caused a further quench of 4%. Neither addition had any 
effect on the value which remained constant at 334nm. These data initially suggested 
that one or more of the four Trp residues in Trx-DrrA was reporting a nucleotide induced 
conformational change in protein structure. However, the adenine ring of ATP is known 
to interfere with fluorescence measurements by absorbing photons, thereby reducing the 
intensity of both the excitation beam and of the observed emission spectrum. This 
phenomenon, known as an inner filter effect, is clearly an important consideration when 
measuring the steady-state fluorescence of ATP-binding proteins. After a series of careful 
controls in which the magnitude of the inner filter effect was calculated for different 
concentrations of ATP, it was determined that the observed 64% decrease in Trx-DrrA 
fluorescence was entirely attributable to an inner filter effect. Given the magnitude of the 
imier filter effect it was considered that any small changes in the tryptophan fluorescence 
of Trx-DrrA, occurring as a result of specific interactions with ATP, were unlikely to be 
detected by this technique.
6. 9 Construction of single tryptophan Trx-DrrA mutants
In order to enhance the detectability of any fluorescent signal associated with ATP 
binding to Trx-DrrA a site-directed mutagenesis approach was adopted. Firstly, it was 
known that Trx-DrrA contained a total of four Trp residues, Trp30 and Trp33 in the 
thioredoxin moiety of the fusion protein, and Trpl 10 and Trp 180 in the DrrA protein. It 
was considered that neither of the tryptophan residues in the thioredoxin moiety was 
likely to be involved in the binding and hydrolysis of ATP by the fusion protein. As such, 
whilst these two residues were undoubtedly contributing to the overall fluorescence of the 
protein, their lack of response in any binding assay would merely produce a background 
fluorescence that would lower the overall signal-to-noise ratio. As a result of these 
considerations it was decided that both Trp30 and Trp33 could be
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Figure 6. 12 Tryptophan fluorescence émission spectra of Trx-DrrA
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0 •—  295 350 400
Wavelength[nm]
The fluorescence emission spectrum o f 2.5pM Trx-DrrA measured at room temperature 
in a buffer o f 50mM MOPS, lOOmM NaCi, pH 7.4. Tryptophan fluorescence was excited 
at a wavelength o f 285nm and emission data measured between 295 and 400nm. Data 
were collected on a Jasco FP-750 spectrofluorimeter with emission and excitation 
bandwidths set at 5nm. The response o f the detection photomultiplier tube was set to 
medium.
1) 2.5)iM Trx-DrrA
2) 2 .5nM Trx-DrrA + ImM ATP
3) 2.5^iM Trx-DrrA + ImM ATP 
+ I mM MgCh
^ax = 334 nm 
Xmax = 334 nm 
Xmax = 334 nm
Peak height = 109 Units 
Peak height = 39.1 Units 
Peak height = 33.9 Units
195
safely mutated to alternative residues without affecting any possible ATP binding signal. 
This was achieved by using oligonucleotide directed mutagenesis; the single primer 
‘Trx2W’ being used to simultaneously mutate tryptophan residues 30 and 33 to glycine 
residues (see chapter 2). A comparison of the primary sequence of DrrA with those of 
structurally defined NBD’s was used to determine the likely location of tiyptophans 110 
and 180. Tipl 10 is in a region of the protein between Walker A and the ABC transporter 
signature-sequence motif. In structurally characterised NBD’s this region is generally 
poorly conserved and contributes to the transitional region between the F rtype ATP- 
binding core of the protein and the ABC transporter-specific a-helical domain. 
TiyptophanlSO on the other hand lies slightly downstream of the Walker B sequence, a 
region of the protein believed to be involved in cation coordination. Using the published 
structures of HisP and the MJ0796 NBD’s as a guide, Tip 180 is likely to be at some 
distance from the ATP binding site in another weakly conseiwed region of the NBD. 
Given the likely presence of the two DrrA Tip residues in catalytically inactive regions of 
the protein, the decision was made to mutate these residues to non-fluorescent glycines 
(using oligonucleotides W1 lOG and W180G, see chapter 2). The combined result of 
these mutational experiments was the construction of a tryptophan-free Trx-DrrA 
molecule in which all four tryptophan residues were replaced by glycines (see figure 
6.13). DNA sequencing of the pTrx-DrrA expression plasmid was used to confiim the 
successful introduction of all four mutations.
The tiyptophan-free Trx-DrrA molecule was used as a low fluorescence backgiound into 
which two alternative mutations were inti’oduced. Each mutant protein was designed to 
have a fluorescently reactive Tip residue in a structurally and/or mechanistically active 
region of the protein. The structures of HisP and MalK both contain aromatic residues at 
positions close to the N-teiminal of the NBD. These residues, Y16 in HisP and W13 in 
MalK, are thought to contribute to an important aromatic-stacking interaction between 
the protein and the adenine ring of a bound ATP molecule, thereby stabilising ATP 
binding (Hung et a l, 1998; Walter et a l, 1992). The equivalent of this residue in M. 
tuberculosis DrrA is tyrosinel7. It was hoped that mutating this residue to tryptophan 
would result in the generation of a Ti’x-DrrA molecule that was spectroscopically active 
in response to ATP binding. Indeed, working with MalK, Schneider and colleagues were 
able to demonstrate a 37% decrease in protein fluorescence in response to the addition of 
ATP, possibly a direct result of the stacking interaction between W13 and ATP
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(Schneider et aL, 1994). A second single-tiyptophan Trx-DrrA mutant was also produced. 
The so-called ABC signature-sequence motif is one of the most highly conseiwed regions 
of all ABC transporter NBD’s. It generally conforms to the consensus ‘LSGGQ’ and is 
found in the ABC transporter-specific a-helical sub-domain of the NBD. A number of 
ciystallographic NBD dimers suggest this motif is part of a composite ATP binding site 
formed by juxtaposition of one NBD’s Walker A motif with the signature-sequence motif 
of a second molecule. In M. tuberculosis DrrA the signature-sequence motif is 
degenerated to the sequence ‘YSGGM’. Mutation of the motifs initial tyrosine residue 
(Y141) to a potentially fluorescently active tryptophan residue is particularly attractive 
because this region of the protein may well be intimately involved in both dimérisation of 
the NBD and the mechanism of ATP hydrolysis.
The two single-tryptophan Trx-Dn A mutants Y141W and Y17W were produced by 
oligonucleotide directed mutagenesis of a plasmid encoding the tiyptophan free molecule 
(see chapter 2). Both molecules were overexpressed in similar quantities to the wild-type 
protein and demonstrated essentially identical ATPase activity (data not shown). The 
positions of all relevant mutations are shown in figure 6.13.
6 .10  Stopped-flow fluorescence spectroscopy of ATP binding to single­
tryptophan mutant Trx-DrrA proteins
Stopped-flow fluorescence spectroscopy allows the very rapid detection of changes in 
protein fluorescence in response to ligand binding. Unlike measurement of changes under 
steady-state conditions, the use of the stopped-flow system negates inner filter effects 
because any reduction in signal due to the presence of ATP occurs prior to the onset of 
data collection. A second advantage of the system is that even veiy small and rapid 
changes in fluorescence that may be missed under steady-state conditions can be detected 
and time-resolved to reveal mechanistic details of the interaction (e.g. see Walmsley et 
aL, 2001).
Fluorescent signals produced by mixing the two mutant proteins with ImM ATP and 
ImM MgCh in the stopped flow instrument are shown in figures 6.14. All data were 
collected at 22 °C in an Applied Photophysics stopped-flow device (see chapter 2).
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Figure 6. 13 Positions of Trx-DrrA tryptophan mutations
W30G W33GI I
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EIAD E Y Q G K L T V A K L N ID HNPGTAPKY G I R G I P T L L LFKNGEVAA
TKVGALSKG QLKEFLDAN LA G SG SG D D DDKLALHMR NDDMAVVVN
▼
GVRKTYGKG K IV A L D D V S F K V R RG E V I GLLGPNGAG K T T M V D IL S
T L T R P D A G S A I I A G Y D V V S E P A G V R R S IMVTGQQVA VD DALSG EQ
NLVLFGRLW G L SK SA AR K R A A E L L E Q F SLVHAGKRR VGTYSGGMR
R R I D I A C G L VVQPQVAFL D E P T T G L D P
t
RSRQAIW DL V A S F K K L G I
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M LVEAARRI D E A R IE L A D lA L R R P S L D HVFLAMTTD P T E S L T H L V
SGSARKLKG E L E G K P I P N P L L G L D S T R TGHHHHHH
-W180G
Positions o f mutations introduced into pTrx-DrrA by oligonucleotide directed 
mutagenesis (section 6.9 and chapter 2). Mutated residues shown in bold.
Red text = Vector encoded sequence
Turquoise text = DrrA Walker A motif
Green text = DrrA ABC transporter signature-sequence
Blue text = DrrA Walker B motif
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Light at 285mn was selected for specific excitation of tiyptophan fluorescence using two 
serially connected monochromators. Changes in protein fluorescence above 320 nm were 
measured using a 320nm cut-off filter covering the window of the detection 
photomultiplier tube. All changes in fluorescence were measured relative to an initial 4 
Volt signal to allow percentage changes in protein fluorescence to be calculated.
As the data in figure 6.14 show, the ATP binding signal for both proteins was extremely 
low, a change of much less than 0.1% of the total protein fluorescence in both cases. 
Whilst minor differences in quality and size of signal can be seen for the two proteins, 
notably on the time-scales over which they occur, little useful infoiination can be derived 
from such data. The major problem encountered during data collection was a consistently 
low signal-to-noise ratio. Neither the magnitude nor rate of changes in tryptophan 
fluorescence could be shown to vary systematically with changes in the concentration of 
ligand (ATP). As such, the small decreases in protein fluorescence observed proved 
impossible to unambiguously assign as being the direct result of protein binding to ATP.
In an attempt to circumvent the problems of the low signal-to-noise ratio observed in the 
tryptophan fluorescence experiments an alternative approach was adopted. M ANT -ATP 
is a fluorescent analogue of ATP whose fluorescence above 420mn increases in direct 
response to being bound to proteins. Using the serial monochromators MANT-ATP 
fluorescence was specifically excited at 255mn in the stopped-flow mixing chamber. 
Emission data were collected above 420nm using an appropriate cut-off filter. However, 
as the data in figure 6.15 shows, very little signal was observed upon mixing lOOpM 
MANT-ATP with Trx-DnA (lOpM) in the stopped-flow device. A similar lack of signal 
was observed when the same mixing experiments were performed in a standard 
spectrofluorimeter under steady-state conditions (data not shown).
The failure of the stopped-flow experiments to generate usable data is difficult to 
reconcile with the known ATP-binding properties of Trx-DirA (as demonstrated by its 
ATPase activity). Possible explanations for these observations are put forward in section 
6 . 11.
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Figure 6.14 Changes in protein fluorescence of Trx-DrrA(Y17W) and Trx- 
DrrA(Y141W) associated with ATP binding
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Figure 6.15 Changes in MANT-ATP fluorescence upon mixing with Trx- 
DrrA
Plot: <data>
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-0.03 -
-0.035
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Stopped-flow fluorescence trace generated by mixing lOpM Trx-DrrA (wild type) with 
lOOpM MANT-ATP + ImM MgCli (mixing chamber concentrations). MANT-ATP 
fluorescence was excited at 255nm and emission data collected above 420nm (Imax 
MANT-ATP = 448nm). All reagents were prepared at twice the mixing chamber 
concentration in a buffer o f 50mM MOPS (pH 7.4), lOOmM NaCl.
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6.11 Discussion
Many of the data presented in this chapter support a working hypothesis in which the M 
tuberculosis DrrA protein comprises the ATP-binding sub-rmit of an ABC transporter. 
Expressed as a soluble fusion protein in the absence of its cognate MSD’s DrrB and 
DrrC, DrrA was shown to retain a number of biochemical char acteristics typical of ABC 
transporter NBD proteins.
Firstly, Trx-DrrA displayed a measurable catalytic activity consistent with a role in 
energising transmembrane transport. The protein was shown to be a cation dependent 
ATPase capable of binding and hydrolysing ATP in a similar manner to the NBD 
proteins of well-characterised prokaryotic ABC transporters. Whilst Choudhur i and 
colleagues have previously shown the native DrrA protein is able to bind ATP 
(Choudhuri et aL, 2002), the data presented here are the first to show functional ATP 
hydrolysis. The calculated V,„ax of ATP hydrolysis by Trx-DrrA was somewhat lower 
than that described for other prokaryotic NBD proteins. However, the affinity of the 
protein for ATP, as measured by the K,n value, lies in a very similar range to those same 
NBD’s (see table 6.16 below).
Table 6. 16
Protein Reference
Tix-DrrA 84.8 52 This Study
HisP {S. typhimurium) 205 500 Nikaido et aL, 1997
PstB (M tuberculosis) 71.5 122 Saiin et aL, 2001
MalK {E. coli) 23.9 322 Morbach er o/., 1993
* nmoles Pj/min/mg
On the basis of the kinetic analyses performed we were not able to find any direct 
evidence of cooperativity with regard to ABC hydrolysis, Trx-DrrA appearing to behave 
as a typical Michaelis-Menten type eirzyme. Wliilst such cooperativity has been 
demonstrated for a few isolated NBD proteins, e.g. Mdllp from S. cervevisiae (Janas et 
aL, 2003), it is by no means a universal property of all NBD’s assayed. For example, 
neither the MalK nor HisP proteins display cooperative ATP hydrolysis when assayed in
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isolation, yet appear to behave cooperatively when part of an intact transporter complex 
(Nikaido et aL, 1997). This raises the important point that NBD behaviour assayed in 
isolation may not necessarily be a true reflection of their behaviour when forming part of 
a complete ABC transporter complex. A great deal of data now suggest that ATP 
hydrolysis is performed by NBD dimers which adopt a similar structure to the Rad50cd 
dimer ciystallised by Hopfner and colleagues (Hopfner et aL, 2000 ). Excellent evidence 
in support of such a model was provided by Janas et al. in their examination of the Mdllp 
NBD. They successflilly demonstrated the existence of stable NBD dimers trapped at 
various stages in the ATP hydrolysis cycle (Janas et aL, 2003). The fonnation of such 
dimers, in which a composite ATP-binding site is fonned by juxtaposition of the Walker 
A region of one NBD with the ‘LSGGQ’ motif of a second NBD, is further supported by 
the work of Davidson and Fetsch. This group used photocleavage experiments to 
demonstrate the proximity of these two stmctural motifs during ATP hydrolysis by MalK 
(Fetsch and Davidson, 2002). The relatively low ATPase activity of Trx-DrrA, and the 
absence of cooperativity, may be perhaps explained in terms of a reduced ability of the 
protein to form ATPase competent dimers. The presence of the thioredoxin moiety near 
to the N-tenninal of Dn*A, where the Walker A sequence is located, is potentially a steric 
hindrance to the formation of dimers. The reduced ATPase activity of the Trx-DrrA 
Walker mutants G47S and K48E clearly demonstrates the importance of this particular 
region of the protein to the overall ATPase mechanism. An alternative explanation for the 
low activity and absence of cooperativity is that DrrA monomers have a very weak 
affinity for one another. Under such circumstances dimer fonnation may require very 
high localised concentrations of the NBD monomers, these conditions only being 
satisfied in the complete transporter complex.
The failure to demonstrate antibiotic stimulated ATPase activity for Trx-DrrA provides 
another example of the potential benefits of working with complete ABC transporter 
complexes. Choudhuri and colleagues successfully demonstrated enhanced ATP binding 
to native M. tuberculosis DrrA in the presence of doxorubicin, one of the potential 
antibiotic substrates of the transporter. This work was however performed using 
membrane vesicles containing both DitA and one of the putative MSD components of the 
transporter, DixB. Combination of that data with the absence of substrate stimulated 
ATPase activity presented here suggests that any transporter-substrate interactions take 
place via the MSD. Under such circumstances enliancement of ATP binding must
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presumably be achieved via conformational changes transmitted from one domain to the 
other.
I
:
Fluorescence spectroscopy has proven to be a powerful tool in the characterisation of 
ABC transporter behaviour. The combined use of intrinsic protein fluorescence and 
external fluorescent probes has allowed researchers to gather important data regarding 
reaction mechanisms, substrate binding, transport rates and the inter-domain interactions 
of ABC transporters (e.g. see Borges-Walmsley et aL, 2003). Unfortunately, the Trx- 
DrrA fusion protein proved remarkably resistant to investigation using these techniques.
The miyor problem encountered in both the steady state and transient binding studies I
using Trx-DrrA was that the protein exhibited a veiy low signal-to-noise ratio during the 
investigations. Despite adopting a rational approach to the construction of single­
tryptophan mutant proteins, this problem was never sufficiently overcome to allow the 
generation of useful data.
A number of scenarios can be put forward to explain the failure of these experiments.
Firstly, it remains possible that no significant structural rearrangements take place during 
the ATP-binding and hydrolysis cycle of DrrA. This however seems unlikely given the 
functional role of ABC transporter NBD’s, i.e. the transduction of energy fiom ATP 
hydrolysis into the gross conformational changes of the transporter required to drive 
transmembrane transport. Additionally, differences in the crystal structures of ATP and 
ADP bound forms of NBD proteins suggest the existence of specific nucleotide-induced 
structural alterations (Yuan et aL, 2001). Moreover, structural changes induced in the S. 
typhimurium MalK protein upon ATP binding have been coirelated with a change in 
proteolytic cleavage pattern, once again suggestive of significant conformational 
rearrangements (Schneider et aL, 1994). A second, more plausible, explanation for the 
lack of a strong signal upon ATP binding to Trx-DirA relates to the presence of the 
thioredoxin moiety and the low ATPase activity of the protein. If NBD dimers are indeed 
the functional fonn giving rise to ATPase activity, it may be that only a small proportion 
of molecules in a given situation are able dimerise due to the steric effects of the 
thioredoxin moiety. Under such circumstances most molecules would not contribute to 
the observed ATPase activity (or give rise to a fluorescent signal). Any observed binding 
signal or activity may be attributable to a much smaller number of active ATPase dimers.
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This interpretation is supported by the absence of a strong signal for the binding of the 
external fluorescence probe MANT-ATP to Trx-DrrA (see section 6.10).
On the whole it seems likely that the M  tuberculosis DitA protein is indeed the NBD of 
an ABC transporter, both sequence data and biochemical data supporting this 
interpretation. However, a more complete understanding of its catalytic behaviour will 
probably require the overexpression and purification of a native fonn of the protein 
lacking an N-tenninal fusion partner. To this end, the publication by Choudhuri and 
colleagues of a system for producing native DrrA in E. coli is of particular interest, 
especially given that the same system may potentially be adapted to co-express the 
MSD’s of the transporter.
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Chapter 7
Investigating the physiological function of the M, tuberculosis DrrABC system
Previous chapters have described attempts to over-express and purify the M. tuberculosis 
DrrABC proteins as individual entities. However, the fact that all three genes of the drr 
system are present in a single, transcriptionally-linked operon suggests that the 
physiological roles of the D it proteins are closely tied to one another at a functional level 
as well as a genetic one. Biochemical evidence presented in the previous chapters, such 
as the membrane localisation of DrrB and the catalytic activity of DrrA, support a model 
of DrrABC function in which DrrA constitutes the energy transducing sub-unit of an 
ABC transporter (the NBD), whilst DrrB contributes to a transmembrane translocation 
pathway. Expression of the third gene, drrC, could not be unambiguously demonstrated 
in E. coli, however its presence in the same operon strongly suggests that it too is part of 
the same transporter complex. The hydrophobic nature of the D itC protein, and its 
homology to DnB (see chapter 3), is an indication that this protein may well be a second 
transmembrane component of the transporter. Given the fact that all ABC transporters 
characterised to date have a minimum of four functional domains, the M. tuberculosis 
DrrABC system seems most likely to operate as ‘ A2 BC’ complex similar to the MalK2FG 
and His?2MQ transporters of E, coli and S. typhimurium respectively.
The experiments described in this chapter were aimed at establishing simultaneous co- 
expression of all three M  tubercidosis drr genes in the heterologous host E.coU. In an 
attempt to identify possible physiological roles of the DnABC transporter, use was made 
of mutant E. coli strains defective in certain transmembrane transport capabilities. 
Throughout this work a number of experimental difficulties were encountered, primarily 
relating to the large evolutionary distance between E. coli and M. tuberculosis. Much of 
the work in this chapter was perfonned before the publication of an ‘artificial operon’ 
system designed for co-expression of the DrrA and B proteins (Choudhuri et al., 2002). A 
number of interesting parallels can be drawn between the work presented here and the 
results of Choudhuri and colleagues. These comparisons also demonstrate how 
differences in experimental systems used to measure ABC transporter activity can have a 
significant bearing on the results obtained.
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7 .1  Heterologous co-expression of DrrA, B and C in E. coli using the pET-
based expression construct pDrrABC
Initial attempts to achieve co-expression of the Drr proteins were performed using the 
pDrrABC expression construct described in chapter 3. This plasmid, based upon the pET- 
33 vector, contained the entire 2.7Kb M. tuberculosis drrP^C  operon cloned between the 
Ndel and Hindlll restrictions sites of the vector MCS. Whereas expression of the 
individual Dn* proteins had used pET-21 based plasmids which encode a single C- 
terminal His-Tag, pET-33 allowed for tagging of two of thi'ee genes present in the 
Dir ABC operon. DrrA, the first gene of the operon, was fused to a vector-encoded N- 
terminal His-Tag sequence, whilst DrrC, the final gene, was fused to a similar tag at its 
C-tenninal end. A schematic representation of the pDrrABC construct is shown in figure 
7.1. As is the case with all pET-series vectors, transcription of the inserted operon was to 
be driven by a bacteriophage T7 promoter located upstream of the cloned sequence. In 
previous studies the DrrB protein had been shown to be prone to aggregation when 
expressed and purified in isolation, whilst no conclusive evidence for successful over­
expression of DrrC had ever been obtained. These results suggested that the membrane 
bound components of the transporter were particularly unstable and/or sensitive to 
degradation within the cell. It was hoped that co-expression of all three genes might lead 
to improved stability of these proteins. Similar co-expression studies have in the past 
facilitated the purification of complete ABC transporter complexes and allowed for 
demonstration of ATP-dependent transport activity in cell-free systems (Ames et al., 
2001).
Expression trials were conducted by transforming the pDrrABC plasmid construct into 
the E. coli host strain BL21(DE3), the DE3 lysogen providing the IPTG inducible T7 
RNA polymerase necessary to drive transcription of the recombinant DNA sequence. 
Recombinant colonies were selected on solid LB-agar medium containing kanamycin at 
50pg/ml. A single recombinant colony was used to inoculate 100ml of fresh liquid LB 
medium containing kanamycin at the same concentration. The liquid culture was grown 
at 30 °C with rotary shaking at approximately 200rpm. It was considered that a reduced 
growth temperature might help to improve the stability of the DnB and C proteins whilst 
reducing inclusion body formation by the aggregation prone DrrA.
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Expression of the c/rrABC operon was induced by the addition of ImM IPTG to the 
liquid culture when the cells reached an ODeoo of 0.6 (mid log phase). After induction the 
cells were grown for a further 3 hours at 30 °C before being harvested by centrifugation 
(6000ipm, Beckman JA-10 rotor).
Both structural and over-expression studies suggest that, in a complete four-domain ABC 
transporter complex, the NBD’s are peripherally associated with the cytoplasmic 
membrane tlmough specific interactions with the MSD’s. As such, successful over­
expression of the drr operon might be expected to result in the presence of a membrane- 
localised complex containing all three Drr proteins. To determine whether or not this was 
the case total cell membranes were isolated from the expression culture as described in 
chapter 2. All membrane bound proteins were solubilised in a buffer containing 8M urea 
and then separated by SDS-P AGE. Given the low expression levels of the DrrB and DrrC 
proteins encountered in previous studies, the decision was made to probe for the presence 
of the membrane bound complex by Western blot. The SDS-PAGE separated proteins 
were transfeired to a PVDF membrane by electro-blotting and probed using an anti-HiSô 
monoclonal antibody to detect the His-tagged DrrA and DrrC proteins. The results of this 
blot along with experimental details of its preparation are shown in figure 7.2.
The results of the Western blot were initially encouraging. A strong signal was observed 
at approximately 40 kDa, a size consistent with His-tagged DrrA. The presence of 
significant quantities of DrrA being associated with the cell membrane was also an 
indication of successful expression of the membrane bound DrrB and C proteins. Two 
much smaller signals were also observed at a size just below 30 IcDa. Either of these 
signals might possibly be attributed to smaller quantities of His-tagged DrrC being 
present in the E. coli membrane.
The need to confirm the identity of the proteins giving rise to positive Western blot 
signals led to a number of attempts to purify the proteins concerned by IMAC 
clu'omatography. The small signals obseiwed below 30 IcDa, putativeiy assigned to DrrC, 
suggested that expression levels of this protein were very low. This factor, combined with 
the known instability of purified MSD’s, dictated that purification experiments be 
performed under denaturing conditions so as to limit yield losses due to proteolysis or
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Figure 7. 2 Western blot of total cell membrane protein isolated from a 
pDrrABC expression culture
40 kDa
30 kDa
Membrane localised 
HiSô-DrrA
Possible DrrC-HiSô 
proteins
Membrane associated proteins from a 100ml pDrrABC expression culture were extracted 
into 5ml o f the following buffer: -
50mM Tris-HCl (pH 8.0), 300mM NaCl, 8M Urea.
The high urea concentration o f the buffer resulted in disruption o f the lipid membranes 
and solubilisation o f associated proteins. 30pl o f the urea extract was mixed with lOp.1 o f  
SDS-PAGE sample buffer and the proteins separated by electrophoresis on a 12% 
polyacrylamide gel. Separated proteins were transferred to PVDF membrane by electro- 
blotting and the resulting blot probed with an anti-His6 monoclonal antibody. The blot 
was developed using the ImmuneStar chemiluminescence detection system (see chapter 
2 ).
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aggregation. A number of purification conditions were tested; typically using total cell 
membranes isolated from a 1 litre expression cultures. Membrane proteins were extracted 
and solubilised in 8M urea buffer and the resulting preparations applied to Ni-NTA spin 
columns. The column resin was washed extensively according to the manufactures 
recommended protocols before bound protein was finally eluted in urea buffer 
supplemented with 600mM imidazole (see chapter 2). The results of one such purification 
experiment are shown in figure 7.3.
A 40kDa protein, believed to be His-tagged DitA, was consistently isolated from 
membrane extracts prepared fi'om cells containing the pDrrABC plasmid. However, 
neither of the approximately 30 kDa proteins identified in Western blots of the same 
membranes could be purified fr om these extracts. A number of explanations for these 
apparently conflicting results can be suggested. Firstly, the failure to purify any His- 
tagged DrrC may simply be a reflection of its extreme instability both within the cell and 
once it is removed from the membrane environment. A second and perhaps more likely 
explanation is that the 30 kDa Western blot signals are experimental artefacts, and that 
little or no DrrC expression occurred using this expression construct. This latter 
interpretation is supported by the earlier results presented in chapter 4 where apparently 
positive Western blot signals attributed to DrrC were later confirmed as being the result 
of a histidine-rich E. coli protein. The failure of the pDn ABC expression construct to 
express all tlrree mycobacterial genes might also be explained in teims of genetic 
differences between E. coli and M  tuberculosis. A  vector-encoded T7 promoter drives 
transcription of the drr ABC operon from pDrrABC via an IPTG induced RNA 
polymerase. However, translation of the mRNA signal is entirely dependent on the host 
cell ribosomal machinery. The overlapping nature of the drr ABC operon means that 
translation of the drrB and drrC genes would require E. coli ribosomes to recognise 
binding sites eneoded within the mycobacterial DNA. The failure of E. coli ribosomes to 
recognise mycobacterial binding sites would simply result in the ribosomes Halling-off 
or failing to bind the mRNA transcript, thereby leading to loss of expression. Translation 
of drr A  would be unaffeeted by this problem since an optimised E. coli ribosome binding 
site is encoded in the vector sequence upstream of drr A.
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Figure 7. 4 Attempted co-purification of the DrrA and DrrC proteins by
IMAC chromatography under denaturing conditions
M El E2
40 kDa -------  ^ j I - ■ His6-DrrA
30 kDa
Candidate DrrC-His6 
proteins absent
Total membrane proteins from a 1 litre expression culture of BL21(DE3)/pDrrABC 
were solubilised in 5ml of a buffer containing 50mM Tris-HCl (pH 8.0), 300mM NaCl, 
8M urea. The resulting extract was applied to a Ni-NTA spin column and unbound 
protein removed by washing with 5x 800pl of the same buffer. Non-specifically bound 
proteins were removed by washing the column resin with 5x 800pl of buffer 
supplemented with 50mM imidazole. Finally, His6-tagged proteins were eluted from the 
resin by washing twice with 400pl of buffer containing 600mM imidazole. Eluted 
proteins were separated by SDS-PAGE and visualised by Coomassie blue staining (Lanes 
El and E2).
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The results show elution of the 40 kDa N-terminal His-tagged DrrA only. No His-tagged 
proteins with molecular weights less than 30 kDa were purified hy this method. These 
results suggested that there was little or no expression of C-terminal His-tagged DrrC in 
these cultures. All of the expression and purification experiments described here were 
performed before the publication of Choudhuri and colleagues. This group encountered 
an exactly analogous series of problems during their attempts to express just two of the 
M. tuberculosis drr genes, A and B. Expressed independently of one another using pBT- 
based constructs, DrrA was found exclusively as inclusion bodies, and the DrrB protein 
localised to the membrane yet was impossible to extract due to its instability. These 
results are very similar to those described in chapter 4 of this work. Additionally, 
expression of the drr A  and B genes in tandem with one another resulted in the detectable 
expression of only the drr A  gene product. To circumvent the co-expression problem 
Choudhuri constructed an artificial operon in which the drr A  and B genes were separated 
from their native overlapping structure and an artificial E. coli ribosome binding site 
incorporated between the end of the drr A  gene and the beginning of drrB. Only when 
this eonstiuct was used were they able to demonstrate the stable, membrane associated 
expression of both the DrrA and B proteins (Choudhuri et aL, 2002).
The experiments of Choudhuri and colleagues are very interesting in that they not only 
describe a potentially successful route to the heterologous co-expression of all three M. 
tubercidosis drr genes, but also further demonstrate the interdependence of ABC 
transporter sub-domains on one another for stability. Additionally their work illustrates 
that differences in the genetics of E. coli and M  tubercidosis can be responsible for the 
failure of heterologous expression.
7. 2 Antibiotic sensitive E, coli bearing the pDrrABC plasmid do not
exhibit increased resistance to anthracycline antibiotics
Despite failure to co-purify the components of a membrane bound DrrABC complex, a 
number of further experiments were perfonned to investigate whether co-expression of 
the DrrABC proteins might be detected on a phenotypic basis. Sequence homologies 
between the DrrABC proteins and components of the S. peucetius doxorubicin/ 
daunorubicin efflux transporter are one indication that the two transporters may share a 
similar function. In order to identify whether cells carrying the pDn'ABC plasmid
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exhibited increased resistance to the anthracycline antibiotics, a host strain sensitive to 
their action was required. Standard laboratory E. coli strains are intrinsically resistant to 
both doxombicin and daunorubicin by virtue of their possessing a number of 
chromosomally encoded multidrug efflux pumps. Foremost among these is the AcrB 
multidrug resistance pump, a member of the RND family of secondary transmembrane 
transporters (Ma et al., 1995). Two further accessory proteins are vital to the function of 
this pump, the AcrA membrane fusion protein and the TolC outer membrane channel 
(Elkins and Nikaido, 2003). E. coli strains deleted for any of these thr ee proteins exhibit 
massively increased susceptibility to a wide range of antibiotics. In a systematic study of 
the contributions different efflux systems make to the intrinsic drug resistance of E. coli, 
Sulavik and colleagues report that both EacrPsB and EtolC knockout strains exhibit 
doxorubicin resistance levels of below Ipg/ml. This compares with a resistance level of 
>80pg/ml for wild-type strains (Sulavik et al., 2001).
In order to enable a direct comparison with the S. peucetius DrrAB transporter, a AacrA 
E.coli strain called ‘N43’ was chosen as the host organism for the pDrrABC plasmid. 
This strain had been successfully used by Kaur to demonstrate the antibiotic transport 
capabilities of the S. peucetius doxorubicin efflux pump (Kaur, 1997). E.coli N43 does 
not possess a chromosomal copy of the DE3 lysogen required to drive transcription from 
pET-series plasmids. This was provided by co-transformation of the mutant strain with a 
second compatible plasmid called pT7 (Aldema et al., 1996). This plasmid encodes an 
IPTG inducible T7 RNA polymerase as well as an ampicillin resistance marker to enable 
selection of doubly transformed cells. Both the pDrrABG and pT7 plasmids were 
transfonned into chemically competent N43 and recombinant colonies were selected on 
solid LB-agar medium containing 25pg/ml kanamycin and 50pg/ml ampicillin.
The antibiotic susceptibilities of both the parent N43 strain and the transformed strain 
were detennined in tenns of a Minimum Inhibitory Concentration (MIC). An MIC is 
defined as the lowest concentration of antibiotic that causes a particular bacterial strain to 
cease growing. MIC’s were determined by the broth microdilution method recommended 
by the National Committee for Clinical Laboratory Standards (see chapter 2). Antibiotic 
susceptibilities with regard to a range of structurally unrelated compounds were tested. 
The results of these experiments are shown in table 7.5.
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Table 7.5 MIC Determinations
Strain MIC (pg/ml)
Drug N43 N43/pDrrABC (-)' N43/pDrrABC (+)
Doxorubicin 4 4 4
Daunorubicin 4 4 4
Erythromycin 4 4 2
Rliodamine-6G 16 8 8
Ethidium Bromide 80 40 40
SDS 100 100 50
* +/- ImM IPTG
The data presented above represent average values from between 4 and 6 independent 
experiments wMi each drug.
The MIC data obtained suggested that the presence of the pDrrABC plasmid had no 
positive effect on levels of antibiotic resistance. In some cases, e.g. the dyes rhodamine- 
6G and ethidium bromide, the plasmid even appeared to cause a lowering of the MIC. 
Addition of ImM IPTG to the cultures had no effect. The MIC’s of daunorubicin and 
doxorubicin were both in the region of 4|iig/ml, a value consistent with that reported by 
Kaur for E. coli N43. These data would tend to support the idea that there is little or no 
expression of a complete/functional DrrABC transporter from the pDrrABC plasmid.
At this point it is worth comparing these data with those obtained by Choudhuri and 
colleagues. Using their artificial operon system for co-expression of the drrA and B 
genes, this group report apparent increases in resistance towards both doxorubicin and 
daunorubicin. The MIC for doxorubicin rose from 20pg/ml to 40pg/ml, while the MIC 
for daunorubicin increased from 20pg/ml to 60p,g/ml. Co-expression of DrrA and B also 
enhanced resistance towards ethidium bromide (where the MIC increased from 20pg/ml 
to 60pg/ml). It should be noted however that these experiments were performed using a 
standard E. coli host strain, BL21(DE3), and that the MIC figures reported are all
214
7. 3 The pDrrABC plasmid does not complement a temperature sensitive
mutation in the E, coli MsbA ABC transporter
somewhat lower than those generally accepted for laboratory strains of if  coli (Kaur, 
1997; Sulavik et a l, 2001).
The MsbA ABC transporter is a homodimeric half-transporter responsible for export of a
7 .
major lipid component of the E. coli outer membrane, ‘Lipid A’. In 2001 Chang and Roth 
produced a high-resolution crystal structure for the MsbA homodimer making it the first 
ABC transporter for which such information was available (Chang and Roth, 2001). In a
■ ■=■
further attempt to identify a specific transport function associated with the M.tiiberculosis y:drrAlQC genes, use was made of a temperature sensitive MsbA mutant. This strain, 
identified by Doerrler, grows normally at 30 °C but is unable to do so at the elevated ytemperature of 44 °C. The biochemical basis of this growth defect was identified as a 
failure to target MsbA to the cytoplasmic membrane at the higher temperature (Doerrler 
et al., 2001). Although E. coli and M. tuberculosis are evolutionarily diverse bacteria 
with very different cellular structures, the broad substrate specificity of some ABC 
transporters towards lipophilic molecules suggested that the DrrABC transporter might be 
able to complement the temperature sensitive defect in Lipid A export.
The temperature sensitive mutant strain, WD2, was co-transfonned with the pDrrABC 
and pT7 plasmids as described in the previous section. Transformants were selected on 
solid LB-agar medium containing 25pg/ml kanamycin and 50pg/ml ampicillin. The 
temperature sensitive nature of the WD2 strain required that transfoimation plates be 
incubated at 30 °C rather than the noimal 37 °C.
A single colony of the doubly transformed WD2 strain (WD2+) was used to inoculate 
10ml of fresh LB medium supplemented with both kanamycin and ampicillin. At the 
same time an untransfoimed WD2 colony was used to prepare a control culture (LB 
only). Both liquid cultures were incubated at 30 °C with rapid rotary shaking. Growth of 
the cultures was monitored by an increase in OD^oo with measurements taken at 30 
minute intervals. The cultures were allowed to grow for 2.5 hours at 30°C in order to 
establish that their growth was nonnal at the permissive temperature. At this point each
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culture was diluted lOx into fresh medium pre-waimed to 30 °C and ImM IPTG was 
added to the WD2+ strain. After a further 30 minutes of growth at 30 °C both liquid 
cultures were transferred to a 44 °C incubator and the effect on growth monitored by 
changes in ODeoo- The growth cuiwes obtained for both cultures are shown in figure 7.6.
As the data show, the pDrrABC plasmid had no effect on the growth of WD2 at either the 
permissive temperature or the elevated temperature. Both the test and control strains 
stopped growing almost imiuediately after they were waimed to 44 °C. The same 
experiment was repeated a number of times with essentially no difference in the results 
observed. These data can only be interpreted as either failure of the DrrABC transporter 
to support Lipid A export, or, more likely in the light of similar results, a failure of the 
pDn ABC expression construct to produce all tluee mycobacterial proteins.
Î
216
Figure 7. 6 Growth of E, coli lipid efflux mutants WD2 and WD2+
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E. coli strains WD2 (blue line) and WD2+ (pink line) were grown at 30 °C in 10ml liquid 
cultures. Growth o f the cultures was monitored by increases in ODôoq (y-axis). After 2.5 
hours each culture was diluted lOx into fresh, pre-warmed medium (in order to prevent 
the emergence o f revertant organisms), and ImM IPTG was added to the WD2+ culture 
to induce expression from the pDrrABC plasmid. At 3 hours the cultures were shifted to 
44 °C and the effect on growth was monitored for a further 3 hours. All OD figures after 
2.5 hours are corrected for the dilution effect.
Both cultures ceased growing almost immediately after the shift to 44 °C indicative o f 
incorrect targeting o f  the E. coli MsbA Lipid A transporter. The presence o f the 
pDrrABC plasmid in the WD2+ organisms clearly had no effect on growth rate o f the 
culture either before or after the shift to 44 °C. These data suggest either a lack o f 
expression from the pDrrABC plasmid, or an inability o f the mycobacterial DrrABC 
proteins to support E. coli Lipid A efflux.
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7.4 Discussion
The various negative results reported in this chapter can largely be attributed to failure of 
the pDrrABC expression construct. They do however demonstrate some of the wider 
difficulties associated with ABC transporter research and with heterologous expression 
systems in general. ABC transporters are distributed thi*oughout all biological kingdoms 
and their activity has been correlated with a range of processes having a direct impact on 
human health. The emerging phenomenon of bacterial multidrug resistance, the 
failure of anti cancer chemotherapy and human genetic diseases have all been linked to 
the function of members of the ABC transporter superfamily. An ability to combat these 
problems will increasingly rely on detailed structural and functional data relating to ABC 
transporter activity. Such data can only be generated if sufficient source material is 
available for scientists to work with, and, as the work presented here and elsewhere has 
shown, generating such source material is far from routine. Researchers are still heavily 
reliant on E. coli as a host for recombinant protein expression, yet this organism is by no 
means ideal for the expression of proteins fi-om evolutionary diverse sources such as 
eukaryotes or the mycobacteria. Moreover, ABC transporters are by their very nature 
multi-domain proteins, the function and stability of the various domains being closely 
tied to one another. If researchers are to continue to rely on E. coli as a vehicle for 
recombinant expression then improved systems for co-expression and correct targeting of 
multi-protein complexes must be developed.
The work of Choudhuri and colleagues is an example of a modified expression system 
that proved to be veiy effective for the co-expression of the M  tuberculosis drrA and B 
genes (Choudhuri et ah, 2002). Their experiments clearly establish successful expression 
of both the mycobacterial drrA and drrB genes in E. coli through the use of an artificial 
operon system. Moreover, the DrrA and B proteins produced were shown to form a 
complex assoeiated with the cytoplasmic membrane, an architecture entirely consistent 
with the hypothesis that these proteins constitute components of an ABC transporter 
complex.
Building on the strength of their expression data, Choudhuri and colleagues presented 
additional experimental results that suggested a possible functional role for the DitA and 
B proteins. Firstly, the accumulation of [^'^C]doxorubicin in E. coli cells co-expressing 
Dn*A and B was shown to be significantly lower than in control strains. Moreover,
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accumulation of [*^ 0^]doxorubicin was shown to revert to control levels when cells 
expressing DrrAB were exposed to sub-lethal concentrations of reserpine, a known 
inliibitor of ABC transporter function (Choudhuri, 2002). These data would seem to 
indicate that the mycobacterial DrrA and B proteins form a functional ABC transporter 
complex very similar to the S. peucetius DrrAB transporter described by Kaur i.e. an 
efflux ABC transporter capable of extruding anthr acycline antibiotics (Kaur, 1997).
A second series of experiments described in the same paper lend further weight to the 
hypothesis that the DrrAB complex is a functional efflux transporter. The probe molecule 
BCECF-AM is a non-fluorescent, neutral compound able to diffuse freely across cellular 
membranes. Once inside a cell BCECF-AM is rapidly hydrolysed to a free acid (BCECF) 
that is fluorescent and no longer able to cross the cytoplasmic membrane. The change in 
fluorescence of a cellular preparation to which BCECF-AM has been added can therefore 
be used as a direct measure of the intracellular accumulation of BCECF. When BCECF- 
AM was added to E. coli cells co-expressing the mycobacterial DitA and B proteins, 
BCECF accumulation was markedly reduced compared with control cells. Once again the 
ABC transporter inhibitor reserpine was shown to reduce the magnitude of this effect. 
Choudhuri and colleagues interpret these data as an indication that BCECF-AM is a 
substrate of the DrrAB transporter complex. This raises the interesting possibility that the 
DrrAB transporter is capable of mediating the efflux of at least two distinct substrate 
types i.e. cationic, hydrophobic molecules such as doxorubicin and neutral compounds 
such as BCECF-AM.
The reduced accumulation of [^"^C]doxorubicin, reduced accumulation of BCECF and 
increased antibiotic resistance exhibited by E. coli cells co-expressing DrrA and B are all 
strong indications that these two mycobacterial proteins combine to generate a functional 
ABC efflux transporter. Given the four-domain architecture of all known ABC 
transporters, Choudhuri’s observations imply the fonnation of a D1TA2 B2 tetramer exactly 
analogous to that proposed by Kaur for the S. peucetius doxorubicin transporter.
However, such a model does not take into account the presence of the drrC gene in the 
same operon as drrA and B, and nor does it correlate with observations of Azad and 
colleagues suggesting that the DrrC protein plays a vital role in the export of 
mycobacterial cell wall lipids (Azad et ah, 1997).
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The two groups of experimental data regarding the physiological function of the M 
tuberculosis DitABC transport system are somewhat difficult to reconcile. Whilst it 
remains possible that the transport complex may be able to adopt two or more different 
stoichiometries, this phenomenon has not previously been described amongst members of 
the ABC transporter superfamily.
A more complete understanding of the physiological role of the DrrAB(C) transport 
system could ideally be achieved by studying the expression of the genes and proteins in 
their native host, M. tuberculosis. However, given the difficulties associated with the 
growth, handling and genetic manipulation of this organism, it seems likely that 
researchers will remain reliant on E. coli as a vehicle for expression and functional 
studies. Against this experimental background, the co-expression and assay systems 
reported by Choudhuri and colleagues represent significant advances. Similar systems 
may eventually allow for simultaneous co-expression of all three M. tuberculosis drr 
genes and the development of new assays to assess the true function of this transporter.
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Chapter 8
Final Discussion
More than 50 years after the discovery of the first effective anti-tubercular agents, 
pulmonary tuberculosis remains the leading cause of mortality due to a bacterial 
pathogen. Around 2-3 million deaths amiually can be attributed to M. tuberculosis 
infection, a situation that is likely to worsen over the next decade as a result of the global 
HIV/AIDS pandemic. Once considered to have been virtually eradicated in the rich, 
industrialised nations of the West, TB has re-emerged in new and deadlier drug-resistant 
forms. The increased availability of air travel and a growing number of displaced people 
have allowed the bacterium to spread rapidly and with no respect for geographical 
borders. Together these various factors have forced national govermiients and the 
scientific community to focus significant efforts on the control and treatment of 
tuberculosis. Many of the current problems associated with TB treatment are related to an 
over-reliance on a limited number of chemotherapeutic agents. The four drugs forming 
the cornerstone of most modem anti-tubercular therapy were all first used in the middle 
of the last century. Worse still, incorrect usage of these drugs has resulted in the 
emergence of new MDR strains that have the potential to become untreatable. Halting the 
spread of TB clearly requires the development of new and effective TB treatments and 
the introduction of a prophylactic vaccine.
The publication of the complete M. tuberculosis genome sequence was a major milestone 
in TB research (Cole et a l, 1998). The genetic sequence of the organism essentially 
represents a detailed map of every possible drug target and antigen that might be used to 
combat the spread of the disease. However, this genetic data is not, in itself, enough to 
ensure the eradication of TB when even some of the most basic facets of mycobacterial 
physiology remain poorly understood. How are the organisms able to avoid immune 
clearance and survive within the hostile intracellular environment? Which factors affect 
mycobacterial doimancy and re-activation of latent infection? Why does M  tuberculosis 
display such a high level of intrinsic drug resistance? Answers to these questions, and 
many more facing the TB research community, will require a sustained international 
effort involving scientists in every field from basic microbiology to X-ray 
crystallography. The work presented in this thesis aimed to address just one tiny aspect of 
the M. tuberculosis puzzle; what is the role of the drr ABC operon?
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TheM  tuberculosis genome sequencing project revealed the existence of as many as 37 
potential ABC transporter systems (Braibant et al., 2000). These versatile, multi-domain 
transmembrane transport systems have been identified in all kingdoms of life, from 
archea through to man, so their presence in the M, tuberculosis genome is far from 
surprising. However, at the outset of these investigations little or nothing was known 
about the role that ABC transporters play in the biology of M  tuberculosis. Much of the 
interest in ABC transporters derives from their many physiological roles. ABC 
transporters from various organisms have been shown to be involved in nutrient 
acquisition, virulence factor export, antibiotic resistance and cellular assembly (see 
chapter 1.2). Any or all of these processes may yet prove to be important detenninants of 
M. tuberculosis pathogenicity.
Of all the potential ABC transporters encoded in the M. tuberculosis genome the drr ABC 
system was revealed to be particularly interesting on a number of levels. Bioinfonnatic 
tools such as primary sequence analysis were used to show that the proteins encoded in 
drr ABC operon bear significant homology to an antibiotic efflux transporter from the 
evolutionarily related actinomycete Streptomyces peucetius. Active efflux of antibiotics is 
not known to be one of the major drug resistance mechanisms employed by M. 
tuberculosis, yet the possibility remains that it may be a contributory factor. A second 
potential function of the drr ABC  genes was identified by the presence of a poorly 
conserved but narrowly distributed amino acid sequence known as the ‘ABC-2’ motif. 
Found in both the Dn'B and C proteins, ABC-2 is restricted to the transmembrane 
components of ABC transporters involved in the assembly of extracellular structures such 
as the cell wall and glycocalix (Reizer et a i, 1992). Could it be that the drr ABC system 
is somehow involved in transport of molecules contributing to the complex and unique 
mycobacterial cell wall? This latter hypothesis was lent a great deal of credence by the 
work of Camacho and colleagues who demonstrated that genetic disruption of the 
drr ABC operon resulted in decreased transport rates for one particular class of complex 
lipids (Camacho et al., 1999). Perhaps even more importantly, this transport deficiency 
could be correlated with decreased virulence of the mutant organisms in a mouse model 
of pulmonaiy tuberculosis (Cox et al., 1999).
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Both potential roles of the drr ABC  system marked this ABC transporter out for further a
study. On one hand drr ABC  is in itself an attractive drug target because of a possible role 
in cell wall assembly, on the other hand an improved understanding of the basic 
mechanisms of mycobacterial drug resistance may help us to design effective new 
chemotheraputics. However useful bioinfonnatic approaches are for identifying members 
of the ABC transporter superfamily and identifying potential functions, it is at the
"ibiochemical level where the most valuable information is to be gained. To this end most
products of the M. tubercidosis drr ABC  operon.
of the work presented thesis was aimed at overexpressing and purifying the protein |
From the earliest days of recombinant DNA technology and the development of 
techniques for the overexpression and purification of proteins, researchers have relied 
heavily on the use of particular model organisms. In the case of prokaryotic protein 
expression E. coli is invariably the organism of choice as no other bacterium is so well 
characterised at a genetic, biochemical or physiological level. Given the extensive 
availability of genetie systems for protein overexpression in E. coli, this organism was 
selected as a heterologous host for studies of the M. tuberculosis DrrABC proteins.
Whilst the use of a rapidly-growing Gram-negative organism as a means of producing 
proteins native to a slow-growing. Gram-positive pathogen is clearly far foom ideal, few 
other options were available because of the many problems associated with working with 
live M  tubercidosis.
ABC transporters are highly modular in nature and consist of a minimum of four 
functional domains, two ATP-binding/hydrolysing domains and two membrane-spanning 
domains (Higgins et al., 1986). The exact mode of expression of these domains varies 
enormously between different members of the ABC transporter superfamily but amongst 
the prokaryotic systems a different gene usually encodes each domain. In the case of the 
drr ABC  operon, sequence analysis indicated that drrA gene encoded the nucleotide- 
binding domains of the transporter, whilst drrB and C each encoded membrane-spanning 
domains. Throughout the history of biochemical research it has been common practice to 
investigate the properties of individual components of a system before analysing how the 
various components contribute to the whole. Such an approach has been highly successful 
in studies of the ABC transporter family, particularly in understanding how the various 
domains contribute to substrate translocation (Davidson et al., 1996). For this reason the
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same approach was initially adopted with regard to the DrrABC proteins. Each protein 
was treated as an individual entity to be expressed in isolation using a separate expression 
constiuct. In the case of the DrrA protein this technique initially yielded huge quantities 
of recombinant protein (using the pET-based construct pDrrA). However, as is so often 
the case with recombinant overexpression systems, the vast majority of the DrrA 
produced was insoluble, inactive inclusion bodies. The lack of biological function 
associated with this form of the protein prevented further biochemical analysis of native 
DrrA. Various attempts were made to refold the inclusion body aggregates into an active 
conformation. Unfortunately these efforts ultimately proved abortive. Inclusion body 
fonnation is in fact a rather common phenomenon when overexpressing the NBD 
proteins of ABC transporters. Yuan and colleagues have suggested that certain structural 
features of the NBD promote non-physiological interactions between individual 
molecules, a process that ultimately results in aggregation and insolubility (Yuan et al., 
2001).
An entirely different set of problems were encountered when attempting to overexpress 
the MSD’s, DrrB and DrrC. In many respects these problems were typical of those facing 
all researchers working with integral membrane proteins and are mostly related to low 
levels of expression and protein instability. DrrB was successfully expressed and purified 
as a C-terminal His-tagged protein but proved to be highly unstable once removed from 
the membrane environment. This instability primarily manifested itself as low yields 
during the purification procedure (even when large culture volumes were used for protein 
preparation), and a tendency towards spontaneous aggregation and precipitation. DrrC on 
the other hand proved impossible to express using a similar pET-based expression 
system. Although a candidate protein was isolated, N-temiinal amino acid sequencing 
identified it as a histidine-rich protein native to E. coli, SlyD. The fact that the protein 
structure databases contain far fewer examples of integral membrane protein structures 
than of soluble proteins is an indication of just how difficult working with these proteins 
is. After almost forty years of ABC transporter research and despite huge advances in 
detergent chemistry, only three complete ABC transporter stmctures are available, two of 
these being variants of the same transporter fi^ om different organisms (Chang and Roth, 
2001 ; Locher et a l, 2002; Chang, 2003). A number of groups have suggested that MSD 
stability is only a property of complete ABC transporter complexes, i.e. the various 
domains are highly dependent upon one another, and possibly also the membrane itself.
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to maintain a stable conformation. Both Kaur and Russell and Choudhuri and colleages 
have reported similar MSD instability in their attempts to overexpress the DrrB proteins 
of S. peucetius and M. tuberculosis respectively (Kaur and Russell, 1998; Choudhuri et 
a l, 2002).
Having failed to express DrrA as a native protein, an alternative mode of expression was 
sought. By expressing the mycobacterial protein as a translational fusion to E. coli f
thioredoxin a stable soluble DrrA was eventually produced in useful quantities. Similar 
techniques have been used extensively in the heterologous overexpression of both 
prokaryotic and eukaryotic ABC transporter NBD’s. The Trx-DrrA fusion protein was
"Ashown to exhibit cation dependent ATPase activity, a feature consistent with the proposed 
role of Dn'A as the energy transducing sub-unit of a mycobacterial ABC transporter.
ATPase activity was shown to be dependent upon the structural integrity of the ‘Walker 
A’ nucleotide-binding motif. Two mutant proteins in which this motif was disrupted by 
site-directed mutagenesis both exhibited dramatically reduced levels of ATP hydrolysis.
This data is the first to show that the M. tuberculosis DrrA protein is a functional ATPase 
and only the second M. tuberculosis ABC transporter NBD to have been characterised in 
this way (the other being the PstB NBD, Sarin et aL, 2002).
The availability of significant quantities of Trx-DrrA allowed the ATPase activity of the 
protein to be investigated in greater detail. Trx-DrrA was shown to have K„j and V^ ax 
parameters broadly similar to those of other isolated NBD’s although the maximal rate of 
ATP hydrolysis was somewhat lower than might have been expected. Trx-DrrA was 
shown to exhibit a degree of substrate promiscuity with regard to both nucleotide 
triphosphates and cation usage. Such promiscuity is very common amongst isolated 
bacterial NBD’s and, although unlikely to be of physiological relevance, is an indication 
that Trx-DiTA behaves as a typical NBD protein. A growing body of biochemical and 
structural data suggest that the ATPase competent form of ABC transporter NBD’s is a 
dimer similar in structure to the RadSOcd dimer crystallised by Hopfner and colleagues 
(Hopfiier et al., 2000; Moody et al., 2002). In fact, a number of researchers have 
proposed that ATP-dependent NBD dimérisation may be a key first stage in driving the 
substrate translocation process. Despite several attempts to identify Trx-DrrA dimer 
fonnation, no biochemical data in support of such a model was obtained. In all respects 
Trx-DrrA behaved as a simple Michaelis-Menten type enzyme hydrolysing ATP with a
1
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Hill coefficient of 1. This data is consistent with that produced for a number of NBD 
proteins and is an indication that the behaviour of isolated NBD’s may be different from 
that which they exhibit when fonning part of an intact ABC transporter complex. A 
second interpretation of this data is that the low ATPase activity of Trx-DrrA may be a 
reflection of a reduced ability to form ATPase active dimers as a direct consequence of 
steric hindrance by the thioredoxin moiety. In order to ascertain this we intend to test an 
alternative expression system in which the thioredoxin molecule is fused at the C- 
terminal end of DrrA, rather than the N-terminal end where the Walker A nucleotide- 
binding motif is located. The possibility that the DitA fusion protein displays non- 
physiological activity when assayed in isolation is a strong argument in favour of treating 
ABC transporters as complex, interdependent multi-component systems. A complete 
understanding of the ABC transporter translocation mechanism will undoubtedly require 
such an approach and begs the question as to how much useful information can be 
derived from investigating the behaviour of individual components.
Having argued that ABC transporter activity should be treated as a multi-domain 
phenomenon, one aspect of NBD activity that is open to investigation in isolation is the 
mechanism of ATP hydrolysis. Intrinsic tryptophan fluorescence spectroscopy is a 
powerful tool for detecting even minor changes in protein structure that may be linked to 
the catalytic cycle of an enzyme (Walmsley et aL, 2001). Unfortunately the ATPase 
activity of Trx-DrrA proved impossible to study by this means despite extensive attempts 
to optimise any signal through the construction of single-tryptophan mutant proteins. It 
was considered that the lack of a strong fluorescence signal during ATP- 
binding/hydrolysis might be a further manifestation of the low activity of the protein. In 
order to address this question, and if time allows, we intend to produce frirther mutant 
proteins with tiyptophan residues inserted at different points within the primary sequence. 
Such an approach may eventually lead to the generation of a spectroscopically active 
protein. It will also be interesting to see if moving the thioredoxin moiety of the protein 
from one end of the molecule to the other has any effect on the fluorescence properties of 
the protein. Tlie ATPase activity of Trx-DrrA was shown to be totally unaffected by the 
presence of the potential DrrABC substrates doxorubicin and daunorubicin. This would 
seem to argue against the presence of an antibiotic binding site or sites anywhere on the 
DrrA molecule. Whilst many ABC transporters exhibit substrate modulated activity, this 
is yet another example of a property that may largely be confined to the intact ABC
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transporter complex. Under such circumstances, and with a few notable exceptions such 
as the E. coli Ai'sA protein, ABC transporters should not be regarded as typical alio steric 
enzymes. It is more likely that the ATPase activity of the NBD is modulated by 
conformational changes brought about through interaction with the substrate-bound 
MSD’s of the transporter, rather than by direct interaction with the transport substrate 
itself.
Clearly demonstration of interdomain interactions requires the ability to co-express more 
than one domain of an ABC transporter simultaneously in the same organism. We 
attemped to achieve this goal by using a very simple system in which the entire c/rrABC 
operon was cloned into a single expression vector. Unfortunately these efforts were 
abortive due to differences in the mycobacterial and E. coli translational machinery. The 
data presented in chapter 7 seems to indicate that E. coli ribosomes are unable to interact 
with the embedded ribosome binding sites present in a transcriptionally linked M. 
tuberculosis operon. As such, only the first gene in the operon, drrA, was coirectly 
translated and expressed, whist there was no evidence for expression of the downstream 
genes drrB and drrC. In 2002 Choudhuri and colleagues, also recognising the potential 
importance of the M  tuberculosis drr system, developed a system for co-expression of 
both the DrrA and B proteins in E. coli (Choudhuri et aL, 2002). By separating the 
overlapping genes, and inserting an E. coli ribosome-binding site upstream of drrB, this 
group were able to effect simultaneous co-expression of both DrrA and DrrB. Whilst this 
group aclaiowledged the probable role of the DrrA and B proteins in mycobacterial lipid 
export, their work focussed largely on the role of the proteins as possible mediators of 
antibiotic resistance. It is rather unclear as to why they chose to express only two of the 
three drr genes but present an argument that DrrA and B alone are able to function as 
doxorubicin/daunorubiciii efflux system. Some of the data presented should perhaps be 
regarded with a degree of scepticism since the use of an intrinsically drug resistant E. coli 
strain to demonstrate antibiotic resistance is not necessarily an entirely appropriate 
experimental system.
The work of Choudhuri does however serve an important proof-of-principle. It seems 
entirely plausible that extending their artificial operon system to include not only the 
drrA and B genes, but also drrC, may provide a route to successfi.il co-expression of all 
tlmee components of the M. tuberculosis ABC transporter. Under such circumstances it
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may eventually be possible to co-purify the entire ABC transporter complex and perhaps 
reconstitute it into a cell free system. Similar experiments have allowed extensive 
characterisation of the transport capability and catalytic activity of a number of ABC 
transporters, most notably the MalFGK2 maltose permease ofE. coli (Davidson et aL,
1996). Another possible advantage of such a co-expression system is a likely 
improvement in stability of the DrrB and C MSD’s. .1
In conclusion, much remains to be learned about the M. tuberculosis DrrABC transporter 
and the role of mycobacterial ABC transporters in general. The studies described in this
...y,
work represent only a tiny advance in our knowledge of these systems yet hint that much 
more remains to be discovered. The multi-domain nature of ABC transporters seems to 
lie at the very heart of their activity but also contributes to the difficulties associated with 
studying them. After forty years of ABC transporter research the publication of three 
complete, atomic-resolution, ABC transporter structures within the last three years should 
serve as a major encouragement to all researchers working in this field.
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